Gene Detail

Filtering

Case insensitive filtering will display rows if any text in any cell matches the filter term
Use simple literal full or partial string matches
Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")

Sorting

Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
Click on any column header arrows to sort by that column
Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.

Molecular Profile	Indication/Tumor Type	Response Type	Therapy Name	Approval Status	Evidence Type	Efficacy Evidence	References
MAP2K1 K57N	lymphatic system cancer	sensitive	Trametinib	Case Reports/Case Series	Actionable	In a clinical case study, a patient with refractory Erdheim-Chester disease harboring a MAP2K1 K57N mutation had a sustained clinical response to Mekinist (trametinib) for over 6 months (PMID: 26566875).	26566875
MAP2K1 K57N	lung non-squamous non-small cell carcinoma	predicted - sensitive	Trametinib	Case Reports/Case Series	Actionable	In a clinical case study, Mekinist (trametinib) treatment resulted in a radiographic response with a decrease in the size of multiple metastatic sites in a patient with non-squamous non-small cell lung cancer harboring MAP2K1 K57N (PMID: 36455195).	36455195
MAP2K1 K57N	Advanced Solid Tumor	sensitive	Trametinib	Preclinical - Biochemical	Actionable	In a preclinical study, Mekinist (trametinib) inhibited Erk phosphorylation in transformed cells expressing MAP2K1 K57N in culture (PMID: 32641410).	32641410
MAP2K1 K57N	Advanced Solid Tumor	sensitive	Trametinib	Preclinical - Cell culture	Actionable	In a preclinical study, Mekinist (trametinib) inhibited viability of a transformed cell line expressing MAP2K1 K57N in culture (PMID: 36442478).	36442478
MAP2K1 K57N	Advanced Solid Tumor	resistant	AZD8330	Preclinical - Cell culture	Actionable	In a preclinical study, Map2k1 K57N displayed resistance to the Mek inhibitor, AZD8330, as demonstrated by constitutive activation of Map2k1 in transformed human kidney cells (PMID: 29753091).	29753091
MAP2K1 K57N	colorectal cancer	resistant	Cetuximab	Preclinical	Actionable	In a preclinical study, colorectal cancer cell lines expressing MAP2K1 K57N were insensitive to Erbitux (cetuximab) in culture (PMID: 26644315).	26644315
MAP2K1 K57N	colorectal cancer	resistant	Panitumumab	Preclinical	Actionable	In a preclinical study, colorectal cancer cell lines expressing MAP2K1 K57N were insensitive to Vectibix (panitumumab) in culture (PMID: 26644315).	26644315
MAP2K1 K57N	colorectal cancer	resistant	Panitumumab	Case Reports/Case Series	Actionable	In a retrospective analysis, two patients with metastatic RAS/BRAF wild-type colorectal cancer demonstrated progressive disease following treatment with Vectibix (panitumumab) and via analysis of archived pretreatment tumor biopsy samples and post-progression liquid biopsy both were found to harbor MAP2K1 K57N (PMID: 36419886).	36419886
MAP2K1 K57N	Advanced Solid Tumor	resistant	Regorafenib	Preclinical - Cell culture	Actionable	In a preclinical study, Map2k1 K57N displayed resistance to Stivarga (regorafenib; BAY 73-4506), as demonstrated by constitutive activation of Map2k1 in transformed human kidney cells (PMID: 29753091).	29753091
MAP2K1 K57N	lung adenocarcinoma	sensitive	Selumetinib	Preclinical - Cell culture	Actionable	In a preclinical study, Koselugo (selumetinib) inhibited phosphorylation of ERK in cells expressing MAP2K1 K57N and inhibited MAP2K1 K57N-dependent growth in cell culture (PMID: 18632602).	18632602
MAP2K1 K57N	Advanced Solid Tumor	sensitive	Selumetinib	Preclinical - Cell culture	Actionable	In a preclinical study, Koselugo (selumetinib) inhibited colony formation of transformed cells expressing MAP2K1 K57N in culture (PMID: 25351745).	25351745
MAP2K1 K57N	Advanced Solid Tumor	sensitive	Selumetinib	Preclinical - Cell culture	Actionable	In a preclinical study, Map2k1 K57N displayed sensitivity to the Mek inhibitor, Selumetinib (AZD6244), as demonstrated by reversal of active Map2k1 in transformed human kidney cells (PMID: 29753091).	29753091
MAP2K1 K57N	Advanced Solid Tumor	sensitive	PLX4720	Preclinical - Cell culture	Actionable	In a preclinical study, Map2k1 K57N displayed sensitivity to the Braf inhibitor, PLX4720, as demonstrated by reversal of active Map2k1 in transformed human kidney cells (PMID: 29753091).	29753091
MAP2K1 K57N	Advanced Solid Tumor	resistant	GDC0879	Preclinical - Cell culture	Actionable	In a preclinical study, Map2k1 K57N displayed resistance to the Braf inhibitor, GDC-0879, as demonstrated by constitutive activation of Map2k1 in transformed human kidney cells (PMID: 29753091).	29753091
MAP2K1 K57N	colorectal cancer	sensitive	Panitumumab + Trametinib	Preclinical	Actionable	In a preclinical study, Vectibix (panitumumab) and Mekinist (trametinib) inhibited colorectal cancer cell lines expressing MAP2K1 K57N in culture (PMID: 26644315).	26644315
MAP2K1 K57N	Advanced Solid Tumor	resistant	PD98059	Preclinical - Cell culture	Actionable	In a preclinical study, Map2k1 K57N displayed resistance to the Mek inhibitor, PD98059, as demonstrated by constitutive activation of Map2k1 in transformed human kidney cells (PMID: 29753091).	29753091
MAP2K1 K57N	Advanced Solid Tumor	predicted - sensitive	SCH772984	Preclinical - Biochemical	Actionable	In a preclinical study, SCH772984 inhibited downstream signaling in transformed cells expressing MAP2K1 K57N in culture (PMID: 32641410).	32641410
MAP2K1 K57N	colorectal cancer	sensitive	Cetuximab + Trametinib	Preclinical	Actionable	In a preclinical study, Erbitux (cetuximab) and Mekinist (trametinib) inhibited colorectal cancer cell lines expressing MAP2K1 K57N in culture (PMID: 26644315).	26644315
ALK rearrange MAP2K1 K57N	lung non-small cell carcinoma	sensitive	Ceritinib + Selumetinib	Preclinical - Patient cell culture	Actionable	In a preclinical study, NSCLC patient derived cells harboring an ALK rearrangement demonstrated resistance to Zykadia (ceritinib) due to the acquired mutation MAP2K1 K57N, however, sensitivity was restored to Zykadia (ceritinib) with the addition of Koselugo (selumetinib), resulting in decreased cell survival in culture and reduced tumor volume in xenograft models (PMID: 25394791).	25394791
BRAF V600E MAP2K1 K57N	melanoma	resistant	Vemurafenib	Preclinical - Cell culture	Actionable	In a preclinical study, a melanoma cell line harboring BRAF V600E and expressing MAP2K1 K57N was resistant to Zelboraf (vemurafenib) in culture (PMID: 36442478).	36442478
BRAF V600E MAP2K1 K57N	melanoma	resistant	Cobimetinib	Preclinical - Cell culture	Actionable	In a preclinical study, a melanoma cell line harboring BRAF V600E and expressing MAP2K1 K57N was resistant to Cotellic (cobimetinib) in culture (PMID: 36442478).	36442478
BRAF V600E MAP2K1 K57N	lung adenocarcinoma	predicted - resistant	Dabrafenib + Trametinib	Case Reports/Case Series	Actionable	In a clinical case study, MAP2K1 K57N was identified on the post-progression biopsy in a patient with metastatic lung adenocarcinoma harboring BRAF V600E, who previously responded to the combination of Tafinlar (dabrafenib) and Mekinist (trametinib) (PMID: 32388065).	32388065
BRAF V600E MAP2K1 K57N	melanoma	sensitive	Cobimetinib + Vemurafenib	Preclinical - Cell culture	Actionable	In a preclinical study, the combination of Zelboraf (vemurafenib) and Cotellic (cobimetinib) synergistically inhibited viability of a melanoma cell line harboring BRAF V600E and expressing MAP2K1 K57N in culture (PMID: 36442478).	36442478
MAP2K1 Q56P	lung adenocarcinoma	sensitive	Trametinib	Preclinical	Actionable	In a preclinical study, a lung adenocarcinoma cell line harboring MAP2K1 Q56P demonstrated sensitivity to Mekinist (trametinib), resulting in decreased cell viability (PMID: 26582713).	26582713
MAP2K1 Q56P	stomach cancer	sensitive	Trametinib	Preclinical	Actionable	In a preclinical study, a gastric cancer cell line harboring MAP2K1 Q56P demonstrated sensitivity to Mekinist (trametinib), resulting in decreased cell viability (PMID: 26582713).	26582713
MAP2K1 Q56P	Advanced Solid Tumor	sensitive	Trametinib	Preclinical - Biochemical	Actionable	In a preclinical study, Mekinist (trametinib) inhibited Erk phosphorylation in transformed cells expressing MAP2K1 Q56P in culture (PMID: 32641410).	32641410
MAP2K1 Q56P	Advanced Solid Tumor	sensitive	Trametinib	Preclinical - Cell culture	Actionable	In a preclinical study, Mekinist (trametinib) inhibited viability of a transformed cell line expressing MAP2K1 Q56P in culture (PMID: 36442478).	36442478
MAP2K1 Q56P	Advanced Solid Tumor	resistant	AZD8330	Preclinical - Cell culture	Actionable	In a preclinical study, Map2k1 Q56P displayed resistance to the Mek inhibitor, AZD8330, as demonstrated by constitutive activation of Map2k1 in transformed human kidney cells (PMID: 29753091).	29753091
MAP2K1 Q56P	lung adenocarcinoma	sensitive	PD-0325901	Preclinical	Actionable	In a preclinical study, a lung adenocarcinoma cell line harboring MAP2K1 Q56P demonstrated sensitivity to PD-0325901, resulting in decreased cell viability (PMID: 26582713).	26582713
MAP2K1 Q56P	lung adenocarcinoma	sensitive	Refametinib	Preclinical	Actionable	In a preclinical study, a lung adenocarcinoma cell line harboring MAP2K1 Q56P demonstrated sensitivity to Refametinib (BAY86-9766), resulting in decreased cell viability (PMID: 26582713).	26582713
MAP2K1 Q56P	Advanced Solid Tumor	resistant	Regorafenib	Preclinical - Cell culture	Actionable	In a preclinical study, Map2k1 Q56P displayed resistance to Stivarga (regorafenib; BAY 73-4506), as demonstrated by constitutive activation of Map2k1 in transformed human kidney cells (PMID: 29753091).	29753091
MAP2K1 Q56P	lung adenocarcinoma	sensitive	Selumetinib	Preclinical	Actionable	In a preclinical study, a lung adenocarcinoma cell line harboring MAP2K1 Q56P demonstrated sensitivity to Selumetinib (AZD6244), resulting in decreased cell viability (PMID: 26582713).	26582713
MAP2K1 Q56P	stomach cancer	sensitive	Selumetinib	Preclinical - Cell culture	Actionable	In a preclinical study, Koselugo (selumetinib) inhibited growth of a gastric cancer cell line that requires MAP2K1 Q56P and inhibited phosphorylation of ERK in these cells (PMID: 22327936).	22327936
MAP2K1 Q56P	Advanced Solid Tumor	sensitive	Selumetinib	Preclinical - Cell culture	Actionable	In a preclinical study, Koselugo (selumetinib) inhibited colony formation of transformed cells expressing MAP2K1 Q56P in culture (PMID: 25351745).	25351745
MAP2K1 Q56P	Advanced Solid Tumor	sensitive	Selumetinib	Preclinical - Cell culture	Actionable	In a preclinical study, Map2k1 Q56P displayed sensitivity to the Mek inhibitor, Selumetinib (AZD6244), as demonstrated by reversal of active Map2k1 in transformed human kidney cells (PMID: 29753091).	29753091
MAP2K1 Q56P	Erdheim-Chester disease	predicted - sensitive	Cobimetinib	Case Reports/Case Series	Actionable	In a clinical case study, a patient with refractory Erdheim-Chester disease harboring a MAP2K1 Q56P mutation had a reduction of lymphatic infiltrates to background within a month of receiving Cotellic (cobimetinib) therapy (PMID: 26566875).	26566875
MAP2K1 Q56P	Erdheim-Chester disease	predicted - sensitive	Cobimetinib	Case Reports/Case Series	Actionable	In a Phase II trial, treatment with Cotellic (cobimetinib) in patients with histiocytic neoplasms resulted in a PET overall response rate of 89% (16/18), with complete response in 72% (13/18) and partial response in 17% (3/18), and stable disease in 6% (1/18) of patients, including a complete response in a patient with Erdheim-Chester disease harboring MAP2K1 Q56P (PMID: 30867592; NCT01953926).	30867592
MAP2K1 Q56P	Advanced Solid Tumor	sensitive	PLX4720	Preclinical - Cell culture	Actionable	In a preclinical study, Map2k1 Q56P displayed sensitivity to the Braf inhibitor, PLX4720, as demonstrated by reversal of active Map2k1 in transformed human kidney cells (PMID: 29753091).	29753091
MAP2K1 Q56P	Advanced Solid Tumor	resistant	GDC0879	Preclinical - Cell culture	Actionable	In a preclinical study, Map2k1 Q56P displayed resistance to the Braf inhibitor, GDC-0879, as demonstrated by constitutive activation of Map2k1 in transformed human kidney cells (PMID: 29753091).	29753091
MAP2K1 Q56P	Advanced Solid Tumor	resistant	PD98059	Preclinical - Cell culture	Actionable	In a preclinical study, Map2k1 Q56P displayed resistance to the Mek inhibitor, PD98059, as demonstrated by constitutive activation of Map2k1 in transformed human kidney cells (PMID: 29753091).	29753091
MAP2K1 Q56P	lung cancer	predicted - sensitive	LY3214996	Preclinical - Cell culture	Actionable	In a preclinical study, a lung cancer cell line harboring MAP2K1 Q56P was sensitive to treatment with LY3214996 in culture, demonstrating decreased cell proliferation (PMID: 31744895).	31744895
BRAF V600E MAP2K1 Q56P	melanoma	conflicting	Trametinib	Preclinical	Actionable	In a preclinical study, human melanoma cell lines harboring BRAF V600E expressing MAP2K1 Q56P displayed reduced sensitivity to Mekinist (trametinib) mediated growth inhibition and retained MEK and ERK signaling (PMID: 22389471).	22389471
BRAF V600E MAP2K1 Q56P	melanoma	conflicting	Trametinib	Preclinical - Cell culture	Actionable	In a preclinical study, Mekinist (trametinib) inhibited growth of a melanoma cell line harboring BRAF V600E and expressing MAP2K1 Q56P in culture (PMID: 28986383).	28986383
BRAF V600E MAP2K1 Q56P	melanoma	conflicting	Trametinib	Preclinical - Cell culture	Actionable	In a preclinical study, Mekinist (trametinib) inhibited viability of a melanoma cell line harboring BRAF V600E and expressing MAP2K1 Q56P in culture (PMID: 36442478).	36442478
BRAF V600E MAP2K1 Q56P	melanoma	resistant	Dabrafenib	Preclinical	Actionable	In a preclinical study, melanoma cell lines harboring BRAF V600E expressing MAP2K1 Q56P were resistant to Tafinlar (dabrafenib) mediated growth inhibition and retained MEK and ERK signaling in culture (PMID: 22389471).	22389471
BRAF V600E MAP2K1 Q56P	melanoma	resistant	Vemurafenib	Preclinical - Cell culture	Actionable	In a preclinical study, a melanoma cell line harboring BRAF V600E and expressing MAP2K1 Q56P was resistant to Zelboraf (vemurafenib) in culture (PMID: 28986383).	28986383
BRAF V600E MAP2K1 Q56P	melanoma	resistant	Vemurafenib	Preclinical - Cell culture	Actionable	In a preclinical study, melanoma cells harboring BRAF V600E and expressing MAP2K1 Q56P demonstrated resistance to treatment with Zelboraf (vemurafenib) in culture (PMID: 28655712).	28655712
BRAF V600E MAP2K1 Q56P	melanoma	resistant	Selumetinib	Preclinical - Cell culture	Actionable	In a preclinical study, expression of MAP2K1 Q56P in melanoma cells harboring BRAF V600E conferred resistance to Koselugo (selumetinib) treatment in culture (PMID: 19915144).	19915144
BRAF V600E MAP2K1 Q56P	melanoma	sensitive	Ulixertinib	Preclinical - Cell culture	Actionable	In a preclinical study, Ulixertinib (BVD-523) inhibited proliferation of melanoma cells harboring BRAF V600E and expressing MAP2K1 Q56P in culture (PMID: 28655712).	28655712
BRAF V600E MAP2K1 Q56P	melanoma	resistant	PLX4720	Preclinical	Actionable	In a preclinical study, expression of MAP2K1 Q56P in melanoma cells harboring BRAF V600E conferred resistance to PLX4720 treatment in culture (PMID: 19915144).	19915144
BRAF V600E MAP2K1 Q56P	melanoma	sensitive	Dabrafenib + Trametinib	Preclinical	Actionable	In a preclinical study, the combination of Talfinlar (dabrafenib) and Mekinist (trametinib) resulted in improved growth inhibition in melanoma cells harboring BRAF V600E and expressing MAP2K1 Q56P in culture (PMID: 22389471).	22389471
BRAF V600E MAP2K1 Q56P NRAS Q61R	melanoma	sensitive	AZD0364	Preclinical - Cell line xenograft	Actionable	In a preclinical study, AZD0364 (ATG-017) decreased phosphorylation of Erk target genes and increased expression of apoptosis markers in melanoma cells harboring BRAF V600E, MAP2K1 Q56P, and NRAS Q61R in culture, and inhibited tumor growth in cell line xenograft models (PMID: 33273059).	33273059
MAP2K1 Q56P MAP2K1 H119Y MAP2K1 D351G	colorectal cancer	predicted - sensitive	LY3214996	Preclinical - Cell line xenograft	Actionable	In a preclinical study, LY3214996 treatment in a colorectal cancer cell line harboring MAP2K1 Q56P, MAP2K1 H119Y, and MAP2K1 D351G led to decreased cell proliferation in culture, and inhibition of tumor growth in a cell line xenograft model (PMID: 31744895).	31744895
MAP2K1 K57E	Advanced Solid Tumor	sensitive	Trametinib	Preclinical - Cell culture	Actionable	In a preclinical study, Mekinist (trametinib) inhibited viability of a transformed cell line expressing MAP2K1 K57E in culture (PMID: 36442478).	36442478
MAP2K1 K57E	melanoma	resistant	Dabrafenib	Preclinical	Actionable	In a preclinical study, MAP2K1 (MEK1) K57E mutations restored extracellular signal-regulated kinase (ERK) activation in the presence of Tafinlar (dabrafenib) in cultured melanoma cell lines (PMID: 24463458).	24463458
MAP2K1 K57E	melanoma	sensitive	Binimetinib + Encorafenib	Preclinical - Cell culture	Actionable	In a preclinical study, the combination of Braftovi (encorafenib) and Mektovi (binimetinib) synergistically inhibited viability of a melanoma cell line harboring BRAF V600E and expressing MAP2K1 K57E in culture (PMID: 36442478).	36442478
BRAF V600E MAP2K1 K57E	melanoma	resistant	Dabrafenib	Preclinical - Cell culture	Actionable	In a preclinical study, a melanoma cell line harboring BRAF V600E and expressing MAP2K1 K57E was resistant to Tafinlar (dabrafenib) in culture (PMID: 36442478).	36442478
BRAF V600E MAP2K1 K57E	melanoma	resistant	Dabrafenib	Preclinical - Cell culture	Actionable	In a preclinical study, expression of MAP2K1 K57E in a melanoma cell line harboring BRAF V600E conferred resistance to Tafinlar (dabrafenib) in culture (PMID: 25370473).	25370473
BRAF V600E MAP2K1 K57E	melanoma	resistant	Vemurafenib	Preclinical - Cell culture	Actionable	In a preclinical study, a melanoma cell line harboring BRAF V600E and expressing MAP2K1 K57E was resistant to Zelboraf (vemurafenib) in culture (PMID: 36442478).	36442478
BRAF V600E MAP2K1 K57E	melanoma	resistant	Encorafenib	Preclinical - Cell culture	Actionable	In a preclinical study, a melanoma cell line harboring BRAF V600E and expressing MAP2K1 K57E was resistant to Braftovi (encorafenib) in culture (PMID: 36442478).	36442478
BRAF V600E MAP2K1 K57E	melanoma	resistant	Cobimetinib	Preclinical - Cell culture	Actionable	In a preclinical study, a melanoma cell line harboring BRAF V600E and expressing MAP2K1 K57E was resistant to Cotellic (cobimetinib) in culture (PMID: 36442478).	36442478
BRAF V600E MAP2K1 K57E	melanoma	sensitive	Dabrafenib + Trametinib	Preclinical - Cell culture	Actionable	In a preclinical study, the combination of Tafinlar (dabrafenib) and Mekinist (trametinib) synergistically inhibited viability of a melanoma cell line harboring BRAF V600E and expressing MAP2K1 K57E in culture (PMID: 36442478).	36442478
BRAF V600E MAP2K1 K57E	melanoma	sensitive	Cobimetinib + Vemurafenib	Preclinical - Cell culture	Actionable	In a preclinical study, the combination of Zelboraf (vemurafenib) and Cotellic (cobimetinib) synergistically inhibited viability of a melanoma cell line harboring BRAF V600E and expressing MAP2K1 K57E in culture (PMID: 36442478).	36442478
MAP2K1 P124S	colorectal cancer	predicted - resistant	Cetuximab + Irinotecan	Case Reports/Case Series	Actionable	In a clinical case study, a patient with KRAS/NRAS-wild-type colorectal cancer who progressed on treatment with Erbitux (cetuximab) and Camptosar (irinotecan) was found through ctDNA testing to have acquired MAP2K1 P124S, and preclinical analysis of colorectal cancer cells expressing MAP2K1 P124S demonstrated increased Erk phosphorylation upon treatment with Erbitux (cetuximab) in culture (PMID: 33322618).	33322618
BRAF V600E MAP2K1 P124S	melanoma	resistant	Trametinib	Preclinical - Biochemical	Actionable	In a preclinical study, Mekinist (trametinib) inhibited Erk phosphorylation in a melanoma cell line harboring BRAF V600E and expressing MAP2K1 P124S in culture (PMID: 36442478).	36442478
BRAF V600E MAP2K1 P124S	melanoma	resistant	Trametinib	Preclinical	Actionable	In a preclinical study, melanoma cells harboring BRAF V600E and expressing MAP2K1 P124S demonstrated resistance to treatment with Mekinist (trametinib) in culture (PMID: 24265153).	24265153
BRAF V600E MAP2K1 P124S	melanoma	resistant	Dabrafenib	Preclinical	Actionable	In a preclinical study, melanoma cells harboring BRAF V600E and expressing MAP2K1 P124S demonstrated resistance to treatment with Tafinlar (dabrafenib) in culture (PMID: 24265153).	24265153
BRAF V600E MAP2K1 P124S	colon adenocarcinoma	resistant	Vemurafenib	Preclinical - Cell culture	Actionable	In a preclinical study, a colon adenocarcinoma cell line harboring BRAF V600E and expressing MAP2K1 P124S was resistant to Zelboraf (vemurafenib) in culture (PMID: 36442478).	36442478
BRAF V600E MAP2K1 P124S	melanoma	resistant	Vemurafenib	Preclinical - Cell culture	Actionable	In a preclinical study, a melanoma cell line harboring BRAF V600E and expressing MAP2K1 P124S was resistant to Zelboraf (vemurafenib) in culture (PMID: 36442478).	36442478
BRAF V600E MAP2K1 P124S	melanoma	decreased response	Selumetinib	Preclinical - Patient cell culture	Actionable	In a preclinical study, patient-derived melanoma cells harboring BRAF V600E and MAP2K1 P124S demonstrated decreased sensitivity to Selumetinib (AZD6244) compared to cells harboring BRAF V600E alone in culture (PMID: 22197931).	22197931
BRAF V600E MAP2K1 P124S	melanoma	decreased response	Ulixertinib	Preclinical - Cell culture	Actionable	In a preclinical study, a melanoma cell line harboring BRAF V600E and expressing MAP2K1 P124S was less responsive to Ulixertinib (BVD-523) compared to cells expressing wild-type MAP2K1 in culture (PMID: 36442478).	36442478
BRAF V600E MAP2K1 P124S	colon adenocarcinoma	resistant	Cobimetinib	Preclinical - Cell culture	Actionable	In a preclinical study, a colon adenocarcinoma cell line harboring BRAF V600E and expressing MAP2K1 P124S was resistant to Cotellic (cobimetinib) in culture (PMID: 36442478).	36442478
BRAF V600E MAP2K1 P124S	melanoma	resistant	Cobimetinib	Preclinical - Cell culture	Actionable	In a preclinical study, a melanoma cell line harboring BRAF V600E and expressing MAP2K1 P124S was resistant to Cotellic (cobimetinib) in culture (PMID: 36442478).	36442478
BRAF V600E MAP2K1 P124S	melanoma	sensitive	Binimetinib + Encorafenib	Preclinical - Cell culture	Actionable	In a preclinical study, the combination of Braftovi (encorafenib) and Mektovi (binimetinib) synergistically inhibited viability of a melanoma cell line harboring BRAF V600E and expressing MAP2K1 P124S in culture (PMID: 36442478).	36442478
BRAF V600E MAP2K1 P124S	melanoma	sensitive	Cobimetinib + Vemurafenib	Preclinical - Cell culture	Actionable	In a preclinical study, the combination of Zelboraf (vemurafenib) and Cotellic (cobimetinib) synergistically inhibited viability in a melanoma cell line harboring BRAF V600E and expressing MAP2K1 P124S, and resulted in an additive effect in a melanoma cell line harboring both BRAF V600E and MAP2K1 P124S in culture (PMID: 36442478).	36442478
BRAF V600E MAP2K1 P124S	melanoma	decreased response	Ravoxertinib	Preclinical - Cell culture	Actionable	In a preclinical study, a melanoma cell line harboring BRAF V600E and expressing MAP2K1 P124S was less responsive to Ravoxertinib (GDC-0994) compared to cells expressing wild-type MAP2K1 in culture (PMID: 36442478).	36442478
BRAF V600E MAP2K1 P124S	melanoma	sensitive	VX-11e	Preclinical	Actionable	In a preclinical study, melanoma cells harboring BRAF V600E and expressing MAP2K1 P124S demonstrated sensitivity to treatment with VX-11e, resulting in decreased cell growth in culture (PMID: 24265153).	24265153
BRAF V600K MAP2K1 P124S	melanoma	predicted - resistant	Dabrafenib	Case Reports/Case Series	Actionable	In a clinical case study, Tafinlar (dabrafenib) treatment resulted in disease progression within 5 weeks in a metastatic melanoma patient harboring BRAF V600K and MAP2K1 P124S (PMID: 24265153).	24265153
MAP2K1 D67N	Advanced Solid Tumor	sensitive	Selumetinib	Preclinical - Cell culture	Actionable	In a preclinical study, Koselugo (selumetinib) inhibited colony formation of transformed cells expressing MAP2K1 D67N in culture (PMID: 25351745).	25351745
BRAF V600E MAP2K1 D67N	melanoma	sensitive	Trametinib	Preclinical - Biochemical	Actionable	In a preclinical study, Mekinist (trametinib) inhibited Erk phosphorylation in a melanoma cell line harboring BRAF V600E and expressing MAP2K1 D67N in culture (PMID: 36442478).	36442478
BRAF V600E MAP2K1 D67N	melanoma	sensitive	Trametinib	Preclinical - Cell culture	Actionable	In a preclinical study, Mekinist (trametinib) inhibited growth of a melanoma cell line harboring BRAF V600E and expressing MAP2K1 D67N in culture (PMID: 28986383).	28986383
BRAF V600E MAP2K1 D67N	colon adenocarcinoma	resistant	Vemurafenib	Preclinical - Cell culture	Actionable	In a preclinical study, a colon adenocarcinoma cell line harboring BRAF V600E and expressing MAP2K1 D67N was resistant to Zelboraf (vemurafenib) in culture (PMID: 36442478).	36442478
BRAF V600E MAP2K1 D67N	melanoma	resistant	Vemurafenib	Preclinical - Cell culture	Actionable	In a preclinical study, a melanoma cell line harboring BRAF V600E and expressing MAP2K1 D67N was resistant to Zelboraf (vemurafenib) in culture (PMID: 28986383).	28986383
BRAF V600E MAP2K1 D67N	melanoma	resistant	Vemurafenib	Preclinical - Cell culture	Actionable	In a preclinical study, a melanoma cell line harboring BRAF V600E and expressing MAP2K1 D67N was resistant to Zelboraf (vemurafenib) in culture (PMID: 36442478).	36442478
BRAF V600E MAP2K1 D67N	melanoma	decreased response	Ulixertinib	Preclinical - Cell culture	Actionable	In a preclinical study, a melanoma cell line harboring BRAF V600E and expressing MAP2K1 D67N was less responsive to Ulixertinib (BVD-523) compared to cells expressing wild-type MAP2K1 in culture (PMID: 36442478).	36442478
BRAF V600E MAP2K1 D67N	colon adenocarcinoma	resistant	Cobimetinib	Preclinical - Cell culture	Actionable	In a preclinical study, a colon adenocarcinoma cell line harboring BRAF V600E and expressing MAP2K1 D67N was resistant to Cotellic (cobimetinib) in culture (PMID: 36442478).	36442478
BRAF V600E MAP2K1 D67N	melanoma	resistant	Cobimetinib	Preclinical - Cell culture	Actionable	In a preclinical study, a melanoma cell line harboring BRAF V600E and expressing MAP2K1 D67N was resistant to Cotellic (cobimetinib) in culture (PMID: 36442478).	36442478
BRAF V600E MAP2K1 D67N	melanoma	sensitive	Dabrafenib + Trametinib	Preclinical - Cell culture	Actionable	In a preclinical study, the combination of Tafinlar (dabrafenib) and Mekinist (trametinib) synergistically inhibited viability of a melanoma cell line harboring BRAF V600E and expressing MAP2K1 D67N in culture (PMID: 36442478).	36442478
BRAF V600E MAP2K1 D67N	melanoma	sensitive	Binimetinib + Encorafenib	Preclinical - Cell culture	Actionable	In a preclinical study, the combination of Braftovi (encorafenib) and Mektovi (binimetinib) synergistically inhibited viability of a melanoma cell line harboring BRAF V600E and expressing MAP2K1 D67N in culture (PMID: 36442478).	36442478
BRAF V600E MAP2K1 D67N	melanoma	decreased response	Ravoxertinib	Preclinical - Cell culture	Actionable	In a preclinical study, a melanoma cell line harboring BRAF V600E and expressing MAP2K1 D67N was less responsive to Ravoxertinib (GDC-0994) compared to cells expressing wild-type MAP2K1 in culture (PMID: 36442478).	36442478
MAP2K1 mutant	Erdheim-Chester disease	sensitive	Trametinib	Guideline	Actionable	Mekinist (trametinib) is included in guidelines as first-line or subsequent-line therapy for patients with Erdheim-Chester disease harboring mutations in the MAPK pathway such as ARAF, NRAS, KRAS, MAP2K1/2, PIK3CA, or with no detectable mutations, or for whom testing is not available (NCCN.org).	detail...
MAP2K1 mutant	Erdheim-Chester disease	sensitive	Cobimetinib	Guideline	Actionable	Cotellic (cobimetinib) is included in guidelines as preferred first-line or subsequent-line therapy for patients with Erdheim-Chester disease harboring mutations in the MAPK pathway such as ARAF, NRAS, KRAS, MAP2K1/2, PIK3CA, or with no detectable mutations, or for whom testing is not available (NCCN.org).	detail...
BRAF V600E MAP2K1 I310L	melanoma	sensitive	Vemurafenib	Preclinical - Cell culture	Actionable	In a preclinical study, Zelboraf (vemurafenib) inhibited viability of a melanoma cell line harboring BRAF V600E and expressing MAP2K1 I310L in culture (PMID: 36442478).	36442478
BRAF V600E MAP2K1 I310L	melanoma	sensitive	Encorafenib	Preclinical - Cell culture	Actionable	In a preclinical study, Braftovi (encorafenib) inhibited viability of a melanoma cell line harboring BRAF V600E and expressing MAP2K1 I310L in culture (PMID: 36442478).	36442478
BRAF V600E MAP2K1 I310L	melanoma	sensitive	Binimetinib	Preclinical - Cell culture	Actionable	In a preclinical study, Mektovi (binimetinib) inhibited viability of a melanoma cell line harboring BRAF V600E and expressing MAP2K1 I310L in culture (PMID: 36442478).	36442478
BRAF V600E MAP2K1 I310L	melanoma	sensitive	Cobimetinib	Preclinical - Cell culture	Actionable	In a preclinical study, Cotellic (cobimetinib) inhibited viability of a melanoma cell line harboring BRAF V600E and expressing MAP2K1 I310L in culture (PMID: 36442478).	36442478
MAP2K1 K57T	Advanced Solid Tumor	sensitive	Trametinib	Preclinical - Cell culture	Actionable	In a preclinical study, Mekinist (trametinib) inhibited viability of a transformed cell line expressing MAP2K1 K57T in culture (PMID: 36442478).	36442478
MAP2K1 K57T	colorectal cancer	predicted - resistant	Cetuximab	Case Reports/Case Series	Actionable	In a clinical case study, a patient with colorectal cancer developed liver metastases harboring MAP2K1 K57T that were insensitive to Erbitux (cetuximab) treatment and the mutation was confirmed to cause resistance in human colorectal cancer cell lines in culture (PMID: 26644315).	26644315
MAP2K1 K57T	colorectal cancer	resistant	Panitumumab	Preclinical	Actionable	In a preclinical study, a colorectal cancer cell line expressing MAP2K1 K57T was resistant to Vectibix (panitumumab) in culture (PMID: 26644315).	26644315
MAP2K1 K57T	colorectal cancer	sensitive	Panitumumab + Trametinib	Case Reports/Case Series	Actionable	In a clinical case study, a combination of Vectibix (panitumumab) and Mekinist (trametinib) caused tumor regression in a patient’s colorectal cancer metastases harboring MAP2K1 K57T after being identified pre-clinically as a combination likely to inhibit MAP2K1 K57T expressing colorectal cancer (PMID: 26644315).	26644315
MAP2K1 K57T	colorectal cancer	sensitive	Cetuximab + Trametinib	Preclinical	Actionable	In a preclinical study, Erbitux (cetuximab) and Mekinist (trametinib) inhibited colorectal cancer cell lines expressing MAP2K1 K57T in culture (PMID: 26644315).	26644315
BRAF V600E MAP2K1 K57T	melanoma	resistant	Dabrafenib	Preclinical - Cell culture	Actionable	In a preclinical study, a melanoma cell line harboring BRAF V600E and expressing MAP2K1 K57T was resistant to Tafinlar (dabrafenib) in culture (PMID: 36442478).	36442478
BRAF V600E MAP2K1 K57T	hairy cell leukemia	predicted - resistant	Vemurafenib	Case Reports/Case Series	Actionable	In a clinical case study, a single patient with hairy cell leukemia harboring BRAF V600E, who relapsed after a 38 week remission in response to Zelboraf (vemurafenib) treatment, was found to have acquired multiple clones with Mek/Erk activating mutations, of which the MAP2K1 K57T clone became dominant (PMID: 30341394).	30341394
BRAF V600E MAP2K1 K57T	melanoma	resistant	Vemurafenib	Preclinical - Cell culture	Actionable	In a preclinical study, a melanoma cell line harboring BRAF V600E and expressing MAP2K1 K57T was resistant to Zelboraf (vemurafenib) in culture (PMID: 36442478).	36442478
BRAF V600E MAP2K1 K57T	melanoma	resistant	Encorafenib	Preclinical - Cell culture	Actionable	In a preclinical study, a melanoma cell line harboring BRAF V600E and expressing MAP2K1 K57T was resistant to Braftovi (encorafenib) in culture (PMID: 36442478).	36442478
BRAF V600E MAP2K1 K57T	melanoma	resistant	Binimetinib	Preclinical - Cell culture	Actionable	In a preclinical study, a melanoma cell line harboring BRAF V600E and expressing MAP2K1 K57T was resistant to Mektovi (binimetinib) in culture (PMID: 36442478).	36442478
BRAF V600E MAP2K1 K57T	melanoma	resistant	Cobimetinib	Preclinical - Cell culture	Actionable	In a preclinical study, a melanoma cell line harboring BRAF V600E and expressing MAP2K1 K57T was resistant to Cotellic (cobimetinib) in culture (PMID: 36442478).	36442478
BRAF V600E MAP2K1 K57T	melanoma	sensitive	Dabrafenib + Trametinib	Preclinical - Cell culture	Actionable	In a preclinical study, the combination of Tafinlar (dabrafenib) and Mekinist (trametinib) synergistically inhibited viability of a melanoma cell line harboring BRAF V600E and expressing MAP2K1 K57T in culture (PMID: 36442478).	36442478
BRAF V600E MAP2K1 K57T	melanoma	sensitive	Binimetinib + Encorafenib	Preclinical - Cell culture	Actionable	In a preclinical study, the combination of Braftovi (encorafenib) and Mektovi (binimetinib) synergistically inhibited viability of a melanoma cell line harboring BRAF V600E and expressing MAP2K1 K57T in culture (PMID: 36442478).	36442478
BRAF V600E MAP2K1 K57T	refractory hairy cell leukemia	predicted - sensitive	Cobimetinib + Vemurafenib	Case Reports/Case Series	Actionable	In a clinical case study, a patient with hairy cell leukemia harboring BRAF V600E who relapsed after initial response to Zelboraf (vemurafenib) and was found to have acquired multiple clones with Mek/Erk activating mutations, including MAP2K1 K57T, demonstrated a sustained response greater than 12 months to combined Zelboraf (vemurafenib) and Cotellic (cobimetinib) treatment (PMID: 30341394).	30341394
BRAF V600E MAP2K1 K57T	melanoma	sensitive	Cobimetinib + Vemurafenib	Preclinical - Cell culture	Actionable	In a preclinical study, the combination of Zelboraf (vemurafenib) and Cotellic (cobimetinib) synergistically inhibited viability of a melanoma cell line harboring BRAF V600E and expressing MAP2K1 K57T in culture (PMID: 36442478).	36442478
BRAF V600E MAP2K1 K57T	colorectal cancer	predicted - resistant	Cetuximab + Fluorouracil + Leucovorin + Vemurafenib	Case Reports/Case Series	Actionable	In a Phase II trial (MODUL), a patient with metastatic colorectal cancer harboring BRAF V600E was found to have acquired MAP2K1 K57T prior to progression on treatment with the combination of Zelboraf (vemurafenib), Erbitux (cetuximab), Adrucil (fluorouracil), and Wellcovorin (leucovorin) (PMID: 36921494; NCT02291289).	36921494
MAP2K1 P124L	lymphatic system cancer	predicted - sensitive	Cobimetinib	Case Reports/Case Series	Actionable	In a Phase II trial, treatment with Cotellic (cobimetinib) in patients with histiocytic neoplasms resulted in a PET overall response rate of 89% (16/18), with complete response in 72% (13/18) and partial response in 17% (3/18), and resulted in stable disease in 6% (1/18) of patients, including a complete response in a patient with mixed histiocytosis harboring MAP2K1 P124L (PMID: 30867592; NCT01953926).	30867592
BRAF V600K MAP2K1 P124L	melanoma	sensitive	Trametinib	Preclinical - Cell culture	Actionable	In a preclinical study, Mekinist (trametinib) inhibited ERK signaling and reduced growth of a melanoma cell line harboring BRAF V600K and MAP2K1 P124L in culture (PMID: 25370473).	25370473
BRAF V600K MAP2K1 P124L	melanoma	decreased response	Dabrafenib	Preclinical - Cell culture	Actionable	In a preclinical study, a melanoma cell line harboring BRAF V600K and MAP2K1 P124L demonstrated decreased sensitivity to Tafinlar (dabrafenib) in culture (PMID: 25370473).	25370473
BRAF V600K MAP2K1 P124L	melanoma	predicted - resistant	Dabrafenib + Trametinib	Case Reports/Case Series	Actionable	In a clinical case study, Tafinlar (dabrafenib) and Mekinist (trametinib) combination treatment resulted in disease progression within one month in a metastatic melanoma patient harboring BRAF V600K and MAP2K1 P124L (PMID: 31980996).	31980996
BRAF V600K MAP2K1 P124L	melanoma	sensitive	VX-11e	Preclinical	Actionable	In a preclinical study, VX-11e inhibited ERK signaling and reduced growth of a melanoma cell line harboring BRAF V600K and MAP2K1 P124L in culture (PMID: 25370473).	25370473
BRAF V600E MAP2K1 P124L	melanoma	decreased response	Trametinib	Preclinical - Cell culture	Actionable	In a preclinical study, melanoma cells harboring BRAF V600E and expressing MAP2K1 P124L demonstrated a decreased response to treatment with Mekinist (trametinib) in culture (PMID: 28655712).	28655712
BRAF V600E MAP2K1 P124L	melanoma	predicted - resistant	Vemurafenib	Case Reports/Case Series	Actionable	In a clinical case study, Zelboraf (vemurafenib) treatment resulted in disease progression within 6 weeks in a metastatic melanoma patient harboring BRAF V600E and MAP2K1 P124L (PMID: 24265153).	24265153
BRAF V600E MAP2K1 P124L	melanoma	predicted - resistant	Vemurafenib	Preclinical - Cell culture	Actionable	In a preclinical study, melanoma cells harboring BRAF V600E and expressing MAP2K1 P124L demonstrated a decreased response to treatment with Zelboraf (vemurafenib) in culture (PMID: 28655712).	28655712
BRAF V600E MAP2K1 P124L	melanoma	resistant	Selumetinib	Preclinical	Actionable	In a preclinical study, expression of MAP2K1 P124L in melanoma cells harboring BRAF V600E conferred resistance to Koselugo (selumetinib) in culture (PMID: 19915144).	19915144
BRAF V600E MAP2K1 P124L	melanoma	resistant	PLX4720	Preclinical - Cell culture	Actionable	In a preclinical study, expression of MAP2K1 P124L in melanoma cells harboring BRAF V600E conferred resistance to PLX4720 treatment in culture (PMID: 19915144).	19915144
BRAF V600E MAP2K1 P124L	melanoma	sensitive	PLX4720 + Selumetinib	Preclinical	Actionable	In a preclinical study, combined treatment with Koselugo (selumetinib) and PLX4720 inhibited growth of melanoma cells harboring BRAF V600E and expressing MAP2K1 P124L in culture (PMID: 19915144).	19915144
BRAF V600E MAP2K1 P124L	melanoma	sensitive	Cobimetinib + Vemurafenib	Preclinical - Cell culture	Actionable	In a preclinical study, the combination of Zelboraf (vemurafenib) and Cotellic (cobimetinib) synergistically inhibited viability of a melanoma cell line harboring BRAF V600E and expressing MAP2K1 P124L in culture (PMID: 36442478).	36442478
MAP2K1 P124Q	lymphatic system cancer	predicted - sensitive	Cobimetinib	Case Reports/Case Series	Actionable	In a Phase II trial, treatment with Cotellic (cobimetinib) in patients with histiocytic neoplasms resulted in a PET overall response rate of 89% (16/18), with complete response in 72% (13/18) and partial response in 17% (3/18), and resulted in stable disease in 6% (1/18) of patients, including a complete response in a patient with Erdheim-Chester disease harboring MAP2K1 P124Q (PMID: 30867592; NCT01953926).	30867592
BRAF V600K MAP2K1 P124Q	melanoma	sensitive	Trametinib	Preclinical - Cell culture	Actionable	In a preclinical study, Mekinist (trametinib) inhibited ERK signaling and reduced growth of a melanoma cell line harboring BRAF V600K and MAP2K1 P124Q in culture (PMID: 25370473).	25370473
BRAF V600K MAP2K1 P124Q	melanoma	decreased response	Dabrafenib	Preclinical - Cell culture	Actionable	In a preclinical study, a melanoma cell line harboring BRAF V600K and MAP2K1 P124Q demonstrated decreased sensitivity to Tafinlar (dabrafenib) in culture (PMID: 25370473).	25370473
BRAF V600K MAP2K1 P124Q	melanoma	sensitive	VX-11e	Preclinical - Cell culture	Actionable	In a preclinical study, VX-11e inhibited ERK signaling and reduced growth of a melanoma cell line harboring BRAF V600K and MAP2K1 P124Q in culture (PMID: 25370473).	25370473
BRAF V600E MAP2K1 P124Q	melanoma	decreased response	Dabrafenib	Preclinical - Cell culture	Actionable	In a preclinical study, a melanoma cell line harboring BRAF V600E and expressing MAP2K1 P124Q demonstrated decreased sensitivity to Tafinlar (dabrafenib) in cell culture (PMID: 25370473).	25370473
BRAF V600E MAP2K1 P124Q	melanoma	sensitive	Dabrafenib + Trametinib	Preclinical - Cell culture	Actionable	In a preclinical study, the combination of Tafinlar (dabrafenib) and Mekinist (trametinib) synergistically inhibited viability of a melanoma cell line harboring BRAF V600E and expressing MAP2K1 P124Q in culture (PMID: 36442478).	36442478
BRAF V600E MAP2K1 P124Q	melanoma	sensitive	Binimetinib + Encorafenib	Preclinical - Cell culture	Actionable	In a preclinical study, the combination of Braftovi (encorafenib) and Mektovi (binimetinib) synergistically inhibited viability of a melanoma cell line harboring BRAF V600E and expressing MAP2K1 P124Q in culture (PMID: 36442478).	36442478
BRAF V600E MAP2K1 R349K	melanoma	sensitive	Trametinib	Preclinical - Cell culture	Actionable	In a preclinical study, Mekinist (trametinib) inhibited viability of a melanoma cell line harboring BRAF V600E and expressing MAP2K1 R349K in culture (PMID: 36442478).	36442478
BRAF V600E MAP2K1 R349K	melanoma	sensitive	Dabrafenib	Preclinical - Cell culture	Actionable	In a preclinical study, Tafinlar (dabrafenib) inhibited viability of a melanoma cell line harboring BRAF V600E and expressing MAP2K1 R349K in culture (PMID: 36442478).	36442478
BRAF V600E MAP2K1 R349K	melanoma	sensitive	Vemurafenib	Preclinical - Cell culture	Actionable	In a preclinical study, Zelboraf (vemurafenib) inhibited viability of a melanoma cell line harboring BRAF V600E and expressing MAP2K1 R349K in culture (PMID: 36442478).	36442478
BRAF V600E MAP2K1 R349K	melanoma	sensitive	Encorafenib	Preclinical - Cell culture	Actionable	In a preclinical study, Braftovi (encorafenib) inhibited viability of a melanoma cell line harboring BRAF V600E and expressing MAP2K1 R349K in culture (PMID: 36442478).	36442478
BRAF V600E MAP2K1 R349K	melanoma	sensitive	Binimetinib	Preclinical - Cell culture	Actionable	In a preclinical study, Mektovi (binimetinib) inhibited viability of a melanoma cell line harboring BRAF V600E and expressing MAP2K1 R349K in culture (PMID: 36442478).	36442478
BRAF V600E MAP2K1 R349K	melanoma	sensitive	Cobimetinib	Preclinical - Cell culture	Actionable	In a preclinical study, Cotellic (cobimetinib) inhibited viability of a melanoma cell line harboring BRAF V600E and expressing MAP2K1 R349K in culture (PMID: 36442478).	36442478
BRAF V600E MAP2K1 D351G	melanoma	sensitive	Trametinib	Preclinical - Cell culture	Actionable	In a preclinical study, Mekinist (trametinib) inhibited viability of a melanoma cell line harboring BRAF V600E and expressing MAP2K1 D351G in culture (PMID: 36442478).	36442478
BRAF V600E MAP2K1 D351G	melanoma	sensitive	Dabrafenib	Preclinical - Cell culture	Actionable	In a preclinical study, Tafinlar (dabrafenib) inhibited viability of a melanoma cell line harboring BRAF V600E and expressing MAP2K1 D351G in culture (PMID: 36442478).	36442478
BRAF V600E MAP2K1 D351G	melanoma	sensitive	Encorafenib	Preclinical - Cell culture	Actionable	In a preclinical study, Braftovi (encorafenib) inhibited viability of a melanoma cell line harboring BRAF V600E and expressing MAP2K1 D351G in culture (PMID: 36442478).	36442478
BRAF V600E MAP2K1 D351G	melanoma	sensitive	Binimetinib	Preclinical - Cell culture	Actionable	In a preclinical study, Mektovi (binimetinib) inhibited viability of a melanoma cell line harboring BRAF V600E and expressing MAP2K1 D351G in culture (PMID: 36442478).	36442478
MAP2K1 H119Y	Advanced Solid Tumor	predicted - sensitive	Trametinib	Preclinical - Biochemical	Actionable	In a preclinical study, Mekinist (trametinib) inhibited Erk phosphorylation in transformed cells expressing MAP2K1 H119Y in culture (PMID: 32641410).	32641410
BRAF V600E MAP2K1 H119Y	melanoma	sensitive	Dabrafenib + Trametinib	Preclinical - Cell culture	Actionable	In a preclinical study, the combination of Tafinlar (dabrafenib) and Mekinist (trametinib) synergistically inhibited viability of a melanoma cell line harboring BRAF V600E and expressing MAP2K1 H119Y in culture (PMID: 36442478).	36442478
BRAF V600E MAP2K1 H119Y	melanoma	sensitive	Binimetinib + Encorafenib	Preclinical - Cell culture	Actionable	In a preclinical study, the combination of Braftovi (encorafenib) and Mektovi (binimetinib) synergistically inhibited viability of a melanoma cell line harboring BRAF V600E and expressing MAP2K1 H119Y in culture (PMID: 36442478).	36442478
MAP2K1 C121S	Advanced Solid Tumor	sensitive	Trametinib	Preclinical - Cell culture	Actionable	In a preclinical study, Mekinist (trametinib) inhibited viability of a transformed cell line expressing MAP2K1 C121S in culture (PMID: 36442478).	36442478
MAP2K1 C121S	Advanced Solid Tumor	resistant	AZD8330	Preclinical - Cell culture	Actionable	In a preclinical study, Map2k1 C121S displayed resistance to the Mek inhibitor, AZD8330, as demonstrated by constitutive activation of Map2k1 in transformed human kidney cells (PMID: 29753091).	29753091
MAP2K1 C121S	colorectal cancer	resistant	Cetuximab	Preclinical - Cell culture	Actionable	In a preclinical study, expression of MAP2K1 C121S conferred resistance to Erbitux (cetuximab) in colorectal cancer cells in culture (PMID: 28179366).	28179366
MAP2K1 C121S	Advanced Solid Tumor	resistant	Regorafenib	Preclinical - Cell culture	Actionable	In a preclinical study, Map2k1 C121S displayed resistance to Stivarga (regorafenib; BAY 73-4506), as demonstrated by constitutive activation of Map2k1 in transformed human kidney cells (PMID: 29753091).	29753091
MAP2K1 C121S	Advanced Solid Tumor	sensitive	Selumetinib	Preclinical - Cell culture	Actionable	In a preclinical study, Map2k1 C121S displayed sensitivity to the Mek inhibitor, Selumetinib (AZD6244), as demonstrated by reversal of active Map2k1 in transformed human kidney cells (PMID: 29753091).	29753091
MAP2K1 C121S	Advanced Solid Tumor	sensitive	PLX4720	Preclinical - Cell culture	Actionable	In a preclinical study, Map2k1 C121S displayed sensitivity to the Braf inhibitor, PLX4720, as demonstrated by reversal of active Map2k1 in transformed human kidney cells (PMID: 29753091).	29753091
MAP2K1 C121S	Advanced Solid Tumor	resistant	GDC0879	Preclinical - Cell culture	Actionable	In a preclinical study, Map2k1 C121S displayed resistance to the Braf inhibitor, GDC-0879, as demonstrated by constitutive activation of Map2k1 in transformed human kidney cells (PMID: 29753091).	29753091
MAP2K1 C121S	Advanced Solid Tumor	resistant	PD98059	Preclinical - Cell culture	Actionable	In a preclinical study, Map2k1 C121S displayed resistance to the Mek inhibitor, PD98059, as demonstrated by constitutive activation of Map2k1 in transformed human kidney cells (PMID: 29753091).	29753091
MAP2K1 C121S	colorectal cancer	sensitive	Cetuximab + Trametinib	Preclinical - Cell culture	Actionable	In a preclinical study, the combination of Erbitux (cetuximab) and Mekinist (trametinib) decreased viability of colorectal cancer cells harboring MAP2K1 C121S in culture (PMID: 28179366).	28179366
BRAF V600E MAP2K1 C121S	melanoma	conflicting	Trametinib	Preclinical - Cell culture	Actionable	In a preclinical study, a melanoma cell line harboring BRAF V600E and expressing MAP2K1 C121S was resistant to Mekinist (trametinib) in culture (PMID: 28986383).	28986383
BRAF V600E MAP2K1 C121S	melanoma	conflicting	Trametinib	Preclinical - Cell culture	Actionable	In a preclinical study, Mekinist (trametinib) inhibited viability of a melanoma cell line harboring BRAF V600E and expressing MAP2K1 C121S in culture (PMID: 36442478).	36442478
BRAF V600E MAP2K1 C121S	melanoma	conflicting	Trametinib	Preclinical - Cell culture	Actionable	In a preclinical study, melanoma cells harboring BRAF V600E and expressing MAP2K1 C121S demonstrated resistance to treatment with Mekinist (trametinib) in culture (PMID: 28655712).	28655712
BRAF V600E MAP2K1 C121S	melanoma	sensitive	Dabrafenib	Preclinical - Cell culture	Actionable	In a preclinical study, Tafinlar (dabrafenib) inhibited viability of a melanoma cell line harboring BRAF V600E and expressing MAP2K1 C121S in culture (PMID: 36442478).	36442478
BRAF V600E MAP2K1 C121S	melanoma	resistant	Vemurafenib	Case Reports/Case Series	Actionable	In a clinical case study, a patient harboring BRAF V600E demonstrated an initial response to treatment with Zelboraf (vemurafenib), but progressed following emergence of a MAP2K1 C121S mutation (PMID: 21383288).	21383288
BRAF V600E MAP2K1 C121S	melanoma	resistant	Vemurafenib	Preclinical - Cell culture	Actionable	In a preclinical study, a melanoma cell line harboring BRAF V600E and expressing MAP2K1 C121S was resistant to Zelboraf (vemurafenib) in culture (PMID: 28986383).	28986383
BRAF V600E MAP2K1 C121S	melanoma	resistant	Vemurafenib	Preclinical - Cell culture	Actionable	In a preclinical study, expression of MAP2K1 C121S conferred resistance to Zelboraf (vemurafenib) in melanoma cell lines harboring BRAF V600E, resulting in decreased sensitivity to Zelboraf (vemurafenib)-induced inhibition of MAPK pathway activation and cell proliferation in culture (PMID: 24448821).	24448821
BRAF V600E MAP2K1 C121S	melanoma	sensitive	Encorafenib	Preclinical - Cell culture	Actionable	In a preclinical study, Braftovi (encorafenib) inhibited viability of a melanoma cell line harboring BRAF V600E and expressing MAP2K1 C121S in culture (PMID: 36442478).	36442478
BRAF V600E MAP2K1 C121S	melanoma	sensitive	Binimetinib	Preclinical - Cell culture	Actionable	In a preclinical study, Mektovi (binimetinib) inhibited viability of a melanoma cell line harboring BRAF V600E and expressing MAP2K1 C121S in culture (PMID: 36442478).	36442478
BRAF V600E MAP2K1 C121S	melanoma	decreased response	Selumetinib	Preclinical	Actionable	In a preclinical study, melanoma cell lines harboring BRAF V600E mutation and overexpressing MAP2K1 C121S were less sensitive than those overexpressing wild-type MAP2K1 to Selumetinib (AZD6244)-induced inhibition of Mapk pathway activation and cell proliferation in culture (PMID: 24448821).	24448821
BRAF V600E MAP2K1 C121S	melanoma	sensitive	E6201	Preclinical	Actionable	In a preclinical study, E6201 inhibited Mapk pathway activation and proliferation of melanoma cell line harboring BRAF V600E mutation and overexpressing MAP2K1 C121S in culture (PMID: 24448821).	24448821
BRAF V600E MAP2K1 C121S	melanoma	resistant	PLX4720	Preclinical	Actionable	In a preclinical study, expression of MAP2K1 C121S conferred resistance to PLX4720 in melanoma cells harboring BRAF V600E in culture (PMID: 21383288).	21383288
BRAF V600E MAP2K1 C121S	melanoma	resistant	Dabrafenib + Trametinib	Preclinical	Actionable	In a preclinical study, MAP2K1 C121S conferred resistance to the combination of Tafinlar (dabrafenib) and Mekinist (trametinib) in BRAF V600E-mutant melanoma cells in culture (PMID: 24265154).	24265154
BRAF V600E MAP2K1 C121S	melanoma	sensitive	VX-11e	Preclinical	Actionable	In a preclinical study, melanoma cells harboring BRAF V600E and expressing MAP2K1 C121S demonstrated sensitivity to treatment with VX-11e, resulting in decreased cell growth in culture (PMID: 24265153).	24265153
MAP2K1 C121S MAP2K1 P124R	melanoma	predicted - sensitive	Trametinib	Case Reports/Case Series	Actionable	In a clinical case study, Mekinist (trametinib) resulted in a partial response after two months of treatment in a patient with melanoma harboring MAP2K1 C121S and MAP2K1 P124R (PMID: 36901951).	36901951
BRAF V600E MAP2K1 A106T	melanoma	sensitive	Trametinib	Preclinical - Cell culture	Actionable	In a preclinical study, Mekinist (trametinib) inhibited viability of a melanoma cell line harboring BRAF V600E and expressing MAP2K1 A106T in culture (PMID: 36442478).	36442478
BRAF V600E MAP2K1 A106T	melanoma	sensitive	Dabrafenib	Preclinical - Cell culture	Actionable	In a preclinical study, Tafinlar (dabrafenib) inhibited viability of a melanoma cell line harboring BRAF V600E and expressing MAP2K1 A106T in culture (PMID: 36442478).	36442478
BRAF V600E MAP2K1 A106T	melanoma	sensitive	Encorafenib	Preclinical - Cell culture	Actionable	In a preclinical study, Braftovi (encorafenib) inhibited viability of a melanoma cell line harboring BRAF V600E and expressing MAP2K1 A106T in culture (PMID: 36442478).	36442478
BRAF V600E MAP2K1 A106T	melanoma	sensitive	Binimetinib	Preclinical - Cell culture	Actionable	In a preclinical study, Mektovi (binimetinib) inhibited viability of a melanoma cell line harboring BRAF V600E and expressing MAP2K1 A106T in culture (PMID: 36442478).	36442478
BRAF V600E MAP2K1 A106T	melanoma	sensitive	Cobimetinib	Preclinical - Cell culture	Actionable	In a preclinical study, Cotellic (cobimetinib) inhibited viability of a melanoma cell line harboring BRAF V600E and expressing MAP2K1 A106T in culture (PMID: 36442478).	36442478
MAP2K1 F53L	colorectal cancer	sensitive	Trametinib	Preclinical	Actionable	In a preclinical study, a colorectal cancer cell line harboring MAP2K1 F53L demonstrated sensitivity to Mekinist (trametinib) in culture, resulting in decreased cell viability (PMID: 26582713).	26582713
MAP2K1 F53L	histiocytic sarcoma	predicted - sensitive	Trametinib	Case Reports/Case Series	Actionable	In a clinical case study, Mekinist (trametinib) treatment resulted in resolution of symptoms within 3 days and a durable complete response for over 2 years in a patient with histiocytic sarcoma harboring MAP2K1 F53L (PMID: 29768143).	29768143
MAP2K1 F53L	Advanced Solid Tumor	sensitive	Trametinib	Preclinical - Biochemical	Actionable	In a preclinical study, Mekinist (trametinib) inhibited Erk phosphorylation in transformed cells expressing MAP2K1 F53L in culture (PMID: 32641410).	32641410
MAP2K1 F53L	Advanced Solid Tumor	sensitive	Trametinib	Preclinical - Cell culture	Actionable	In a preclinical study, Mekinist (trametinib) inhibited viability of a transformed cell line expressing MAP2K1 F53L in culture (PMID: 36442478).	36442478
MAP2K1 F53L	Advanced Solid Tumor	resistant	AZD8330	Preclinical - Cell culture	Actionable	In a preclinical study, Map2k1 F53L displayed resistance to the Mek inhibitor, AZD8330, as demonstrated by constitutive activation of Map2k1 in transformed human kidney cells (PMID: 29753091).	29753091
MAP2K1 F53L	colorectal cancer	resistant	Cetuximab	Preclinical - Cell culture	Actionable	In a preclinical study, expression of MAP2K1 F53L conferred resistance to Erbitux (cetuximab) in colorectal cancer cells in culture (PMID: 28179366).	28179366
MAP2K1 F53L	Advanced Solid Tumor	resistant	Regorafenib	Preclinical - Cell culture	Actionable	In a preclinical study, Map2k1 F53L displayed resistance to Stivarga (regorafenib; BAY 73-4506), as demonstrated by constitutive activation of Map2k1 in transformed human kidney cells (PMID: 29753091).	29753091
MAP2K1 F53L	Advanced Solid Tumor	sensitive	Selumetinib	Preclinical - Cell culture	Actionable	In a preclinical study, Koselugo (selumetinib) inhibited colony formation of transformed cells expressing MAP2K1 F53L in culture (PMID: 25351745).	25351745
MAP2K1 F53L	Advanced Solid Tumor	sensitive	Selumetinib	Preclinical - Cell culture	Actionable	In a preclinical study, Map2k1 F53L displayed sensitivity to the Mek inhibitor, Selumetinib (AZD6244), as demonstrated by reversal of active Map2k1 in transformed human kidney cells (PMID: 29753091).	29753091
MAP2K1 F53L	Advanced Solid Tumor	sensitive	PLX4720	Preclinical - Cell culture	Actionable	In a preclinical study, Map2k1 F53L displayed sensitivity to the Braf inhibitor, PLX4720, as demonstrated by reversal of active Map2k1 in transformed human kidney cells (PMID: 29753091).	29753091
MAP2K1 F53L	Advanced Solid Tumor	resistant	GDC0879	Preclinical - Cell culture	Actionable	In a preclinical study, Map2k1 F53L displayed resistance to the Braf inhibitor, GDC-0879, as demonstrated by constitutive activation of Map2k1 in transformed human kidney cells (PMID: 29753091).	29753091
MAP2K1 F53L	Advanced Solid Tumor	resistant	PD98059	Preclinical - Cell culture	Actionable	In a preclinical study, Map2k1 F53L displayed resistance to the Mek inhibitor, PD98059, as demonstrated by constitutive activation of Map2k1 in transformed human kidney cells (PMID: 29753091).	29753091
MAP2K1 F53L	colorectal cancer	sensitive	Cetuximab + Trametinib	Preclinical - Cell culture	Actionable	In a preclinical study, the combination of Erbitux (cetuximab) and Mekinist (trametinib) decreased viability of colorectal cancer cells harboring MAP2K1 F53L in culture (PMID: 28179366).	28179366
BRAF V600E MAP2K1 F53L	melanoma	conflicting	Trametinib	Preclinical - Biochemical	Actionable	In a preclinical study, Mekinist (trametinib) inhibited Erk phosphorylation in a melanoma cell line harboring BRAF V600E and expressing MAP2K1 F53L in culture (PMID: 36442478).	36442478
BRAF V600E MAP2K1 F53L	melanoma	conflicting	Trametinib	Preclinical - Cell culture	Actionable	In a preclinical study, Mekinist (trametinib) inhibited Mek but not Erk phosphorylation and did not inhibit proliferation in a melanoma cell line harboring BRAF V600E and expressing MAP2K1 F53L in culture (PMID: 36622773).	36622773
BRAF V600E MAP2K1 F53L	melanoma	resistant	Dabrafenib	Preclinical - Cell culture	Actionable	In a preclinical study, a melanoma cell line harboring BRAF V600E and expressing MAP2K1 F53L was resistant to Tafinlar (dabrafenib) in culture (PMID: 36442478).	36442478
BRAF V600E MAP2K1 F53L	melanoma	resistant	Dabrafenib	Preclinical - Cell culture	Actionable	In a preclinical study, Tafinlar (dabrafenib) inhibited Erk and Mek phosphorylation but did not inhibit proliferation in a melanoma cell line harboring BRAF V600E and expressing MAP2K1 F53L in culture (PMID: 36622773).	36622773
BRAF V600E MAP2K1 F53L	melanoma	resistant	Vemurafenib	Preclinical - Cell culture	Actionable	In a preclinical study, a melanoma cell line harboring BRAF V600E and expressing MAP2K1 F53L was resistant to Zelboraf (vemurafenib) in culture (PMID: 36442478).	36442478
BRAF V600E MAP2K1 F53L	melanoma	resistant	Encorafenib	Preclinical - Cell culture	Actionable	In a preclinical study, a melanoma cell line harboring BRAF V600E and expressing MAP2K1 F53L was resistant to Braftovi (encorafenib) in culture (PMID: 36442478).	36442478
BRAF V600E MAP2K1 F53L	melanoma	sensitive	Dabrafenib + Trametinib	Preclinical - Cell culture	Actionable	In a preclinical study, the combination of Tafinlar (dabrafenib) and Mekinist (trametinib) synergistically inhibited viability of a melanoma cell line harboring BRAF V600E and expressing MAP2K1 F53L in culture (PMID: 36442478).	36442478
BRAF V600E MAP2K1 F53L	melanoma	sensitive	Binimetinib + Encorafenib	Preclinical - Cell culture	Actionable	In a preclinical study, the combination of Braftovi (encorafenib) and Mektovi (binimetinib) synergistically inhibited viability of a melanoma cell line harboring BRAF V600E and expressing MAP2K1 F53L in culture (PMID: 36442478).	36442478
BRAF V600E MAP2K1 F53L	melanoma	sensitive	Cobimetinib + Vemurafenib	Preclinical - Cell culture	Actionable	In a preclinical study, the combination of Zelboraf (vemurafenib) and Cotellic (cobimetinib) synergistically inhibited viability in a melanoma cell line harboring BRAF V600E and expressing MAP2K1 F53L in culture (PMID: 36442478).	36442478
BRAF V600E MAP2K1 F53L	colorectal cancer	predicted - resistant	Binimetinib + Cetuximab + Encorafenib	Case Reports/Case Series	Actionable	In a Phase III (BEACON CRC) trial, two patients with colorectal cancer harboring BRAF V600E demonstrated resistance to treatment with the combination of Braftovi (encorafenib), Mektovi (binimetinib), and Erbitux (cetuximab), and were found to have acquired MAP2K1 F53L in end-of-treatment ctDNA samples (PMID: 39313594; NCT02928224).	39313594
BRAF V600E MAP2K1 F53L	melanoma	sensitive	DS03090629	Preclinical - Cell culture	Actionable	In a preclinical study, DS03090629 inhibited Erk and Mek phosphorylation and proliferation in a melanoma cell line harboring BRAF V600E and expressing MAP2K1 F53L in culture (PMID: 36622773).	36622773
BRAF V600E MAP2K1 A132V	melanoma	sensitive	Trametinib	Preclinical - Cell culture	Actionable	In a preclinical study, Mekinist (trametinib) inhibited viability of a melanoma cell line harboring BRAF V600E and expressing MAP2K1 A132V in culture (PMID: 36442478).	36442478
BRAF V600E MAP2K1 A132V	melanoma	sensitive	Dabrafenib	Preclinical - Cell culture	Actionable	In a preclinical study, Tafinlar (dabrafenib) inhibited viability of a melanoma cell line harboring BRAF V600E and expressing MAP2K1 A132V in culture (PMID: 36442478).	36442478
BRAF V600E MAP2K1 A132V	melanoma	sensitive	Vemurafenib	Preclinical - Cell culture	Actionable	In a preclinical study, Zelboraf (vemurafenib) inhibited viability of a melanoma cell line harboring BRAF V600E and expressing MAP2K1 A132V in culture (PMID: 36442478).	36442478
BRAF V600E MAP2K1 A132V	melanoma	sensitive	Encorafenib	Preclinical - Cell culture	Actionable	In a preclinical study, Braftovi (encorafenib) inhibited viability of a melanoma cell line harboring BRAF V600E and expressing MAP2K1 A132V in culture (PMID: 36442478).	36442478
BRAF V600E MAP2K1 A132V	melanoma	sensitive	Binimetinib	Preclinical - Cell culture	Actionable	In a preclinical study, Mektovi (binimetinib) inhibited viability of a melanoma cell line harboring BRAF V600E and expressing MAP2K1 A132V in culture (PMID: 36442478).	36442478
BRAF V600E MAP2K1 A132V	melanoma	sensitive	Cobimetinib	Preclinical - Cell culture	Actionable	In a preclinical study, Cotellic (cobimetinib) inhibited viability of a melanoma cell line harboring BRAF V600E and expressing MAP2K1 A132V in culture (PMID: 36442478).	36442478
BRAF V600E MAP2K1 D336H	melanoma	sensitive	Trametinib	Preclinical - Cell culture	Actionable	In a preclinical study, Mekinist (trametinib) inhibited viability of a melanoma cell line harboring BRAF V600E and expressing MAP2K1 D336H in culture (PMID: 36442478).	36442478
BRAF V600E MAP2K1 D336H	melanoma	sensitive	Dabrafenib	Preclinical - Cell culture	Actionable	In a preclinical study, Tafinlar (dabrafenib) inhibited viability of a melanoma cell line harboring BRAF V600E and expressing MAP2K1 D336H in culture (PMID: 36442478).	36442478
BRAF V600E MAP2K1 D336H	melanoma	sensitive	Vemurafenib	Preclinical - Cell culture	Actionable	In a preclinical study, Zelboraf (vemurafenib) inhibited viability of a melanoma cell line harboring BRAF V600E and expressing MAP2K1 D336H in culture (PMID: 36442478).	36442478
BRAF V600E MAP2K1 D336H	melanoma	sensitive	Encorafenib	Preclinical - Cell culture	Actionable	In a preclinical study, Braftovi (encorafenib) inhibited viability of a melanoma cell line harboring BRAF V600E and expressing MAP2K1 D336H in culture (PMID: 36442478).	36442478
BRAF V600E MAP2K1 D336H	melanoma	sensitive	Binimetinib	Preclinical - Cell culture	Actionable	In a preclinical study, Mektovi (binimetinib) inhibited viability of a melanoma cell line harboring BRAF V600E and expressing MAP2K1 D336H in culture (PMID: 36442478).	36442478
BRAF V600E MAP2K1 D336H	melanoma	sensitive	Cobimetinib	Preclinical - Cell culture	Actionable	In a preclinical study, Cotellic (cobimetinib) inhibited viability of a melanoma cell line harboring BRAF V600E and expressing MAP2K1 D336H in culture (PMID: 36442478).	36442478
MAP2K1 E102_I103del	histiocytosis	predicted - sensitive	Trametinib	Case Reports/Case Series	Actionable	In a clinical case study, Mekinist (trametinib) treatment resulted in complete remission of cutaneous lesions and resolution of the pituitary gland enlargement and associated symptoms in a patient with Langerhans cell histiocytosis harboring MAP2K1 E102_I103del (PMID: 35172489).	35172489
MAP2K1 E102_I103del	histiocytosis	predicted - sensitive	Trametinib	Case Reports/Case Series	Actionable	In a clinical case study, Mekinist (trametinib) treatment resulted in symptom improvement, resolution of the partial pneumothorax, and reduction in cystic lesions in a patient with pulmonary Langerhans cell histiocytosis harboring MAP2K1 E102_I103del (PMID: 29694792).	29694792
MAP2K1 E102_I103del	histiocytosis	predicted - sensitive	Trametinib	Case Reports/Case Series	Actionable	In a clinical case study, treatment with Mekinist (trametinib) resulted in complete remission in a pediatric patient with Langerhans cell histiocytosis harboring MAP2K1 E102_I103del, with treatment ongoing for at least 10 months (PMID: 36730444).	36730444
MAP2K1 E102_I103del	Advanced Solid Tumor	resistant	Trametinib	Preclinical - Biochemical	Actionable	In a preclinical study, transformed cells expressing MAP2K1 E102_I103del were less sensitive to Mekinist (trametinib) compared to to similar mutations in the negative regulatory domain of the Map2k1 protein in culture (PMID: 32641410).	32641410
MAP2K1 E102_I103del	Advanced Solid Tumor	resistant	Trametinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing MAP2K1 E102_I103del were resistant to Mekinist (trametinib) in culture (PMID: 36442478).	36442478
MAP2K1 E102_I103del	histiocytosis	predicted - sensitive	Cobimetinib	Case Reports/Case Series	Actionable	In a clinical case study, Cotellic (cobimetinib) resulted in dramatic clinical improvement and decreased variant allele frequency in a patient with mixed histiocytosis harboring MAP2K1 E102_I103del, with the patient remaining disease free at least 3 years after treatment initiation (PMID: 36406830).	36406830
MAP2K1 E102_I103del	Advanced Solid Tumor	predicted - sensitive	SCH772984	Preclinical - Biochemical	Actionable	In a preclinical study, SCH772984 inhibited downstream signaling in transformed cells expressing MAP2K1 E102_I103del in culture (PMID: 32641410).	32641410
BRAF V600E MAP2K1 E102_I103del	melanoma	resistant	Dabrafenib	Preclinical - Cell culture	Actionable	In a preclinical study, a melanoma cell line harboring BRAF V600E and expressing MAP2K1 E102_I103del was resistant to Tafinlar (dabrafenib) in culture (PMID: 36442478).	36442478
BRAF V600E MAP2K1 E102_I103del	melanoma	resistant	Vemurafenib	Preclinical - Cell culture	Actionable	In a preclinical study, a melanoma cell line harboring BRAF V600E and expressing MAP2K1 E102_I103del was resistant to Zelboraf (vemurafenib) in culture (PMID: 36442478).	36442478
BRAF V600E MAP2K1 E102_I103del	melanoma	resistant	Encorafenib	Preclinical - Cell culture	Actionable	In a preclinical study, a melanoma cell line harboring BRAF V600E and expressing MAP2K1 E102_I103del was resistant to Braftovi (encorafenib) in culture (PMID: 36442478).	36442478
BRAF V600E MAP2K1 E102_I103del	melanoma	resistant	Binimetinib	Preclinical - Cell culture	Actionable	In a preclinical study, a melanoma cell line harboring BRAF V600E and expressing MAP2K1 E102_I103del was resistant to Mektovi (binimetinib) in culture (PMID: 36442478).	36442478
BRAF V600E MAP2K1 E102_I103del	melanoma	sensitive	Dabrafenib + Trametinib	Preclinical - Cell culture	Actionable	In a preclinical study, the combination of Tafinlar (dabrafenib) and Mekinist (trametinib) synergistically inhibited viability of a melanoma cell line harboring BRAF V600E and expressing MAP2K1 E102_I103del in culture (PMID: 36442478).	36442478
BRAF V600E MAP2K1 E102_I103del	melanoma	sensitive	Binimetinib + Encorafenib	Preclinical - Cell culture	Actionable	In a preclinical study, the combination of Braftovi (encorafenib) and Mektovi (binimetinib) synergistically inhibited viability of a melanoma cell line harboring BRAF V600E and expressing MAP2K1 E102_I103del in culture (PMID: 36442478).	36442478
BRAF V600E MAP2K1 E102_I103del	melanoma	sensitive	Cobimetinib + Vemurafenib	Preclinical - Cell culture	Actionable	In a preclinical study, the combination of Zelboraf (vemurafenib) and Cotellic (cobimetinib) synergistically inhibited viability of a melanoma cell line harboring BRAF V600E and expressing MAP2K1 E102_I103del in culture (PMID: 36442478).	36442478
MAP2K1 E203K	Advanced Solid Tumor	sensitive	Trametinib	Preclinical - Cell culture	Actionable	In a preclinical study, Mekinist (trametinib) inhibited viability of a transformed cell line expressing MAP2K1 E203K in culture (PMID: 36442478).	36442478
MAP2K1 E203K	Advanced Solid Tumor	predicted - sensitive	SCH772984	Preclinical - Biochemical	Actionable	In a preclinical study, SCH772984 inhibited downstream signaling in transformed cells expressing MAP2K1 E203K in culture (PMID: 32641410).	32641410
BRAF V600E MAP2K1 E203K	melanoma	conflicting	Trametinib	Preclinical - Biochemical	Actionable	In a preclinical study, Mekinist (trametinib) inhibited Erk phosphorylation in a melanoma cell line harboring BRAF V600E and expressing MAP2K1 E203K in culture (PMID: 36442478).	36442478
BRAF V600E MAP2K1 E203K	melanoma	conflicting	Trametinib	Preclinical - Cell culture	Actionable	In a preclinical study, Mekinist (trametinib) inhibited growth of a melanoma cell line harboring BRAF V600E and expressing MAP2K1 E203K in culture (PMID: 28986383).	28986383
BRAF V600E MAP2K1 E203K	melanoma	conflicting	Trametinib	Preclinical - Cell culture	Actionable	In a preclinical study, melanoma cells harboring BRAF V600E and expressing MAP2K1 E203K demonstrated resistance to treatment with Mekinist (trametinib) in culture (PMID: 28655712).	28655712
BRAF V600E MAP2K1 E203K	melanoma	resistant	Dabrafenib	Preclinical - Cell culture	Actionable	In a preclinical study, a melanoma cell line harboring BRAF V600E and expressing MAP2K1 E203K was resistant to Tafinlar (dabrafenib) in culture (PMID: 36442478).	36442478
BRAF V600E MAP2K1 E203K	colon adenocarcinoma	resistant	Vemurafenib	Preclinical - Cell culture	Actionable	In a preclinical study, a colon adenocarcinoma cell line harboring BRAF V600E and expressing MAP2K1 E203K was resistant to Zelboraf (vemurafenib) in culture (PMID: 36442478).	36442478
BRAF V600E MAP2K1 E203K	melanoma	resistant	Vemurafenib	Preclinical - Cell culture	Actionable	In a preclinical study, a melanoma cell line harboring BRAF V600E and expressing MAP2K1 E203K was resistant to Zelboraf (vemurafenib) in culture (PMID: 28986383).	28986383
BRAF V600E MAP2K1 E203K	melanoma	resistant	Vemurafenib	Preclinical - Cell culture	Actionable	In a preclinical study, a melanoma cell line harboring BRAF V600E and expressing MAP2K1 E203K was resistant to Zelboraf (vemurafenib) in culture (PMID: 36442478).	36442478
BRAF V600E MAP2K1 E203K	melanoma	resistant	Vemurafenib	Preclinical - Cell culture	Actionable	In a preclinical study, melanoma cells harboring BRAF V600E and expressing MAP2K1 E203K demonstrated resistance to treatment with Zelboraf (vemurafenib) in culture (PMID: 28655712).	28655712
BRAF V600E MAP2K1 E203K	melanoma	resistant	Encorafenib	Preclinical - Cell culture	Actionable	In a preclinical study, a melanoma cell line harboring BRAF V600E and expressing MAP2K1 E203K was resistant to Braftovi (encorafenib) in culture (PMID: 36442478).	36442478
BRAF V600E MAP2K1 E203K	melanoma	conflicting	Ulixertinib	Preclinical - Cell culture	Actionable	In a preclinical study, a melanoma cell line harboring BRAF V600E and expressing MAP2K1 E203K was less responsive to Ulixertinib (BVD-523) compared to cells expressing wild-type MAP2K1 in culture (PMID: 36442478).	36442478
BRAF V600E MAP2K1 E203K	melanoma	conflicting	Ulixertinib	Preclinical - Cell culture	Actionable	In a preclinical study, Ulixertinib (BVD-523) inhibited proliferation of melanoma cells harboring BRAF V600E and expressing MAP2K1 E203K in culture (PMID: 28655712).	28655712
BRAF V600E MAP2K1 E203K	colon adenocarcinoma	resistant	Cobimetinib	Preclinical - Cell culture	Actionable	In a preclinical study, a colon adenocarcinoma cell line harboring BRAF V600E and expressing MAP2K1 E203K was resistant to Cotellic (cobimetinib) in culture (PMID: 36442478).	36442478
BRAF V600E MAP2K1 E203K	melanoma	resistant	Cobimetinib	Preclinical - Cell culture	Actionable	In a preclinical study, a melanoma cell line harboring BRAF V600E and expressing MAP2K1 E203K was resistant to Cotellic (cobimetinib) in culture (PMID: 36442478).	36442478
BRAF V600E MAP2K1 E203K	melanoma	sensitive	Dabrafenib + Trametinib	Preclinical - Cell culture	Actionable	In a preclinical study, the combination of Tafinlar (dabrafenib) and Mekinist (trametinib) synergistically inhibited viability of a melanoma cell line harboring BRAF V600E and expressing MAP2K1 E203K in culture (PMID: 36442478).	36442478
BRAF V600E MAP2K1 E203K	melanoma	sensitive	Binimetinib + Encorafenib	Preclinical - Cell culture	Actionable	In a preclinical study, the combination of Braftovi (encorafenib) and Mektovi (binimetinib) synergistically inhibited viability of a melanoma cell line harboring BRAF V600E and expressing MAP2K1 E203K in culture (PMID: 36442478).	36442478
BRAF V600E MAP2K1 E203K	melanoma	sensitive	Cobimetinib + Vemurafenib	Preclinical - Cell culture	Actionable	In a preclinical study, the combination of Zelboraf (vemurafenib) and Cotellic (cobimetinib) synergistically inhibited viability of a melanoma cell line harboring BRAF V600E and expressing MAP2K1 E203K in culture (PMID: 36442478).	36442478
BRAF V600E MAP2K1 E203K	melanoma	decreased response	Ravoxertinib	Preclinical - Cell culture	Actionable	In a preclinical study, a melanoma cell line harboring BRAF V600E and expressing MAP2K1 E203K was less responsive to Ravoxertinib (GDC-0994) compared to cells expressing wild-type MAP2K1 in culture (PMID: 36442478).	36442478
MAP2K1 E203K PIK3CA amp	skin squamous cell carcinoma	predicted - sensitive	Metformin + Trametinib	Case Reports/Case Series	Actionable	In a clinical case study, a combination of Glucophage (metformin) and Mekinist (trametinib) resulted in a complete clinical response and continued remission for over two years in a patient with cutaneous squamous cell carcinoma with amplification of PIK3CA and harboring MAP2K1 E203K (PMID: 35005996).	35005996
MAP2K1 F129L	ovarian serous carcinoma	resistant	Trametinib	Preclinical - Cell culture	Actionable	In a preclinical study, MAP2K1 F129L was identified in a low grade serous ovarian cancer cell line that developed resistance to treatment with Mekinist (trametinib) in culture (PMID: 36198031).	36198031
MAP2K1 F129L	Advanced Solid Tumor	sensitive	Trametinib	Preclinical - Cell culture	Actionable	In a preclinical study, Mekinist (trametinib) inhibited viability of a transformed cell line expressing MAP2K1 F129L in culture (PMID: 36442478).	36442478
MAP2K1 F129L	Advanced Solid Tumor	resistant	AZD8330	Preclinical - Cell culture	Actionable	In a preclinical study, Map2k1 F129L displayed resistance to the Mek inhibitor, AZD8330, as demonstrated by constitutive activation of Map2k1 in transformed human kidney cells (PMID: 29753091).	29753091
MAP2K1 F129L	ovarian serous carcinoma	resistant	Binimetinib	Preclinical - Cell culture	Actionable	In a preclinical study, a low grade serous ovarian cancer cell line harboring MAP2K1 F129L was resistant to treatment with Mektovi (binimetinib) in culture (PMID: 36198031).	36198031
MAP2K1 F129L	ovarian serous carcinoma	resistant	Refametinib	Preclinical - Cell culture	Actionable	In a preclinical study, a low grade serous ovarian cancer cell line harboring MAP2K1 F129L was resistant to treatment with Refametinib (BAY86-9766) in culture (PMID: 36198031).	36198031
MAP2K1 F129L	Advanced Solid Tumor	resistant	Regorafenib	Preclinical - Cell culture	Actionable	In a preclinical study, Map2k1 F129L displayed resistance to Stivarga (regorafenib; BAY 73-4506), as demonstrated by constitutive activation of Map2k1 in transformed human kidney cells (PMID: 29753091).	29753091
MAP2K1 F129L	ovarian serous carcinoma	resistant	Selumetinib	Preclinical - Cell culture	Actionable	In a preclinical study, a low grade serous ovarian cancer cell line harboring MAP2K1 F129L was resistant to treatment with Koselugo (selumetinib) in culture (PMID: 36198031).	36198031
MAP2K1 F129L	Advanced Solid Tumor	sensitive	Selumetinib	Preclinical - Cell culture	Actionable	In a preclinical study, Map2k1 F129L displayed sensitivity to the Mek inhibitor, Selumetinib (AZD6244), as demonstrated by reversal of active Map2k1 in transformed human kidney cells (PMID: 29753091).	29753091
MAP2K1 F129L	Advanced Solid Tumor	sensitive	PLX4720	Preclinical - Cell culture	Actionable	In a preclinical study, Map2k1 F129L displayed sensitivity to the Braf inhibitor, PLX4720, as demonstrated by reversal of active Map2k1 in transformed human kidney cells (PMID: 29753091).	29753091
MAP2K1 F129L	Advanced Solid Tumor	resistant	GDC0879	Preclinical - Cell culture	Actionable	In a preclinical study, Map2k1 F129L displayed resistance to the Braf inhibitor, GDC-0879, as demonstrated by constitutive activation of Map2k1 in transformed human kidney cells (PMID: 29753091).	29753091
MAP2K1 F129L	Advanced Solid Tumor	resistant	PD98059	Preclinical - Cell culture	Actionable	In a preclinical study, Map2k1 F129L displayed resistance to the Mek inhibitor, PD98059, as demonstrated by constitutive activation of Map2k1 in transformed human kidney cells (PMID: 29753091).	29753091
MAP2K1 F129L	colorectal cancer	sensitive	RO4927350	Preclinical - Cell line xenograft	Actionable	In a preclinical study, a colorectal cancer cell line harboring MAP2K1 F129L demonstrated sensitivity to treatment with RO4927350 in culture and in cell line xenograft models, demonstrating inhibition of tumor growth (PMID: 21705440).	21705440
BRAF V600E MAP2K1 F129L	melanoma	sensitive	Dabrafenib + Trametinib	Preclinical - Cell culture	Actionable	In a preclinical study, the combination of Tafinlar (dabrafenib) and Mekinist (trametinib) synergistically inhibited viability of a melanoma cell line harboring BRAF V600E and expressing MAP2K1 F129L in culture (PMID: 36442478).	36442478
BRAF V600E MAP2K1 F129L	melanoma	sensitive	Binimetinib + Encorafenib	Preclinical - Cell culture	Actionable	In a preclinical study, the combination of Braftovi (encorafenib) and Mektovi (binimetinib) synergistically inhibited viability of a melanoma cell line harboring BRAF V600E and expressing MAP2K1 F129L in culture (PMID: 36442478).	36442478
MAP2K1 F53_Q58delinsL	Advanced Solid Tumor	sensitive	Trametinib	Preclinical - Cell culture	Actionable	In a preclinical study, Mekinist (trametinib) inhibited viability of a transformed cell line expressing MAP2K1 F53_Q58delinsL in culture (PMID: 36442478).	36442478
BRAF V600E MAP2K1 F53_Q58delinsL	melanoma	resistant	Trametinib	Preclinical - Cell culture	Actionable	In a preclinical study, a melanoma cell line harboring BRAF V600E and expressing MAP2K1 F53_Q58delinsL was resistant to Mekinist (trametinib) in culture (PMID: 36442478).	36442478
BRAF V600E MAP2K1 F53_Q58delinsL	melanoma	resistant	Dabrafenib	Preclinical - Cell culture	Actionable	In a preclinical study, a melanoma cell line harboring BRAF V600E and expressing MAP2K1 F53_Q58delinsL was resistant to Tafinlar (dabrafenib) in culture (PMID: 36442478).	36442478
BRAF V600E MAP2K1 F53_Q58delinsL	melanoma	resistant	Vemurafenib	Preclinical - Cell culture	Actionable	In a preclinical study, a melanoma cell line harboring BRAF V600E and expressing MAP2K1 F53_Q58delinsL was resistant to Zelboraf (vemurafenib) in culture (PMID: 36442478).	36442478
BRAF V600E MAP2K1 F53_Q58delinsL	melanoma	resistant	Encorafenib	Preclinical - Cell culture	Actionable	In a preclinical study, a melanoma cell line harboring BRAF V600E and expressing MAP2K1 F53_Q58delinsL was resistant to Braftovi (encorafenib) in culture (PMID: 36442478).	36442478
BRAF V600E MAP2K1 F53_Q58delinsL	melanoma	resistant	Binimetinib	Preclinical - Cell culture	Actionable	In a preclinical study, a melanoma cell line harboring BRAF V600E and expressing MAP2K1 F53_Q58delinsL was resistant to Mektovi (binimetinib) in culture (PMID: 36442478).	36442478
BRAF V600E MAP2K1 F53_Q58delinsL	melanoma	resistant	Cobimetinib	Preclinical - Cell culture	Actionable	In a preclinical study, a melanoma cell line harboring BRAF V600E and expressing MAP2K1 F53_Q58delinsL was resistant to Cotellic (cobimetinib) in culture (PMID: 36442478).	36442478
BRAF V600E MAP2K1 F53_Q58delinsL	melanoma	sensitive	Dabrafenib + Trametinib	Preclinical - Cell culture	Actionable	In a preclinical study, the combination of Tafinlar (dabrafenib) and Mekinist (trametinib) synergistically inhibited viability of a melanoma cell line harboring BRAF V600E and expressing MAP2K1 F53_Q58delinsL in culture (PMID: 36442478).	36442478
BRAF V600E MAP2K1 F53_Q58delinsL	melanoma	sensitive	Binimetinib + Encorafenib	Preclinical - Cell culture	Actionable	In a preclinical study, the combination of Braftovi (encorafenib) and Mektovi (binimetinib) synergistically inhibited viability of a melanoma cell line harboring BRAF V600E and expressing MAP2K1 F53_Q58delinsL in culture (PMID: 36442478).	36442478
MAP2K1 F53I	Advanced Solid Tumor	sensitive	Trametinib	Preclinical - Cell culture	Actionable	In a preclinical study, Mekinist (trametinib) inhibited viability of a transformed cell line expressing MAP2K1 F53I in culture (PMID: 36442478).	36442478
BRAF V600E MAP2K1 F53I	melanoma	resistant	Dabrafenib	Preclinical - Cell culture	Actionable	In a preclinical study, a melanoma cell line harboring BRAF V600E and expressing MAP2K1 F53I was resistant to Tafinlar (dabrafenib) in culture (PMID: 36442478).	36442478
BRAF V600E MAP2K1 F53I	melanoma	resistant	Vemurafenib	Preclinical - Cell culture	Actionable	In a preclinical study, a melanoma cell line harboring BRAF V600E and expressing MAP2K1 F53I was resistant to Zelboraf (vemurafenib) in culture (PMID: 36442478).	36442478
BRAF V600E MAP2K1 F53I	melanoma	resistant	Encorafenib	Preclinical - Cell culture	Actionable	In a preclinical study, a melanoma cell line harboring BRAF V600E and expressing MAP2K1 F53I was resistant to Braftovi (encorafenib) in culture (PMID: 36442478).	36442478
BRAF V600E MAP2K1 F53I	melanoma	resistant	Cobimetinib	Preclinical - Cell culture	Actionable	In a preclinical study, a melanoma cell line harboring BRAF V600E and expressing MAP2K1 F53I was resistant to Cotellic (cobimetinib) in culture (PMID: 36442478).	36442478
BRAF V600E MAP2K1 F53I	melanoma	sensitive	Dabrafenib + Trametinib	Preclinical - Cell culture	Actionable	In a preclinical study, the combination of Tafinlar (dabrafenib) and Mekinist (trametinib) synergistically inhibited viability of a melanoma cell line harboring BRAF V600E and expressing MAP2K1 F53I in culture (PMID: 36442478).	36442478
BRAF V600E MAP2K1 F53I	melanoma	sensitive	Binimetinib + Encorafenib	Preclinical - Cell culture	Actionable	In a preclinical study, the combination of Braftovi (encorafenib) and Mektovi (binimetinib) synergistically inhibited viability of a melanoma cell line harboring BRAF V600E and expressing MAP2K1 F53I in culture (PMID: 36442478).	36442478
BRAF V600E MAP2K1 F53I	melanoma	sensitive	Cobimetinib + Vemurafenib	Preclinical - Cell culture	Actionable	In a preclinical study, the combination of Zelboraf (vemurafenib) and Cotellic (cobimetinib) synergistically inhibited viability of a melanoma cell line harboring BRAF V600E and expressing MAP2K1 F53I in culture (PMID: 36442478).	36442478
BRAF V600E MAP2K1 F53Y	melanoma	resistant	Vemurafenib	Preclinical - Cell culture	Actionable	In a preclinical study, a melanoma cell line harboring BRAF V600E and expressing MAP2K1 F53Y was resistant to Zelboraf (vemurafenib) in culture (PMID: 36442478).	36442478
BRAF V600E MAP2K1 F53Y	melanoma	sensitive	Dabrafenib + Trametinib	Preclinical - Cell culture	Actionable	In a preclinical study, the combination of Tafinlar (dabrafenib) and Mekinist (trametinib) synergistically inhibited viability of a melanoma cell line harboring BRAF V600E and expressing MAP2K1 F53Y in culture (PMID: 36442478).	36442478
BRAF V600E MAP2K1 F53Y	melanoma	sensitive	Binimetinib + Encorafenib	Preclinical - Cell culture	Actionable	In a preclinical study, the combination of Braftovi (encorafenib) and Mektovi (binimetinib) synergistically inhibited viability of a melanoma cell line harboring BRAF V600E and expressing MAP2K1 F53Y in culture (PMID: 36442478).	36442478
BRAF V600E MAP2K1 G294E	melanoma	sensitive	Trametinib	Preclinical - Cell culture	Actionable	In a preclinical study, Mekinist (trametinib) inhibited viability of a melanoma cell line harboring BRAF V600E and expressing MAP2K1 G294E in culture (PMID: 36442478).	36442478
BRAF V600E MAP2K1 G294E	melanoma	sensitive	Dabrafenib	Preclinical - Cell culture	Actionable	In a preclinical study, Tafinlar (dabrafenib) inhibited viability of a melanoma cell line harboring BRAF V600E and expressing MAP2K1 G294E in culture (PMID: 36442478).	36442478
BRAF V600E MAP2K1 G294E	melanoma	sensitive	Vemurafenib	Preclinical - Cell culture	Actionable	In a preclinical study, Zelboraf (vemurafenib) inhibited viability of a melanoma cell line harboring BRAF V600E and expressing MAP2K1 G294E in culture (PMID: 36442478).	36442478
BRAF V600E MAP2K1 G294E	melanoma	sensitive	Encorafenib	Preclinical - Cell culture	Actionable	In a preclinical study, Braftovi (encorafenib) inhibited viability of a melanoma cell line harboring BRAF V600E and expressing MAP2K1 G294E in culture (PMID: 36442478).	36442478
BRAF V600E MAP2K1 G294E	melanoma	sensitive	Binimetinib	Preclinical - Cell culture	Actionable	In a preclinical study, Mektovi (binimetinib) inhibited viability of a melanoma cell line harboring BRAF V600E and expressing MAP2K1 G294E in culture (PMID: 36442478).	36442478
BRAF V600E MAP2K1 G294E	melanoma	sensitive	Cobimetinib	Preclinical - Cell culture	Actionable	In a preclinical study, Cotellic (cobimetinib) inhibited viability of a melanoma cell line harboring BRAF V600E and expressing MAP2K1 G294E in culture (PMID: 36442478).	36442478
BRAF V600E MAP2K1 G79V	melanoma	sensitive	Trametinib	Preclinical - Cell culture	Actionable	In a preclinical study, Mekinist (trametinib) inhibited viability of a melanoma cell line harboring BRAF V600E and expressing MAP2K1 G79V in culture (PMID: 36442478).	36442478
BRAF V600E MAP2K1 G79V	melanoma	sensitive	Dabrafenib	Preclinical - Cell culture	Actionable	In a preclinical study, Tafinlar (dabrafenib) inhibited viability of a melanoma cell line harboring BRAF V600E and expressing MAP2K1 G79V in culture (PMID: 36442478).	36442478
BRAF V600E MAP2K1 G79V	melanoma	sensitive	Vemurafenib	Preclinical - Cell culture	Actionable	In a preclinical study, Zelboraf (vemurafenib) inhibited viability of a melanoma cell line harboring BRAF V600E and expressing MAP2K1 G79V in culture (PMID: 36442478).	36442478
BRAF V600E MAP2K1 G79V	melanoma	sensitive	Encorafenib	Preclinical - Cell culture	Actionable	In a preclinical study, Braftovi (encorafenib) inhibited viability of a melanoma cell line harboring BRAF V600E and expressing MAP2K1 G79V in culture (PMID: 36442478).	36442478
BRAF V600E MAP2K1 G79V	melanoma	sensitive	Binimetinib	Preclinical - Cell culture	Actionable	In a preclinical study, Mektovi (binimetinib) inhibited viability of a melanoma cell line harboring BRAF V600E and expressing MAP2K1 G79V in culture (PMID: 36442478).	36442478
BRAF V600E MAP2K1 G79V	melanoma	sensitive	Cobimetinib	Preclinical - Cell culture	Actionable	In a preclinical study, Cotellic (cobimetinib) inhibited viability of a melanoma cell line harboring BRAF V600E and expressing MAP2K1 G79V in culture (PMID: 36442478).	36442478
MAP2K1 H119Q	Advanced Solid Tumor	predicted - sensitive	Trametinib	Preclinical - Biochemical	Actionable	In a preclinical study, Mekinist (trametinib) inhibited Erk phosphorylation in transformed cells expressing MAP2K1 H119Q in culture (PMID: 32641410).	32641410
MAP2K1 H119Q	Advanced Solid Tumor	predicted - sensitive	SCH772984	Preclinical - Biochemical	Actionable	In a preclinical study, SCH772984 inhibited downstream signaling in transformed cells expressing MAP2K1 H119Q in culture (PMID: 32641410).	32641410
BRAF V600E MAP2K1 K4N	melanoma	sensitive	Trametinib	Preclinical - Cell culture	Actionable	In a preclinical study, Mekinist (trametinib) inhibited viability of a melanoma cell line harboring BRAF V600E and expressing MAP2K1 K4N in culture (PMID: 36442478).	36442478
BRAF V600E MAP2K1 K4N	melanoma	sensitive	Dabrafenib	Preclinical - Cell culture	Actionable	In a preclinical study, Tafinlar (dabrafenib) inhibited viability of a melanoma cell line harboring BRAF V600E and expressing MAP2K1 K4N in culture (PMID: 36442478).	36442478
BRAF V600E MAP2K1 K4N	melanoma	sensitive	Vemurafenib	Preclinical - Cell culture	Actionable	In a preclinical study, Zelboraf (vemurafenib) inhibited viability of a melanoma cell line harboring BRAF V600E and expressing MAP2K1 K4N in culture (PMID: 36442478).	36442478
BRAF V600E MAP2K1 K4N	melanoma	sensitive	Encorafenib	Preclinical - Cell culture	Actionable	In a preclinical study, Braftovi (encorafenib) inhibited viability of a melanoma cell line harboring BRAF V600E and expressing MAP2K1 K4N in culture (PMID: 36442478).	36442478
BRAF V600E MAP2K1 K4N	melanoma	sensitive	Binimetinib	Preclinical - Cell culture	Actionable	In a preclinical study, Mektovi (binimetinib) inhibited viability of a melanoma cell line harboring BRAF V600E and expressing MAP2K1 K4N in culture (PMID: 36442478).	36442478
BRAF V600E MAP2K1 K4N	melanoma	sensitive	Cobimetinib	Preclinical - Cell culture	Actionable	In a preclinical study, Cotellic (cobimetinib) inhibited viability of a melanoma cell line harboring BRAF V600E and expressing MAP2K1 K4N in culture (PMID: 36442478).	36442478
MAP2K1 L177M	Advanced Solid Tumor	predicted - sensitive	Trametinib	Preclinical - Biochemical	Actionable	In a preclinical study, Mekinist (trametinib) inhibited Erk phosphorylation in transformed cells expressing MAP2K1 L177M in culture (PMID: 32641410).	32641410
MAP2K1 L177M	Advanced Solid Tumor	predicted - sensitive	SCH772984	Preclinical - Biochemical	Actionable	In a preclinical study, SCH772984 inhibited downstream signaling in transformed cells expressing MAP2K1 L177M in culture (PMID: 32641410).	32641410
BRAF V600E MAP2K1 L235H	melanoma	sensitive	Trametinib	Preclinical - Cell culture	Actionable	In a preclinical study, Mekinist (trametinib) inhibited viability of a melanoma cell line harboring BRAF V600E and expressing MAP2K1 L235H in culture (PMID: 36442478).	36442478
BRAF V600E MAP2K1 L235H	melanoma	sensitive	Dabrafenib	Preclinical - Cell culture	Actionable	In a preclinical study, Tafinlar (dabrafenib) inhibited viability of a melanoma cell line harboring BRAF V600E and expressing MAP2K1 L235H in culture (PMID: 36442478).	36442478
BRAF V600E MAP2K1 L235H	melanoma	sensitive	Vemurafenib	Preclinical - Cell culture	Actionable	In a preclinical study, Zelboraf (vemurafenib) inhibited viability of a melanoma cell line harboring BRAF V600E and expressing MAP2K1 L235H in culture (PMID: 36442478).	36442478
BRAF V600E MAP2K1 L235H	melanoma	sensitive	Encorafenib	Preclinical - Cell culture	Actionable	In a preclinical study, Braftovi (encorafenib) inhibited viability of a melanoma cell line harboring BRAF V600E and expressing MAP2K1 L235H in culture (PMID: 36442478).	36442478
BRAF V600E MAP2K1 L235H	melanoma	sensitive	Binimetinib	Preclinical - Cell culture	Actionable	In a preclinical study, Mektovi (binimetinib) inhibited viability of a melanoma cell line harboring BRAF V600E and expressing MAP2K1 L235H in culture (PMID: 36442478).	36442478
BRAF V600E MAP2K1 L235H	melanoma	sensitive	Cobimetinib	Preclinical - Cell culture	Actionable	In a preclinical study, Cotellic (cobimetinib) inhibited viability of a melanoma cell line harboring BRAF V600E and expressing MAP2K1 L235H in culture (PMID: 36442478).	36442478
MAP2K1 L42F	Advanced Solid Tumor	predicted - sensitive	Trametinib	Preclinical - Biochemical	Actionable	In a preclinical study, Mekinist (trametinib) inhibited Erk phosphorylation in transformed cells expressing MAP2K1 L42F in culture (PMID: 32641410).	32641410
BRAF V600E MAP2K1 M146I	melanoma	sensitive	Trametinib	Preclinical - Cell culture	Actionable	In a preclinical study, Mekinist (trametinib) inhibited viability of a melanoma cell line harboring BRAF V600E and expressing MAP2K1 M146I in culture (PMID: 36442478).	36442478
BRAF V600E MAP2K1 M146I	melanoma	sensitive	Dabrafenib	Preclinical - Cell culture	Actionable	In a preclinical study, Tafinlar (dabrafenib) inhibited viability of a melanoma cell line harboring BRAF V600E and expressing MAP2K1 M146I in culture (PMID: 36442478).	36442478
BRAF V600E MAP2K1 M146I	melanoma	sensitive	Vemurafenib	Preclinical - Cell culture	Actionable	In a preclinical study, Zelboraf (vemurafenib) inhibited viability of a melanoma cell line harboring BRAF V600E and expressing MAP2K1 M146I in culture (PMID: 36442478).	36442478
BRAF V600E MAP2K1 M146I	melanoma	sensitive	Encorafenib	Preclinical - Cell culture	Actionable	In a preclinical study, Braftovi (encorafenib) inhibited viability of a melanoma cell line harboring BRAF V600E and expressing MAP2K1 M146I in culture (PMID: 36442478).	36442478
BRAF V600E MAP2K1 M146I	melanoma	sensitive	Binimetinib	Preclinical - Cell culture	Actionable	In a preclinical study, Mektovi (binimetinib) inhibited viability of a melanoma cell line harboring BRAF V600E and expressing MAP2K1 M146I in culture (PMID: 36442478).	36442478
BRAF V600E MAP2K1 M146I	melanoma	sensitive	Cobimetinib	Preclinical - Cell culture	Actionable	In a preclinical study, Cotellic (cobimetinib) inhibited viability of a melanoma cell line harboring BRAF V600E and expressing MAP2K1 M146I in culture (PMID: 36442478).	36442478
BRAF V600E MAP2K1 P193S	melanoma	sensitive	Trametinib	Preclinical - Cell culture	Actionable	In a preclinical study, Mekinist (trametinib) inhibited viability of a melanoma cell line harboring BRAF V600E and expressing MAP2K1 P193S in culture (PMID: 36442478).	36442478
BRAF V600E MAP2K1 P193S	melanoma	sensitive	Dabrafenib	Preclinical - Cell culture	Actionable	In a preclinical study, Tafinlar (dabrafenib) inhibited viability of a melanoma cell line harboring BRAF V600E and expressing MAP2K1 P193S in culture (PMID: 36442478).	36442478
BRAF V600E MAP2K1 P193S	melanoma	sensitive	Encorafenib	Preclinical - Cell culture	Actionable	In a preclinical study, Braftovi (encorafenib) inhibited viability of a melanoma cell line harboring BRAF V600E and expressing MAP2K1 P193S in culture (PMID: 36442478).	36442478
BRAF V600E MAP2K1 P193S	melanoma	sensitive	Binimetinib	Preclinical - Cell culture	Actionable	In a preclinical study, Mektovi (binimetinib) inhibited viability of a melanoma cell line harboring BRAF V600E and expressing MAP2K1 P193S in culture (PMID: 36442478).	36442478
BRAF V600E MAP2K1 P264S	melanoma	sensitive	Trametinib	Preclinical - Cell culture	Actionable	In a preclinical study, Mekinist (trametinib) inhibited viability of a melanoma cell line harboring BRAF V600E and expressing MAP2K1 P264S in culture (PMID: 36442478).	36442478
BRAF V600E MAP2K1 P264S	melanoma	sensitive	Dabrafenib	Preclinical - Cell culture	Actionable	In a preclinical study, Tafinlar (dabrafenib) inhibited viability of a melanoma cell line harboring BRAF V600E and expressing MAP2K1 P264S in culture (PMID: 36442478).	36442478
BRAF V600E MAP2K1 P264S	melanoma	sensitive	Vemurafenib	Preclinical - Cell culture	Actionable	In a preclinical study, Zelboraf (vemurafenib) inhibited viability of a melanoma cell line harboring BRAF V600E and expressing MAP2K1 P264S in culture (PMID: 36442478).	36442478
BRAF V600E MAP2K1 P264S	melanoma	sensitive	Encorafenib	Preclinical - Cell culture	Actionable	In a preclinical study, Braftovi (encorafenib) inhibited viability of a melanoma cell line harboring BRAF V600E and expressing MAP2K1 P264S in culture (PMID: 36442478).	36442478
BRAF V600E MAP2K1 P264S	melanoma	sensitive	Binimetinib	Preclinical - Cell culture	Actionable	In a preclinical study, Mektovi (binimetinib) inhibited viability of a melanoma cell line harboring BRAF V600E and expressing MAP2K1 P264S in culture (PMID: 36442478).	36442478
BRAF V600E MAP2K1 P264S	melanoma	sensitive	Cobimetinib	Preclinical - Cell culture	Actionable	In a preclinical study, Cotellic (cobimetinib) inhibited viability of a melanoma cell line harboring BRAF V600E and expressing MAP2K1 P264S in culture (PMID: 36442478).	36442478
BRAF V600E MAP2K1 R108Q	melanoma	sensitive	Trametinib	Preclinical - Cell culture	Actionable	In a preclinical study, Mekinist (trametinib) inhibited viability of a melanoma cell line harboring BRAF V600E and expressing MAP2K1 R108Q in culture (PMID: 36442478).	36442478
BRAF V600E MAP2K1 R108Q	melanoma	sensitive	Dabrafenib	Preclinical - Cell culture	Actionable	In a preclinical study, Tafinlar (dabrafenib) inhibited viability of a melanoma cell line harboring BRAF V600E and expressing MAP2K1 R108Q in culture (PMID: 36442478).	36442478
BRAF V600E MAP2K1 R108Q	melanoma	sensitive	Vemurafenib	Preclinical - Cell culture	Actionable	In a preclinical study, Zelboraf (vemurafenib) inhibited viability of a melanoma cell line harboring BRAF V600E and expressing MAP2K1 R108Q in culture (PMID: 36442478).	36442478
BRAF V600E MAP2K1 R108Q	melanoma	sensitive	Encorafenib	Preclinical - Cell culture	Actionable	In a preclinical study, Braftovi (encorafenib) inhibited viability of a melanoma cell line harboring BRAF V600E and expressing MAP2K1 R108Q in culture (PMID: 36442478).	36442478
BRAF V600E MAP2K1 R108Q	melanoma	sensitive	Binimetinib	Preclinical - Cell culture	Actionable	In a preclinical study, Mektovi (binimetinib) inhibited viability of a melanoma cell line harboring BRAF V600E and expressing MAP2K1 R108Q in culture (PMID: 36442478).	36442478
BRAF V600E MAP2K1 R108Q	melanoma	sensitive	Cobimetinib	Preclinical - Cell culture	Actionable	In a preclinical study, Cotellic (cobimetinib) inhibited viability of a melanoma cell line harboring BRAF V600E and expressing MAP2K1 R108Q in culture (PMID: 36442478).	36442478
BRAF V600E MAP2K1 R201C	melanoma	sensitive	Trametinib	Preclinical - Cell culture	Actionable	In a preclinical study, Mekinist (trametinib) inhibited viability of a melanoma cell line harboring BRAF V600E and expressing MAP2K1 R201C in culture (PMID: 36442478).	36442478
BRAF V600E MAP2K1 R201C	melanoma	sensitive	Dabrafenib	Preclinical - Cell culture	Actionable	In a preclinical study, Tafinlar (dabrafenib) inhibited viability of a melanoma cell line harboring BRAF V600E and expressing MAP2K1 R201C in culture (PMID: 36442478).	36442478
BRAF V600E MAP2K1 R201C	melanoma	sensitive	Vemurafenib	Preclinical - Cell culture	Actionable	In a preclinical study, Zelboraf (vemurafenib) inhibited viability of a melanoma cell line harboring BRAF V600E and expressing MAP2K1 R201C in culture (PMID: 36442478).	36442478
BRAF V600E MAP2K1 R201C	melanoma	sensitive	Encorafenib	Preclinical - Cell culture	Actionable	In a preclinical study, Braftovi (encorafenib) inhibited viability of a melanoma cell line harboring BRAF V600E and expressing MAP2K1 R201C in culture (PMID: 36442478).	36442478
BRAF V600E MAP2K1 R201C	melanoma	sensitive	Binimetinib	Preclinical - Cell culture	Actionable	In a preclinical study, Mektovi (binimetinib) inhibited viability of a melanoma cell line harboring BRAF V600E and expressing MAP2K1 R201C in culture (PMID: 36442478).	36442478
BRAF V600E MAP2K1 R201C	melanoma	sensitive	Cobimetinib	Preclinical - Cell culture	Actionable	In a preclinical study, Cotellic (cobimetinib) inhibited viability of a melanoma cell line harboring BRAF V600E and expressing MAP2K1 R201C in culture (PMID: 36442478).	36442478
BRAF V600E MAP2K1 R47Q	melanoma	sensitive	Trametinib	Preclinical - Cell culture	Actionable	In a preclinical study, Mekinist (trametinib) inhibited viability of a melanoma cell line harboring BRAF V600E and expressing MAP2K1 R47Q in culture (PMID: 36442478).	36442478
BRAF V600E MAP2K1 R47Q	melanoma	sensitive	Dabrafenib	Preclinical - Cell culture	Actionable	In a preclinical study, Tafinlar (dabrafenib) inhibited viability of a melanoma cell line harboring BRAF V600E and expressing MAP2K1 R47Q in culture (PMID: 36442478).	36442478
BRAF V600E MAP2K1 R47Q	melanoma	sensitive	Encorafenib	Preclinical - Cell culture	Actionable	In a preclinical study, Braftovi (encorafenib) inhibited viability of a melanoma cell line harboring BRAF V600E and expressing MAP2K1 R47Q in culture (PMID: 36442478).	36442478
BRAF V600E MAP2K1 R47Q	melanoma	sensitive	Binimetinib	Preclinical - Cell culture	Actionable	In a preclinical study, Mektovi (binimetinib) inhibited viability of a melanoma cell line harboring BRAF V600E and expressing MAP2K1 R47Q in culture (PMID: 36442478).	36442478
BRAF V600E MAP2K1 R49C	melanoma	sensitive	Trametinib	Preclinical - Cell culture	Actionable	In a preclinical study, Mekinist (trametinib) inhibited viability of a melanoma cell line harboring BRAF V600E and expressing MAP2K1 R49C in culture (PMID: 36442478).	36442478
BRAF V600E MAP2K1 R49C	melanoma	sensitive	Encorafenib	Preclinical - Cell culture	Actionable	In a preclinical study, Braftovi (encorafenib) inhibited viability of a melanoma cell line harboring BRAF V600E and expressing MAP2K1 R49C in culture (PMID: 36442478).	36442478
BRAF V600E MAP2K1 R49C	melanoma	sensitive	Binimetinib	Preclinical - Cell culture	Actionable	In a preclinical study, Mektovi (binimetinib) inhibited viability of a melanoma cell line harboring BRAF V600E and expressing MAP2K1 R49C in culture (PMID: 36442478).	36442478
BRAF V600E MAP2K1 R96K	melanoma	sensitive	Trametinib	Preclinical - Cell culture	Actionable	In a preclinical study, Mekinist (trametinib) inhibited viability of a melanoma cell line harboring BRAF V600E and expressing MAP2K1 R96K in culture (PMID: 36442478).	36442478
BRAF V600E MAP2K1 R96K	melanoma	sensitive	Dabrafenib	Preclinical - Cell culture	Actionable	In a preclinical study, Tafinlar (dabrafenib) inhibited viability of a melanoma cell line harboring BRAF V600E and expressing MAP2K1 R96K in culture (PMID: 36442478).	36442478
BRAF V600E MAP2K1 R96K	melanoma	sensitive	Encorafenib	Preclinical - Cell culture	Actionable	In a preclinical study, Braftovi (encorafenib) inhibited viability of a melanoma cell line harboring BRAF V600E and expressing MAP2K1 R96K in culture (PMID: 36442478).	36442478
BRAF V600E MAP2K1 R96K	melanoma	sensitive	Binimetinib	Preclinical - Cell culture	Actionable	In a preclinical study, Mektovi (binimetinib) inhibited viability of a melanoma cell line harboring BRAF V600E and expressing MAP2K1 R96K in culture (PMID: 36442478).	36442478
BRAF V600E MAP2K1 R96K	melanoma	sensitive	Cobimetinib	Preclinical - Cell culture	Actionable	In a preclinical study, Cotellic (cobimetinib) inhibited viability of a melanoma cell line harboring BRAF V600E and expressing MAP2K1 R96K in culture (PMID: 36442478).	36442478
BRAF V600E MAP2K1 S327T	melanoma	sensitive	Trametinib	Preclinical - Cell culture	Actionable	In a preclinical study, Mekinist (trametinib) inhibited viability of a melanoma cell line harboring BRAF V600E and expressing MAP2K1 S327T in culture (PMID: 36442478).	36442478
BRAF V600E MAP2K1 S327T	melanoma	sensitive	Dabrafenib	Preclinical - Cell culture	Actionable	In a preclinical study, Tafinlar (dabrafenib) inhibited viability of a melanoma cell line harboring BRAF V600E and expressing MAP2K1 S327T in culture (PMID: 36442478).	36442478
BRAF V600E MAP2K1 S327T	melanoma	sensitive	Vemurafenib	Preclinical - Cell culture	Actionable	In a preclinical study, Zelboraf (vemurafenib) inhibited viability of a melanoma cell line harboring BRAF V600E and expressing MAP2K1 S327T in culture (PMID: 36442478).	36442478
BRAF V600E MAP2K1 S327T	melanoma	sensitive	Encorafenib	Preclinical - Cell culture	Actionable	In a preclinical study, Braftovi (encorafenib) inhibited viability of a melanoma cell line harboring BRAF V600E and expressing MAP2K1 S327T in culture (PMID: 36442478).	36442478
BRAF V600E MAP2K1 S327T	melanoma	sensitive	Binimetinib	Preclinical - Cell culture	Actionable	In a preclinical study, Mektovi (binimetinib) inhibited viability of a melanoma cell line harboring BRAF V600E and expressing MAP2K1 S327T in culture (PMID: 36442478).	36442478
BRAF V600E MAP2K1 S327T	melanoma	sensitive	Cobimetinib	Preclinical - Cell culture	Actionable	In a preclinical study, Cotellic (cobimetinib) inhibited viability of a melanoma cell line harboring BRAF V600E and expressing MAP2K1 S327T in culture (PMID: 36442478).	36442478
BRAF V600E MAP2K1 S331R	melanoma	sensitive	Trametinib	Preclinical - Cell culture	Actionable	In a preclinical study, Mekinist (trametinib) inhibited viability of a melanoma cell line harboring BRAF V600E and expressing MAP2K1 S331R in culture (PMID: 36442478).	36442478
BRAF V600E MAP2K1 S331R	melanoma	sensitive	Dabrafenib	Preclinical - Cell culture	Actionable	In a preclinical study, Tafinlar (dabrafenib) inhibited viability of a melanoma cell line harboring BRAF V600E and expressing MAP2K1 S331R in culture (PMID: 36442478).	36442478
BRAF V600E MAP2K1 S331R	melanoma	sensitive	Vemurafenib	Preclinical - Cell culture	Actionable	In a preclinical study, Zelboraf (vemurafenib) inhibited viability of a melanoma cell line harboring BRAF V600E and expressing MAP2K1 S331R in culture (PMID: 36442478).	36442478
BRAF V600E MAP2K1 S331R	melanoma	sensitive	Encorafenib	Preclinical - Cell culture	Actionable	In a preclinical study, Braftovi (encorafenib) inhibited viability of a melanoma cell line harboring BRAF V600E and expressing MAP2K1 S331R in culture (PMID: 36442478).	36442478
BRAF V600E MAP2K1 S331R	melanoma	sensitive	Binimetinib	Preclinical - Cell culture	Actionable	In a preclinical study, Mektovi (binimetinib) inhibited viability of a melanoma cell line harboring BRAF V600E and expressing MAP2K1 S331R in culture (PMID: 36442478).	36442478
BRAF V600E MAP2K1 S331R	melanoma	sensitive	Cobimetinib	Preclinical - Cell culture	Actionable	In a preclinical study, Cotellic (cobimetinib) inhibited viability of a melanoma cell line harboring BRAF V600E and expressing MAP2K1 S331R in culture (PMID: 36442478).	36442478
BRAF V600E MAP2K1 S86A	melanoma	sensitive	Trametinib	Preclinical - Cell culture	Actionable	In a preclinical study, Mekinist (trametinib) inhibited viability of a melanoma cell line harboring BRAF V600E and expressing MAP2K1 S86A in culture (PMID: 36442478).	36442478
BRAF V600E MAP2K1 S86A	melanoma	sensitive	Vemurafenib	Preclinical - Cell culture	Actionable	In a preclinical study, Zelboraf (vemurafenib) inhibited viability of a melanoma cell line harboring BRAF V600E and expressing MAP2K1 S86A in culture (PMID: 36442478).	36442478
BRAF V600E MAP2K1 S86A	melanoma	sensitive	Encorafenib	Preclinical - Cell culture	Actionable	In a preclinical study, Braftovi (encorafenib) inhibited viability of a melanoma cell line harboring BRAF V600E and expressing MAP2K1 S86A in culture (PMID: 36442478).	36442478
BRAF V600E MAP2K1 S86A	melanoma	sensitive	Binimetinib	Preclinical - Cell culture	Actionable	In a preclinical study, Mektovi (binimetinib) inhibited viability of a melanoma cell line harboring BRAF V600E and expressing MAP2K1 S86A in culture (PMID: 36442478).	36442478
BRAF V600E MAP2K1 S86A	melanoma	sensitive	Cobimetinib	Preclinical - Cell culture	Actionable	In a preclinical study, Cotellic (cobimetinib) inhibited viability of a melanoma cell line harboring BRAF V600E and expressing MAP2K1 S86A in culture (PMID: 36442478).	36442478
BRAF V600E MAP2K1 V224M	melanoma	sensitive	Vemurafenib	Preclinical - Cell culture	Actionable	In a preclinical study, Zelboraf (vemurafenib) inhibited viability of a melanoma cell line harboring BRAF V600E and expressing MAP2K1 V224M in culture (PMID: 36442478).	36442478
BRAF V600E MAP2K1 V224M	melanoma	sensitive	Cobimetinib	Preclinical - Cell culture	Actionable	In a preclinical study, Cotellic (cobimetinib) inhibited viability of a melanoma cell line harboring BRAF V600E and expressing MAP2K1 V224M in culture (PMID: 36442478).	36442478
BRAF V600E MAP2K1 V258I	melanoma	sensitive	Trametinib	Preclinical - Cell culture	Actionable	In a preclinical study, Mekinist (trametinib) inhibited viability of a melanoma cell line harboring BRAF V600E and expressing MAP2K1 V258I in culture (PMID: 36442478).	36442478
BRAF V600E MAP2K1 V258I	melanoma	sensitive	Dabrafenib	Preclinical - Cell culture	Actionable	In a preclinical study, Tafinlar (dabrafenib) inhibited viability of a melanoma cell line harboring BRAF V600E and expressing MAP2K1 V258I in culture (PMID: 36442478).	36442478
BRAF V600E MAP2K1 V258I	melanoma	sensitive	Vemurafenib	Preclinical - Cell culture	Actionable	In a preclinical study, Zelboraf (vemurafenib) inhibited viability of a melanoma cell line harboring BRAF V600E and expressing MAP2K1 V258I in culture (PMID: 36442478).	36442478
BRAF V600E MAP2K1 V258I	melanoma	sensitive	Encorafenib	Preclinical - Cell culture	Actionable	In a preclinical study, Braftovi (encorafenib) inhibited viability of a melanoma cell line harboring BRAF V600E and expressing MAP2K1 V258I in culture (PMID: 36442478).	36442478
BRAF V600E MAP2K1 V258I	melanoma	sensitive	Binimetinib	Preclinical - Cell culture	Actionable	In a preclinical study, Mektovi (binimetinib) inhibited viability of a melanoma cell line harboring BRAF V600E and expressing MAP2K1 V258I in culture (PMID: 36442478).	36442478
BRAF V600E MAP2K1 V258I	melanoma	sensitive	Cobimetinib	Preclinical - Cell culture	Actionable	In a preclinical study, Cotellic (cobimetinib) inhibited viability of a melanoma cell line harboring BRAF V600E and expressing MAP2K1 V258I in culture (PMID: 36442478).	36442478
BRAF V600E MAP2K1 V93F	melanoma	sensitive	Trametinib	Preclinical - Cell culture	Actionable	In a preclinical study, Mekinist (trametinib) inhibited viability of a melanoma cell line harboring BRAF V600E and expressing MAP2K1 V93F in culture (PMID: 36442478).	36442478
BRAF V600E MAP2K1 V93F	melanoma	sensitive	Dabrafenib	Preclinical - Cell culture	Actionable	In a preclinical study, Tafinlar (dabrafenib) inhibited viability of a melanoma cell line harboring BRAF V600E and expressing MAP2K1 V93F in culture (PMID: 36442478).	36442478
BRAF V600E MAP2K1 V93F	melanoma	sensitive	Vemurafenib	Preclinical - Cell culture	Actionable	In a preclinical study, Zelboraf (vemurafenib) inhibited viability of a melanoma cell line harboring BRAF V600E and expressing MAP2K1 V93F in culture (PMID: 36442478).	36442478
BRAF V600E MAP2K1 V93F	melanoma	sensitive	Encorafenib	Preclinical - Cell culture	Actionable	In a preclinical study, Braftovi (encorafenib) inhibited viability of a melanoma cell line harboring BRAF V600E and expressing MAP2K1 V93F in culture (PMID: 36442478).	36442478
BRAF V600E MAP2K1 V93F	melanoma	sensitive	Binimetinib	Preclinical - Cell culture	Actionable	In a preclinical study, Mektovi (binimetinib) inhibited viability of a melanoma cell line harboring BRAF V600E and expressing MAP2K1 V93F in culture (PMID: 36442478).	36442478
BRAF V600E MAP2K1 V93F	melanoma	sensitive	Cobimetinib	Preclinical - Cell culture	Actionable	In a preclinical study, Cotellic (cobimetinib) inhibited viability of a melanoma cell line harboring BRAF V600E and expressing MAP2K1 V93F in culture (PMID: 36442478).	36442478
BRAF V600E MAP2K1 W247*	melanoma	sensitive	Trametinib	Preclinical - Cell culture	Actionable	In a preclinical study, Mekinist (trametinib) inhibited viability of a melanoma cell line harboring BRAF V600E and expressing MAP2K1 W247* in culture (PMID: 36442478).	36442478
BRAF V600E MAP2K1 W247*	melanoma	sensitive	Dabrafenib	Preclinical - Cell culture	Actionable	In a preclinical study, Tafinlar (dabrafenib) inhibited viability of a melanoma cell line harboring BRAF V600E and expressing MAP2K1 W247* in culture (PMID: 36442478).	36442478
BRAF V600E MAP2K1 W247*	melanoma	sensitive	Vemurafenib	Preclinical - Cell culture	Actionable	In a preclinical study, Zelboraf (vemurafenib) inhibited viability of a melanoma cell line harboring BRAF V600E and expressing MAP2K1 W247* in culture (PMID: 36442478).	36442478
BRAF V600E MAP2K1 W247*	melanoma	sensitive	Encorafenib	Preclinical - Cell culture	Actionable	In a preclinical study, Braftovi (encorafenib) inhibited viability of a melanoma cell line harboring BRAF V600E and expressing MAP2K1 W247* in culture (PMID: 36442478).	36442478
BRAF V600E MAP2K1 W247*	melanoma	sensitive	Binimetinib	Preclinical - Cell culture	Actionable	In a preclinical study, Mektovi (binimetinib) inhibited viability of a melanoma cell line harboring BRAF V600E and expressing MAP2K1 W247* in culture (PMID: 36442478).	36442478
BRAF V600E MAP2K1 W247*	melanoma	sensitive	Cobimetinib	Preclinical - Cell culture	Actionable	In a preclinical study, Cotellic (cobimetinib) inhibited viability of a melanoma cell line harboring BRAF V600E and expressing MAP2K1 W247* in culture (PMID: 36442478).	36442478
BRAF V600E MAP2K1 Y134C	melanoma	sensitive	Trametinib	Preclinical - Cell culture	Actionable	In a preclinical study, Mekinist (trametinib) inhibited growth of a melanoma cell line harboring BRAF V600E and expressing MAP2K1 Y134C in culture (PMID: 28986383).	28986383
BRAF V600E MAP2K1 Y134C	melanoma	sensitive	Trametinib	Preclinical - Cell culture	Actionable	In a preclinical study, Mekinist (trametinib) inhibited viability of a melanoma cell line harboring BRAF V600E and expressing MAP2K1 Y134C in culture (PMID: 36442478).	36442478
BRAF V600E MAP2K1 Y134C	melanoma	sensitive	Dabrafenib	Preclinical - Cell culture	Actionable	In a preclinical study, Tafinlar (dabrafenib) inhibited viability of a melanoma cell line harboring BRAF V600E and expressing MAP2K1 Y134C in culture (PMID: 36442478).	36442478
BRAF V600E MAP2K1 Y134C	melanoma	resistant	Vemurafenib	Preclinical - Cell culture	Actionable	In a preclinical study, a melanoma cell line harboring BRAF V600E and expressing MAP2K1 Y134C was resistant to Zelboraf (vemurafenib) in culture (PMID: 28986383).	28986383
BRAF V600E MAP2K1 Y134C	melanoma	sensitive	Encorafenib	Preclinical - Cell culture	Actionable	In a preclinical study, Braftovi (encorafenib) inhibited viability of a melanoma cell line harboring BRAF V600E and expressing MAP2K1 Y134C in culture (PMID: 36442478).	36442478
BRAF V600E MAP2K1 Y134C	melanoma	sensitive	Binimetinib	Preclinical - Cell culture	Actionable	In a preclinical study, Mektovi (binimetinib) inhibited viability of a melanoma cell line harboring BRAF V600E and expressing MAP2K1 Y134C in culture (PMID: 36442478).	36442478
BRAF V600E MAP2K1 Y134C	melanoma	sensitive	Cobimetinib	Preclinical - Cell culture	Actionable	In a preclinical study, Cotellic (cobimetinib) inhibited viability of a melanoma cell line harboring BRAF V600E and expressing MAP2K1 Y134C in culture (PMID: 36442478).	36442478
MAP2K1 L115P	Advanced Solid Tumor	resistant	Trametinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing MAP2K1 L115P were resistant to Mekinist (trametinib) in culture (PMID: 36442478).	36442478
MAP2K1 L115P	Advanced Solid Tumor	resistant	CI-1040	Preclinical - Biochemical	Actionable	In a preclinical study, CI-1040 (PD184352) did not inhibit kinase activity of MAP2K1 L115P in an in vitro assay and failed to suppress Erk phosphorylation in cells expressing MAP2K1 L115P in culture (PMID: 12370306).	12370306
BRAF V600E MAP2K1 L115P	melanoma	conflicting	Trametinib	Preclinical - Cell culture	Actionable	In a preclinical study, a melanoma cell line harboring BRAF V600E and expressing MAP2K1 L115P was resistant to Mekinist (trametinib) in culture (PMID: 36442478).	36442478
BRAF V600E MAP2K1 L115P	melanoma	conflicting	Trametinib	Preclinical - Cell culture	Actionable	In a preclinical study, Mekinist (trametinib) inhibited growth of a melanoma cell line harboring BRAF V600E and expressing MAP2K1 L115P in culture (PMID: 28986383).	28986383
BRAF V600E MAP2K1 L115P	melanoma	conflicting	Trametinib	Preclinical - Cell culture	Actionable	In a preclinical study, melanoma cells harboring BRAF V600E and expressing MAP2K1 L115P demonstrated resistance to treatment with Mekinist (trametinib) in culture (PMID: 28655712).	28655712
BRAF V600E MAP2K1 L115P	melanoma	conflicting	Vemurafenib	Preclinical - Cell culture	Actionable	In a preclinical study, a melanoma cell line harboring BRAF V600E and expressing MAP2K1 L115P was resistant to Zelboraf (vemurafenib) in culture (PMID: 28986383).	28986383
BRAF V600E MAP2K1 L115P	melanoma	conflicting	Vemurafenib	Preclinical - Cell culture	Actionable	In a preclinical study, Zelboraf (vemurafenib) inhibited proliferation of melanoma cells harboring BRAF V600E and expressing MAP2K1 L115P in culture (PMID: 28655712).	28655712
BRAF V600E MAP2K1 L115P	melanoma	conflicting	Vemurafenib	Preclinical - Cell culture	Actionable	In a preclinical study, Zelboraf (vemurafenib) inhibited viability in a melanoma cell line harboring BRAF V600E and expressing MAP2K1 L115P in culture (PMID: 36442478).	36442478
BRAF V600E MAP2K1 L115P	melanoma	resistant	CI-1040	Preclinical - Cell culture	Actionable	In a preclinical study, expression of MAP2K1 L115P in melanoma cells harboring BRAF V600E conferred resistance to CI-1040 (PD184352) treatment in culture (PMID: 19915144).	19915144
BRAF V600E MAP2K1 L115P	melanoma	sensitive	Encorafenib	Preclinical - Cell culture	Actionable	In a preclinical study, Braftovi (encorafenib) inhibited viability of a melanoma cell line harboring BRAF V600E and expressing MAP2K1 L115P in culture (PMID: 36442478).	36442478
BRAF V600E MAP2K1 L115P	melanoma	resistant	Binimetinib	Preclinical - Cell culture	Actionable	In a preclinical study, a melanoma cell line harboring BRAF V600E and expressing MAP2K1 L115P was resistant to Mektovi (binimetinib) in culture (PMID: 36442478).	36442478
BRAF V600E MAP2K1 L115P	melanoma	resistant	PD-0325901	Preclinical	Actionable	In a preclinical study, overexpression of MAP2K1 L115P in melanoma cells harboring BRAF V600E resulted in insensitivity to growth inhibition by PD-0325901 in cell culture (PMID: 26267534).	26267534
BRAF V600E MAP2K1 L115P	melanoma	resistant	Selumetinib	Preclinical - Cell culture	Actionable	In a preclinical study, expression of MAP2K1 L115P in melanoma cells harboring BRAF V600E conferred resistance to Koselugo (selumetinib) treatment in culture (PMID: 19915144).	19915144
BRAF V600E MAP2K1 L115P	colon adenocarcinoma	resistant	Cobimetinib	Preclinical - Cell culture	Actionable	In a preclinical study, a colon adenocarcinoma cell line harboring BRAF V600E and expressing MAP2K1 L115P was resistant to Cotellic (cobimetinib) in culture (PMID: 36442478).	36442478
BRAF V600E MAP2K1 L115P	melanoma	resistant	Cobimetinib	Preclinical - Cell culture	Actionable	In a preclinical study, a melanoma cell line harboring BRAF V600E and expressing MAP2K1 L115P was resistant to Cotellic (cobimetinib) in culture (PMID: 36442478).	36442478
BRAF V600E MAP2K1 L115P	colorectal cancer	resistant	Dabrafenib + Trametinib	Preclinical - Cell culture	Actionable	In a preclinical study, colorectal cancer cells harboring BRAF V600E developed sustained activation of Mapk signaling and resistance to Tafinlar (dabrafenib) and Mekinist (trametinib) combination treatment in culture, likely due to the acquired secondary resistance mutation MAP2K1 L115P (PMID: 27312529).	27312529
BRAF V600E MAP2K1 L115P	colorectal cancer	sensitive	Cetuximab + Vemurafenib	Preclinical - Cell culture	Actionable	In a preclinical study, combination therapy consisting of Erbitux (cetuximab) and Zelboraf (vemurafenib) inhibited survival of colorectal cancer cells harboring BRAF V600E that acquired a MAP2K1 L115P mutation and subsequent resistance to Tafinlar (dabrafenib) and Mekinist (trametinib) combination treatment in culture (PMID: 27312529).	27312529
BRAF V600E MAP2K1 L115P	colorectal cancer	sensitive	Cetuximab + Encorafenib	Preclinical - Cell culture	Actionable	In a preclinical study, combination therapy consisting of Erbitux (cetuximab) and Encorafenib (LGX818) inhibited survival of colorectal cancer cells harboring BRAF V600E that acquired a MAP2K1 L115P mutation and subsequent resistance to Tafinlar (dabrafenib) and Mekinist (trametinib) combination treatment in culture (PMID: 27312529).	27312529
BRAF V600E MAP2K1 L115P	colorectal cancer	sensitive	Alpelisib + Cetuximab + Encorafenib	Preclinical - Cell culture	Actionable	In a preclinical study, combination therapy consisting of Erbitux (cetuximab), Encorafenib (LGX818) and Alpelisib (BYL719) inhibited survival of colorectal cancer cells harboring BRAF V600E that acquired a MAP2K1 L115P mutation and subsequent resistance to Tafinlar (dabrafenib) and Mekinist (trametinib) combination treatment in culture (PMID: 27312529).	27312529
BRAF V600E MAP2K1 L115P	colorectal cancer	sensitive	SCH772984	Preclinical - Cell culture	Actionable	In a preclinical study, SCH772984 inhibited survival of colorectal cancer cells harboring BRAF V600E that acquired a MAP2K1 L115P mutation and subsequent resistance to Tafinlar (dabrafenib) and Mekinist (trametinib) combination treatment in culture (PMID: 27312529).	27312529
BRAF V600E MAP2K1 L115P	melanoma	sensitive	DEL-22379	Preclinical - Cell culture	Actionable	In a preclinical study, DEL-22379 inhibited growth of a melanoma cell line harboring BRAF V600E and expressing MAP2K1 L115P in culture (PMID: 26267534).	26267534
BRAF V600E MAP2K1 L115P	colorectal cancer	sensitive	Cetuximab + Dabrafenib	Preclinical - Cell culture	Actionable	In a preclinical study, combination therapy consisting of Erbitux (cetuximab) and Tafinlar (dabrafenib) inhibited survival of colorectal cancer cells harboring BRAF V600E that acquired a MAP2K1 L115P mutation and subsequent resistance to Tafinlar (dabrafenib) and Mekinist (trametinib) combination treatment in culture (PMID: 27312529).	27312529
BRAF V600E MAP2K1 L115P	colorectal cancer	sensitive	Cetuximab + Dabrafenib + Trametinib	Preclinical - Cell culture	Actionable	In a preclinical study, combination therapy consisting of Erbitux (cetuximab), Tafinlar (dabrafenib), and Mekinist (trametinib) inhibited survival of colorectal cancer cells harboring BRAF V600E that acquired a MAP2K1 L115P mutation and subsequent resistance to Tafinlar (dabrafenib) and Mekinist (trametinib) combination treatment in culture (PMID: 27312529).	27312529
BRAF V600E MAP2K1 L115P	colorectal cancer	sensitive	Cetuximab + Dabrafenib + SCH772984	Preclinical - Cell culture	Actionable	In a preclinical study, combination therapy consisting of Erbitux (cetuximab), Tafinlar (dabrafenib), and SCH772984 inhibited survival of colorectal cancer cells harboring BRAF V600E that acquired a MAP2K1 L115P mutation and subsequent resistance to Tafinlar (dabrafenib) and Mekinist (trametinib) combination treatment in culture (PMID: 27312529).	27312529
BRAF V600E MAP2K1 L115P	colorectal cancer	sensitive	Cetuximab + SCH772984	Preclinical - Cell culture	Actionable	In a preclinical study, combination therapy consisting of Erbitux (cetuximab) and SCH772984 inhibited survival of colorectal cancer cells harboring BRAF V600E that acquired a MAP2K1 L115P mutation and subsequent resistance to Tafinlar (dabrafenib) and Mekinist (trametinib) combination treatment in culture (PMID: 27312529).	27312529
BRAF V600E MAP2K1 L115P	colorectal cancer	sensitive	Dabrafenib + SCH772984	Preclinical - Cell culture	Actionable	In a preclinical study, combination therapy consisting of Tafinlar (dabrafenib) and SCH772984 inhibited survival of colorectal cancer cells harboring BRAF V600E that acquired a MAP2K1 L115P mutation and subsequent resistance to Tafinlar (dabrafenib) and Mekinist (trametinib) combination treatment in culture (PMID: 27312529).	27312529
MAP2K1 I103N	Advanced Solid Tumor	decreased response	CI-1040	Preclinical - Biochemical	Actionable	In a preclinical study, MAP2K1 I103N demonstrated decreased sensitivity to CI-1040 (PD184352) in an in vitro kinase assay (PMID: 12370306).	12370306
MAP2K1 I103N	Advanced Solid Tumor	predicted - sensitive	SCH772984	Preclinical - Biochemical	Actionable	In a preclinical study, SCH772984 inhibited downstream signaling in transformed cells expressing MAP2K1 I103N in culture (PMID: 32641410).	32641410
BRAF V600E MAP2K1 I103N	melanoma	resistant	Dabrafenib	Preclinical - Cell culture	Actionable	In a preclinical study, a melanoma cell line harboring BRAF V600E and expressing MAP2K1 I103N was resistant to Tafinlar (dabrafenib) in culture (PMID: 36442478).	36442478
BRAF V600E MAP2K1 I103N	melanoma	resistant	Vemurafenib	Preclinical - Cell culture	Actionable	In a preclinical study, a melanoma cell line harboring BRAF V600E and expressing MAP2K1 I103N was resistant to Zelboraf (vemurafenib) in culture (PMID: 36442478).	36442478
BRAF V600E MAP2K1 I103N	melanoma	resistant	CI-1040	Preclinical - Cell culture	Actionable	In a preclinical study, expression of MAP2K1 I103N in melanoma cells harboring BRAF V600E conferred resistance to CI-1040 (PD184352) treatment in culture (PMID: 19915144).	19915144
BRAF V600E MAP2K1 I103N	melanoma	resistant	Encorafenib	Preclinical - Cell culture	Actionable	In a preclinical study, a melanoma cell line harboring BRAF V600E and expressing MAP2K1 I103N was resistant to Braftovi (encorafenib) in culture (PMID: 36442478).	36442478
BRAF V600E MAP2K1 I103N	melanoma	resistant	PD-0325901	Preclinical - Cell culture	Actionable	In a preclinical study, overexpression of MAP2K1 I103N in melanoma cells harboring BRAF V600E resulted in insensitivity to growth inhibition by PD-0325901 in cell culture (PMID: 26267534).	26267534
BRAF V600E MAP2K1 I103N	melanoma	resistant	Selumetinib	Preclinical - Cell culture	Actionable	In a preclinical study, expression of MAP2K1 I103N in melanoma cells harboring BRAF V600E conferred resistance to Koselugo (selumetinib) treatment in culture (PMID: 19915144).	19915144
BRAF V600E MAP2K1 I103N	melanoma	sensitive	Dabrafenib + Trametinib	Preclinical - Cell culture	Actionable	In a preclinical study, the combination of Tafinlar (dabrafenib) and Mekinist (trametinib) synergistically inhibited viability of a melanoma cell line harboring BRAF V600E and expressing MAP2K1 I103N in culture (PMID: 36442478).	36442478
BRAF V600E MAP2K1 I103N	melanoma	sensitive	Binimetinib + Encorafenib	Preclinical - Cell culture	Actionable	In a preclinical study, the combination of Braftovi (encorafenib) and Mektovi (binimetinib) synergistically inhibited viability of a melanoma cell line harboring BRAF V600E and expressing MAP2K1 I103N in culture (PMID: 36442478).	36442478
BRAF V600E MAP2K1 I103N	melanoma	sensitive	Cobimetinib + Vemurafenib	Preclinical - Cell culture	Actionable	In a preclinical study, the combination of Zelboraf (vemurafenib) and Cotellic (cobimetinib) synergistically inhibited viability of a melanoma cell line harboring BRAF V600E and expressing MAP2K1 I103N in culture (PMID: 36442478).	36442478
BRAF V600E MAP2K1 I103N	melanoma	sensitive	DEL-22379	Preclinical - Cell culture	Actionable	In a preclinical study, DEL-22379 inhibited growth of a melanoma cell line harboring BRAF V600E and expressing MAP2K1 I103N in culture (PMID: 26267534).	26267534
MAP2K1 I111P	Advanced Solid Tumor	predicted - resistant	CI-1040	Preclinical - Biochemical	Actionable	In a preclinical study, CI-1040 (PD184352) did not inhibit kinase activity of MAP2K1 I111P in an in vitro assay (PMID: 12370306).	12370306
MAP2K1 I111A	Advanced Solid Tumor	decreased response	CI-1040	Preclinical - Biochemical	Actionable	In a preclinical study, MAP2K1 I111A demonstrated decreased sensitivity to CI-1040 (PD184352) in an in vitro kinase assay (PMID: 12370306).	12370306
MAP2K1 I111R	Advanced Solid Tumor	predicted - resistant	CI-1040	Preclinical - Biochemical	Actionable	In a preclinical study, CI-1040 (PD184352) did not inhibit kinase activity of MAP2K1 I111R in an in vitro assay (PMID: 12370306).	12370306
BRAF V600E MAP2K1 I111N	melanoma	resistant	Trametinib	Preclinical - Cell culture	Actionable	In a preclinical study, melanoma cells harboring BRAF V600E and expressing MAP2K1 I111N demonstrated resistance to treatment with Mekinist (trametinib) in culture (PMID: 28655712).	28655712
BRAF V600E MAP2K1 I111N	melanoma	sensitive	Vemurafenib	Preclinical - Cell culture	Actionable	In a preclinical study, Zelboraf (vemurafenib) inhibited proliferation of melanoma cells harboring BRAF V600E and expressing MAP2K1 I111N in culture (PMID: 28655712).	28655712
BRAF V600E MAP2K1 I111N	melanoma	resistant	CI-1040	Preclinical - Cell culture	Actionable	In a preclinical study, expression of MAP2K1 I111N in melanoma cells harboring BRAF V600E conferred resistance to CI-1040 (PD184352) treatment in culture (PMID: 19915144).	19915144
BRAF V600E MAP2K1 I111N	melanoma	resistant	Selumetinib	Preclinical - Cell culture	Actionable	In a preclinical study, expression of MAP2K1 I111N in melanoma cells harboring BRAF V600E conferred resistance to Koselugo (selumetinib) treatment in culture (PMID: 19915144).	19915144
MAP2K1 V211D	Advanced Solid Tumor	resistant	AZD8330	Preclinical - Cell culture	Actionable	In a preclinical study, Map2k1 V211D displayed resistance to the Mek inhibitor, AZD8330, as demonstrated by constitutive activation of Map2k1 in transformed human kidney cells (PMID: 29753091).	29753091
MAP2K1 V211D	Advanced Solid Tumor	predicted - resistant	Binimetinib	Preclinical - Biochemical	Actionable	In a preclinical study, Mektovi (binimetinib) did not inhibit kinase activity of MAP2K1 V211D in an in vitro assay (PMID: 31227518).	31227518
MAP2K1 V211D	Advanced Solid Tumor	resistant	Regorafenib	Preclinical - Cell culture	Actionable	In a preclinical study, Map2k1 V211D displayed resistance to Stivarga (regorafenib; BAY 73-4506), as demonstrated by constitutive activation of Map2k1 in transformed human kidney cells (PMID: 29753091).	29753091
MAP2K1 V211D	Advanced Solid Tumor	resistant	Selumetinib	Preclinical	Actionable	In a preclinical study, Map2k1 V211D displayed resistance to the Mek inhibitor, Selumetinib (AZD6244), as demonstrated by constitutive activation of Map2k1 in transformed human kidney cells (PMID: 29753091).	29753091
MAP2K1 V211D	Advanced Solid Tumor	predicted - resistant	Cobimetinib	Preclinical - Biochemical	Actionable	In a preclinical study, Cotellic (cobimetinib) did not inhibit kinase activity of MAP2K1 V211D in an in vitro assay (PMID: 31227518).	31227518
MAP2K1 V211D	Advanced Solid Tumor	sensitive	PLX4720	Preclinical - Cell culture	Actionable	In a preclinical study, Map2k1 V211D displayed sensitivity to the Braf inhibitor, PLX4720, as demonstrated by reversal of active Map2k1 in transformed human kidney cells (PMID: 29753091).	29753091
MAP2K1 V211D	Advanced Solid Tumor	resistant	GDC0879	Preclinical - Cell culture	Actionable	In a preclinical study, Map2k1 V211D displayed resistance to the Braf inhibitor, GDC-0879, as demonstrated by constitutive activation of Map2k1 in transformed human kidney cells (PMID: 29753091).	29753091
MAP2K1 V211D	Advanced Solid Tumor	resistant	PD98059	Preclinical - Cell culture	Actionable	In a preclinical study, Map2k1 V211D displayed resistance to the Mek inhibitor, PD98059, as demonstrated by constitutive activation of Map2k1 in transformed human kidney cells (PMID: 29753091).	29753091
BRAF V600E MAP2K1 V211D	melanoma	resistant	Trametinib	Preclinical - Cell culture	Actionable	In a preclinical study, melanoma cells harboring BRAF V600E and expressing MAP2K1 V211D demonstrated resistance to treatment with Mekinist (trametinib) in culture (PMID: 28655712).	28655712
BRAF V600E MAP2K1 V211D	melanoma	sensitive	Vemurafenib	Preclinical - Cell culture	Actionable	In a preclinical study, Zelboraf (vemurafenib) inhibited proliferation of melanoma cells harboring BRAF V600E and expressing MAP2K1 V211D in culture (PMID: 28655712).	28655712
BRAF V600E MAP2K1 V211D	melanoma	resistant	CI-1040	Preclinical	Actionable	In a preclinical study, expression of MAP2K1 V211D in melanoma cells harboring BRAF V600E conferred resistance to CI-1040 (PD184352) treatment in culture (PMID: 19915144).	19915144
BRAF V600E MAP2K1 V211D	melanoma	resistant	Selumetinib	Preclinical	Actionable	In a preclinical study, expression of MAP2K1 V211D in melanoma cells harboring BRAF V600E conferred resistance to Koselugo (selumetinib) treatment in culture (PMID: 19915144).	19915144
BRAF V600E MAP2K1 V211D	melanoma	sensitive	Ulixertinib	Preclinical - Cell culture	Actionable	In a preclinical study, Ulixertinib (BVD-523) inhibited proliferation of melanoma cells harboring BRAF V600E and expressing MAP2K1 V211D in culture (PMID: 28655712).	28655712
BRAF V600E MAP2K1 V211D	colorectal cancer	resistant	Dabrafenib + Trametinib	Preclinical - Cell culture	Actionable	In a preclinical study, colorectal cancer cells harboring BRAF V600E that acquired a MAP2K1 V211D mutation and subsequent resistance to Erbitux (cetuximab) and Selumetinib (AZD6244) combination treatment were resistant to combination therapy consisting of Tafinlar (dabrafenib) and Mekinist (trametinib) in culture (PMID: 27312529).	27312529
BRAF V600E MAP2K1 V211D	colorectal cancer	resistant	Cetuximab + Encorafenib	Preclinical - Cell culture	Actionable	In a preclinical study, colorectal cancer cells harboring BRAF V600E that acquired a MAP2K1 V211D mutation and subsequent resistance to Erbitux (cetuximab) and Selumetinib (AZD6244) combination treatment were resistant to combination therapy consisting of Erbitux (cetuximab) and Encorafenib (LGX818) in culture (PMID: 27312529).	27312529
BRAF V600E MAP2K1 V211D	colorectal cancer	resistant	SCH772984	Preclinical - Cell culture	Actionable	In a preclinical study, colorectal cancer cells harboring BRAF V600E that acquired a MAP2K1 V211D mutation and subsequent resistance to Erbitux (cetuximab) and Selumetinib (AZD6244) combination treatment were resistant to SCH772984 in culture (PMID: 27312529).	27312529
BRAF V600E MAP2K1 V211D	colorectal cancer	resistant	Cetuximab + Selumetinib	Preclinical - Cell culture	Actionable	In a preclinical study, colorectal cancer cells harboring BRAF V600E developed sustained activation of Mapk signaling and resistance to Koselugo (selumetinib) and Erbitux (cetuximab) combination treatment in culture, likely due to the acquired secondary resistant mutation of MAP2K1 V211D (PMID: 27312529).	27312529
BRAF V600E MAP2K1 V211D	colorectal cancer	resistant	Cetuximab + Dabrafenib + Trametinib	Preclinical - Cell culture	Actionable	In a preclinical study, colorectal cancer cells harboring BRAF V600E that acquired a MAP2K1 V211D mutation and subsequent resistance to Erbitux (cetuximab) and Selumetinib (AZD6244) combination treatment were resistant to combination therapy consisting of Erbitux (cetuximab), Tafinlar (dabrafenib), and Mekinist (trametinib) in culture (PMID: 27312529).	27312529
BRAF K601E MAP2K1 V211D	colon cancer	resistant	Binimetinib	Preclinical - Pdx	Actionable	In a preclinical study, Mektovi (binimetinib) did not inhibit Rsk and Erk phosphorylation, and had no effect on tumor growth in patient-derived xenograft (PDX) models of metastatic colon cancer harboring BRAF K601E and MAP2K1 V211D (PMID: 31227518).	31227518
BRAF K601E MAP2K1 V211D	colon cancer	predicted - resistant	Binimetinib + Panitumumab	Case Reports/Case Series	Actionable	In a clinical case study, a patient with metastatic colon cancer harboring BRAF K601E developed progressive disease after 6 weeks of Mektovi (binimetinib) and Vectibix (panitumumab) combination treatment, MAP2K1 V211D was identified as a co-occuring mutation in the biopsy from the new metastasis site (PMID: 31227518).	31227518
BRAF K601E MAP2K1 V211D	colon cancer	sensitive	MAP855	Preclinical - Pdx	Actionable	In a preclinical study, MAP855 inhibited Rsk and Erk phosphorylation, and resulted in 30% tumor regression in patient-derived xenograft (PDX) models of metastatic colon cancer harboring BRAF K601E and MAP2K1 V211D (PMID: 31227518).	31227518
BRAF K601E MAP2K1 V211D	colon cancer	resistant	Binimetinib + Cetuximab	Preclinical - Pdx	Actionable	In a preclinical study, Mektovi (binimetinib) and Erbitux (cetuximab) combination did not inhibit Rsk and Erk phosphorylation, and had no effect on tumor growth in patient-derived xenograft (PDX) models of metastatic colon cancer harboring BRAF K601E and MAP2K1 V211D (PMID: 31227518).	31227518
BRAF V600E MAP2K1 P387S NRAS A146T	melanoma	decreased response	Trametinib	Preclinical	Actionable	In a preclinical study, melanoma cell lines harboring BRAF V600E, NRAS A146T and MAP2K1 P387S were >20-fold less sensitive to growth inhibition by Mekinist (trametinib) than parental cell lines harboring BRAF V600E and also had reduced sensitivity in comparison to cell lines harboring BRAF V600E and NRAS A146T in culture (PMID: 22389471).	22389471
BRAF V600E MAP2K1 P387S NRAS A146T	melanoma	resistant	Dabrafenib	Preclinical	Actionable	In a preclinical study, human melanoma cell lines harboring BRAF V600E, NRAS A146T and MAP2K1 P387S were resistant to Tafinlar (dabrafenib) mediated growth inhibition in culture (PMID: 22389471).	22389471
BRAF V600E MAP2K1 P387S NRAS A146T	melanoma	resistant	Vemurafenib	Preclinical	Actionable	In a preclinical study, melanoma cell lines harboring BRAF V600E, NRAS A146T and MAP2K1 P387S were resistant to Zelboraf (vemurafenib) growth inhibition in culture (PMID: 22389471).	22389471
BRAF V600E MAP2K1 P387S NRAS A146T	melanoma	decreased response	GSK2126458	Preclinical	Actionable	In a preclinical study, melanoma cell lines harboring BRAF V600E, NRAS A146T and MAP2K1 P387S had reduced sensitivity to Omipalisib (GSK2126458) in comparison to parental cell lines harboring BRAF V600E in culture (PMID: 22389471).	22389471
BRAF V600E MAP2K1 P387S NRAS A146T	melanoma	sensitive	GSK2126458 + Trametinib	Preclinical	Actionable	In a preclinical study, Mekinist (trametinib) in combination with Omipalisib (GSK2126458) resulted in improved growth inhibition in melanoma cell lines harboring BRAF V600E, NRAS A146T and MAP2K1 P387S in culture, compared to either agent alone (PMID: 22389471).	22389471
BRAF V600E MAP2K1 P387S NRAS A146T	melanoma	no benefit	Dabrafenib + GSK2126458	Preclinical	Actionable	In a preclinical study, Talfinlar (dabrafenib) in combination with Omipalisib (GSK2126458) did not improve the response to human melanoma cell lines harboring BRAF V600E, NRAS A146T and MAP2K1 P387S in culture (PMID: 22389471).	22389471
BRAF V600E MAP2K1 P387S NRAS Q61K	melanoma	decreased response	Trametinib	Preclinical	Actionable	In a preclinical study, human melanoma cell lines harboring BRAF V600E, NRAS Q61K and MAP2K1 P387S were >20-fold less sensitive to growth inhibition by Mekinist (trametinib) than parental cell lines harboring BRAF V600E in culture (PMID: 22389471).	22389471
BRAF V600E MAP2K1 P387S NRAS Q61K	melanoma	resistant	Dabrafenib	Preclinical	Actionable	In a preclinical study, human melanoma cell lines harboring BRAF V600E, NRAS Q61K and MAP2K1 P387S were resistant to Tafinlar (dabrafenib) mediated growth inhibition in culture (PMID: 22389471).	22389471
BRAF V600E MAP2K1 P387S NRAS Q61K	melanoma	resistant	Vemurafenib	Preclinical	Actionable	In a preclinical study, human melanoma cell lines harboring BRAF V600E, NRAS Q61K and MAP2K1 P387S were resistant to growth inhibition by Zelboraf (vemurafenib) in culture (PMID: 22389471).	22389471
BRAF V600E MAP2K1 P387S NRAS Q61K	melanoma	decreased response	GSK2126458	Preclinical	Actionable	In a preclinical study, human melanoma cell lines harboring BRAF V600E, NRAS Q61K and MAP2K1 P387S had reduced sensitivity to Omipalisib (GSK2126458) in comparison to parental cell lines harboring BRAF V600E in culture (PMID: 22389471).	22389471
BRAF V600E MAP2K1 P387S NRAS Q61K	melanoma	sensitive	GSK2126458 + Trametinib	Preclinical	Actionable	In a preclinical study, Mekinist (trametinib) in combination with Omipalisib (GSK2126458) resulted in improved growth inhibition of human melanoma cell lines harboring BRAF V600E, NRAS Q61K, and MAP2K1 P387S in culture, compared to either agent alone (PMID: 22389471).	22389471
BRAF V600E MAP2K1 P387S NRAS Q61K	melanoma	conflicting	Dabrafenib + GSK2126458	Preclinical	Actionable	In a preclinical study, the response of human melanoma cell lines harboring BRAF V600E, NRAS Q61K, and MAP2K1 P387S to Tafinlar (dabrafenib) in combination with Omipalisib (GSK2126458) was conflicting as one cell line with this mutation profile responded to the combination and another cell line with the mutation profile did not (PMID: 22389471).	22389471
BRAF V600E MAP2K1 P387S NRAS Q61K NRAS A146T	melanoma	resistant	Trametinib	Preclinical	Actionable	In a preclinical study, melanoma cell lines harboring BRAF V600E, NRAS Q61K, NRAS A146T and MAP2K1 P387S were resistant to growth inhibition by Mekinist (trametinib) in culture (PMID: 22389471).	22389471
BRAF V600E MAP2K1 P387S NRAS Q61K NRAS A146T	melanoma	resistant	Dabrafenib	Preclinical	Actionable	In a preclinical study, melanoma cell lines harboring BRAF V600E, NRAS Q61K, NRAS A146T and MAP2K1 P387S were resistant Tafinlar (dabrafenib) mediated growth inhibition in culture (PMID: 22389471).	22389471
BRAF V600E MAP2K1 P387S NRAS Q61K NRAS A146T	melanoma	resistant	Vemurafenib	Preclinical	Actionable	In a preclinical study, melanoma cell lines harboring BRAF V600E, NRAS Q61K, A146T and MAP2K1 P387S were resistant to Zelboraf (vemurafenib) growth inhibition in culture (PMID: 22389471).	22389471
BRAF V600E MAP2K1 P387S NRAS Q61K NRAS A146T	melanoma	decreased response	GSK2126458	Preclinical	Actionable	In a preclinical study, melanoma cell lines harboring BRAF V600E, NRAS Q61K, NRAS A146T and MAP2K1 P387S had reduced sensitivity to Omipalisib (GSK2126458) in comparison to parental cell lines harboring BRAF V600E in culture (PMID: 22389471).	22389471
BRAF V600E MAP2K1 P387S NRAS Q61K NRAS A146T	melanoma	sensitive	GSK2126458 + Trametinib	Preclinical	Actionable	In a preclinical study, Mekinist (trametinib) in combination with Omipalisib (GSK2126458) resulted in improved growth inhibition in melanoma cell lines harboring BRAF V600E, NRAS Q61K, NRAS A146T and MAP2K1 P387S in culture, compared to either agent alone (PMID: 22389471).	22389471
BRAF V600E MAP2K1 P387S	melanoma	sensitive	Trametinib	Preclinical - Cell culture	Actionable	In a preclinical study, Mekinist (trametinib) inhibited viability of a melanoma cell line harboring BRAF V600E and expressing MAP2K1 P387S in culture (PMID: 36442478).	36442478
BRAF V600E MAP2K1 P387S	melanoma	sensitive	Dabrafenib	Preclinical - Cell culture	Actionable	In a preclinical study, Tafinlar (dabrafenib) inhibited viability of a melanoma cell line harboring BRAF V600E and expressing MAP2K1 P387S in culture (PMID: 36442478).	36442478
BRAF V600E MAP2K1 P387S	melanoma	sensitive	Encorafenib	Preclinical - Cell culture	Actionable	In a preclinical study, Braftovi (encorafenib) inhibited viability of a melanoma cell line harboring BRAF V600E and expressing MAP2K1 P387S in culture (PMID: 36442478).	36442478
BRAF V600E MAP2K1 P387S	melanoma	sensitive	Binimetinib	Preclinical - Cell culture	Actionable	In a preclinical study, Mektovi (binimetinib) inhibited viability of a melanoma cell line harboring BRAF V600E and expressing MAP2K1 P387S in culture (PMID: 36442478).	36442478
BRAF V600E MAP2K1 P387S	melanoma	sensitive	Cobimetinib	Preclinical - Cell culture	Actionable	In a preclinical study, Cotellic (cobimetinib) inhibited viability of a melanoma cell line harboring BRAF V600E and expressing MAP2K1 P387S in culture (PMID: 36442478).	36442478
MAP2K1 K59del	Advanced Solid Tumor	sensitive	Trametinib	Preclinical - Cell culture	Actionable	In a preclinical study, Mekinist (trametinib) inhibited viability of a transformed cell line expressing MAP2K1 K59del in culture (PMID: 36442478).	36442478
BRAF V600E MAP2K1 K59del	melanoma	resistant	Trametinib	Preclinical	Actionable	In a preclinical study, human melanoma cell lines harboring BRAF V600E and MAP2K1 K59del were resistant to growth inhibition by Mekinist (trametinib) in culture (PMID: 22389471).	22389471
BRAF V600E MAP2K1 K59del	melanoma	resistant	Dabrafenib	Preclinical	Actionable	In a preclinical study, human melanoma cell lines harboring BRAF V600E and MAP2K1 K59del were resistant to Tafinlar (dabrafenib) mediated growth inhibition in culture (PMID: 22389471).	22389471
BRAF V600E MAP2K1 K59del	melanoma	resistant	Vemurafenib	Preclinical	Actionable	In a preclinical study, human melanoma cell lines harboring BRAF V600E and MAP2K1 K59del were resistant to Zelboraf (vemurafenib) growth inhibition in culture (PMID: 22389471).	22389471
BRAF V600E MAP2K1 K59del	melanoma	decreased response	GSK2126458	Preclinical	Actionable	In a preclinical study, human melanoma cell lines harboring BRAF V600E and MAP2K1 K59del had reduced sensitivity to Omipalisib (GSK2126458) in comparison to parental cell lines harboring BRAF V600E in culture (PMID: 22389471).	22389471
BRAF V600E MAP2K1 K59del	melanoma	sensitive	Dabrafenib + Trametinib	Preclinical	Actionable	In a preclinical study, Talfinlar (dabrafenib) in combination with Mekinist (trametinib) resulted in improved growth inhibition of human melanoma cell lines harboring BRAF V600E harboring MAP2K1 K59del in culture (PMID: 22389471).	22389471
BRAF V600E MAP2K1 K59del	melanoma	sensitive	GSK2126458 + Trametinib	Preclinical	Actionable	In a preclinical study, Mekinist (trametinib) in combination with Omipalisib (GSK2126458) resulted in improved growth inhibition of human melanoma cell lines harboring BRAF V600E and MAP2K1 K59del in culture, compared to either agent alone (PMID: 22389471).	22389471
BRAF V600E MAP2K1 K59del	melanoma	sensitive	Dabrafenib + GSK2126458	Preclinical	Actionable	In a preclinical study, Tafinlar (dabrafenib) in combination with Omipalisib (GSK2126458) resulted in improved growth inhibition of human melanoma cell lines harboring BRAF V600E and MAP2K1 K59del in culture, compared to either agent alone (PMID: 22389471).	22389471
MAP2K1 Q58_E62del	Advanced Solid Tumor	sensitive	Trametinib	Preclinical - Cell culture	Actionable	In a preclinical study, Mekinist (trametinib) inhibited viability of a transformed cell line expressing MAP2K1 Q58_E62del in culture (PMID: 36442478).	36442478
BRAF V600E MAP2K1 Q58_E62del	melanoma	sensitive	Trametinib	Preclinical - Cell culture	Actionable	In a preclinical study, Mekinist (trametinib) inhibited viability of a melanoma cell line harboring BRAF V600E and expressing MAP2K1 Q58_E62del in culture (PMID: 36442478).	36442478
BRAF V600E MAP2K1 Q58_E62del	melanoma	sensitive	Dabrafenib	Preclinical - Cell culture	Actionable	In a preclinical study, Tafinlar (dabrafenib) inhibited viability of a melanoma cell line harboring BRAF V600E and expressing MAP2K1 Q58_E62del in culture (PMID: 36442478).	36442478
BRAF V600E MAP2K1 Q58_E62del	melanoma	resistant	Vemurafenib	Preclinical - Cell culture	Actionable	In a preclinical study, a melanoma cell line harboring BRAF V600E and expressing MAP2K1 Q58_E62del was resistant to Zelboraf (vemurafenib) in culture (PMID: 36442478).	36442478
MAP2K1 R49L	Advanced Solid Tumor	sensitive	Trametinib	Preclinical - Cell culture	Actionable	In a preclinical study, Mekinist (trametinib) inhibited viability of a transformed cell line expressing MAP2K1 R49L in culture (PMID: 36442478).	36442478
BRAF V600E MAP2K1 R49L	melanoma	sensitive	Trametinib	Preclinical - Cell culture	Actionable	In a preclinical study, Mekinist (trametinib) inhibited viability of a melanoma cell line harboring BRAF V600E and expressing MAP2K1 R49L in culture (PMID: 36442478).	36442478
BRAF V600E MAP2K1 R49L	melanoma	sensitive	Cobimetinib + Vemurafenib	Preclinical - Cell culture	Actionable	In a preclinical study, the combination of Zelboraf (vemurafenib) and Cotellic (cobimetinib) synergistically inhibited viability of a melanoma cell line harboring BRAF V600E and expressing MAP2K1 R49L in culture (PMID: 36442478).	36442478
MAP2K1 F53S	Advanced Solid Tumor	sensitive	CI-1040	Preclinical - Biochemical	Actionable	In a preclinical study, CI-1040 (PD184352) inhibited kinase activity of MAP2K1 F53S in an in vitro assay and decreased Erk phosphorylation in cells expressing MAP2K1 F53S in culture (PMID: 12370306).	12370306
BRAF V600E MAP2K1 F53S	melanoma	sensitive	Trametinib	Preclinical - Cell culture	Actionable	In a preclinical study, Mekinist (trametinib) inhibited growth of a melanoma cell line harboring BRAF V600E and expressing MAP2K1 F53S in culture (PMID: 28986383).	28986383
BRAF V600E MAP2K1 F53S	melanoma	resistant	Vemurafenib	Preclinical - Cell culture	Actionable	In a preclinical study, a melanoma cell line harboring BRAF V600E and expressing MAP2K1 F53S was resistant to Zelboraf (vemurafenib) in culture (PMID: 28986383).	28986383
MAP2K1 F53V	Advanced Solid Tumor	sensitive	Trametinib	Preclinical - Cell culture	Actionable	In a preclinical study, Mekinist (trametinib) inhibited viability of a transformed cell line expressing MAP2K1 F53V in culture (PMID: 36442478).	36442478
BRAF V600E MAP2K1 F53V	melanoma	resistant	Dabrafenib	Preclinical - Cell culture	Actionable	In a preclinical study, a melanoma cell line harboring BRAF V600E and expressing MAP2K1 F53V was resistant to Tafinlar (dabrafenib) in culture (PMID: 36442478).	36442478
BRAF V600E MAP2K1 F53V	melanoma	resistant	Vemurafenib	Preclinical - Cell culture	Actionable	In a preclinical study, a melanoma cell line harboring BRAF V600E and expressing MAP2K1 F53V was resistant to Zelboraf (vemurafenib) in culture (PMID: 36442478).	36442478
BRAF V600E MAP2K1 F53V	melanoma	resistant	Encorafenib	Preclinical - Cell culture	Actionable	In a preclinical study, a melanoma cell line harboring BRAF V600E and expressing MAP2K1 F53V was resistant to Braftovi (encorafenib) in culture (PMID: 36442478).	36442478
BRAF V600E MAP2K1 F53V	melanoma	sensitive	Dabrafenib + Trametinib	Preclinical - Cell culture	Actionable	In a preclinical study, the combination of Tafinlar (dabrafenib) and Mekinist (trametinib) synergistically inhibited viability of a melanoma cell line harboring BRAF V600E and expressing MAP2K1 F53V in culture (PMID: 36442478).	36442478
BRAF V600E MAP2K1 F53V	melanoma	sensitive	Binimetinib + Encorafenib	Preclinical - Cell culture	Actionable	In a preclinical study, the combination of Braftovi (encorafenib) and Mektovi (binimetinib) synergistically inhibited viability of a melanoma cell line harboring BRAF V600E and expressing MAP2K1 F53V in culture (PMID: 36442478).	36442478
MAP2K1 F53C	Advanced Solid Tumor	sensitive	Trametinib	Preclinical - Cell culture	Actionable	In a preclinical study, Mekinist (trametinib) inhibited viability of a transformed cell line expressing MAP2K1 F53C in culture (PMID: 36442478).	36442478
MAP2K1 F53C	lymphoma	predicted - resistant	Vemurafenib	Preclinical - Cell culture	Actionable	In a preclinical study, expression of MAP2K1 F53C in a lymphoma cell line conferred resistance to inhibition of Erk phosphorylation by Zelboraf (vemurafenib) in culture (PMID: 30341394).	30341394
BRAF V600E MAP2K1 F53C	melanoma	resistant	Dabrafenib	Preclinical - Cell culture	Actionable	In a preclinical study, a melanoma cell line harboring BRAF V600E and expressing MAP2K1 F53C was resistant to Tafinlar (dabrafenib) in culture (PMID: 36442478).	36442478
BRAF V600E MAP2K1 F53C	melanoma	resistant	Vemurafenib	Preclinical - Cell culture	Actionable	In a preclinical study, a melanoma cell line harboring BRAF V600E and expressing MAP2K1 F53C was resistant to Zelboraf (vemurafenib) in culture (PMID: 36442478).	36442478
BRAF V600E MAP2K1 F53C	melanoma	resistant	Encorafenib	Preclinical - Cell culture	Actionable	In a preclinical study, a melanoma cell line harboring BRAF V600E and expressing MAP2K1 F53C was resistant to Braftovi (encorafenib) in culture (PMID: 36442478).	36442478
BRAF V600E MAP2K1 F53C	melanoma	sensitive	Dabrafenib + Trametinib	Preclinical - Cell culture	Actionable	In a preclinical study, the combination of Tafinlar (dabrafenib) and Mekinist (trametinib) synergistically inhibited viability of a melanoma cell line harboring BRAF V600E and expressing MAP2K1 F53C in culture (PMID: 36442478).	36442478
BRAF V600E MAP2K1 F53C	melanoma	sensitive	Binimetinib + Encorafenib	Preclinical - Cell culture	Actionable	In a preclinical study, the combination of Braftovi (encorafenib) and Mektovi (binimetinib) synergistically inhibited viability of a melanoma cell line harboring BRAF V600E and expressing MAP2K1 F53C in culture (PMID: 36442478).	36442478
MAP2K1 V60E	melanoma	resistant	Trametinib	Preclinical	Actionable	In a preclinical study, a melanoma cell line expressing MAP2K1 V60E demonstrated resistance to Mekinist (trametinib) in culture (PMID: 24265153).	24265153
MAP2K1 V60E	Advanced Solid Tumor	sensitive	Trametinib	Preclinical - Biochemical	Actionable	In a preclinical study, Mekinist (trametinib) inhibited Erk phosphorylation in transformed cells expressing MAP2K1 V60E in culture (PMID: 32641410).	32641410
MAP2K1 V60E	Advanced Solid Tumor	sensitive	Trametinib	Preclinical - Cell culture	Actionable	In a preclinical study, Mekinist (trametinib) inhibited viability of a transformed cell line expressing MAP2K1 V60E in culture (PMID: 36442478).	36442478
MAP2K1 V60E	melanoma	resistant	Dabrafenib	Preclinical	Actionable	In a preclinical study, a melanoma cell line expressing MAP2K1 V60E demonstrated resistance to Tafinlar (dabrafenib) in culture (PMID: 24265153).	24265153
BRAF V600E MAP2K1 V60E	melanoma	resistant	Dabrafenib	Preclinical - Cell culture	Actionable	In a preclinical study, a melanoma cell line harboring BRAF V600E and expressing MAP2K1 V60E was resistant to Tafinlar (dabrafenib) in culture (PMID: 36442478).	36442478
BRAF V600E MAP2K1 V60E	melanoma	resistant	Dabrafenib	Preclinical	Actionable	In a preclinical study, melanoma cells harboring BRAF V600E and expressing MAP2K1 V60E demonstrated resistance to treatment with Tafinlar (dabrafenib) in culture, resulting in sustained Map2k1/2 and Erk1/2 phosphorylation (PMID: 24265153).	24265153
BRAF V600E MAP2K1 V60E	melanoma	resistant	Vemurafenib	Preclinical - Cell culture	Actionable	In a preclinical study, a melanoma cell line harboring BRAF V600E and expressing MAP2K1 V60E was resistant to Zelboraf (vemurafenib) in culture (PMID: 36442478).	36442478
BRAF V600E MAP2K1 V60E	melanoma	resistant	Encorafenib	Preclinical - Cell culture	Actionable	In a preclinical study, a melanoma cell line harboring BRAF V600E and expressing MAP2K1 V60E was resistant to Braftovi (encorafenib) in culture (PMID: 36442478).	36442478
BRAF V600E MAP2K1 V60E	melanoma	sensitive	Dabrafenib + Trametinib	Preclinical - Cell culture	Actionable	In a preclinical study, the combination of Tafinlar (dabrafenib) and Mekinist (trametinib) synergistically inhibited viability of a melanoma cell line harboring BRAF V600E and expressing MAP2K1 V60E in culture (PMID: 36442478).	36442478
BRAF V600E MAP2K1 V60E	melanoma	sensitive	Binimetinib + Encorafenib	Preclinical - Cell culture	Actionable	In a preclinical study, the combination of Braftovi (encorafenib) and Mektovi (binimetinib) synergistically inhibited viability of a melanoma cell line harboring BRAF V600E and expressing MAP2K1 V60E in culture (PMID: 36442478).	36442478
BRAF V600E MAP2K1 V60E	melanoma	sensitive	VX-11e	Preclinical	Actionable	In a preclinical study, melanoma cells harboring BRAF V600E and expressing MAP2K1 V60E demonstrated sensitivity to treatment with VX-11e, resulting in decreased cell growth in culture (PMID: 24265153).	24265153
BRAF V600X MAP2K1 V60E NRAS T58I NRAS Q61R	melanoma	predicted - resistant	Vemurafenib	Clinical Study - Cohort	Actionable	In a clinical study, a melanoma patient harboring a BRAF V600 mutation developed resistance-associated mutations, MAP2K1 V60E, NRAS T58I, and NRAS Q61R, after 18 weeks of treatment with Zelboraf (vemurafenib) (PMID: 24265153).	24265153
BRAF V600E MAP2K1 L115R	melanoma	resistant	CI-1040	Preclinical - Cell culture	Actionable	In a preclinical study, expression of MAP2K1 L115R in melanoma cells harboring BRAF V600E conferred resistance to CI-1040 (PD184352) treatment in culture (PMID: 19915144).	19915144
BRAF V600E MAP2K1 L115R	melanoma	resistant	Selumetinib	Preclinical - Cell culture	Actionable	In a preclinical study, expression of MAP2K1 L115R in melanoma cells harboring BRAF V600E conferred resistance to Koselugo (selumetinib) treatment in culture (PMID: 19915144).	19915144
BRAF V600E MAP2K1 L115R	melanoma	resistant	PLX4720	Preclinical - Cell culture	Actionable	In a preclinical study, expression of MAP2K1 L115R in melanoma cells harboring BRAF V600E conferred resistance to PLX4720 treatment in culture (PMID: 19915144).	19915144
BRAF V600E MAP2K1 H119P	melanoma	resistant	CI-1040	Preclinical - Cell culture	Actionable	In a preclinical study, expression of MAP2K1 H119P in melanoma cells harboring BRAF V600E conferred resistance to CI-1040 (PD184352) treatment in culture (PMID: 19915144).	19915144
BRAF V600E MAP2K1 H119P	melanoma	resistant	Selumetinib	Preclinical	Actionable	In a preclinical study, expression of MAP2K1 H119P in melanoma cells harboring BRAF V600E conferred resistance to Koselugo (selumetinib) treatment in culture (PMID: 19915144).	19915144
BRAF V600E MAP2K1 G128V	melanoma	resistant	Trametinib	Preclinical	Actionable	In a preclinical study, melanoma cells harboring BRAF V600E and expressing MAP2K1 G128V demonstrated resistance to treatment with Mekinist (trametinib) in culture, resulting in sustained Map2k1/2 and Erk1/2 phosphorylation (PMID: 24265153).	24265153
BRAF V600E MAP2K1 G128V	melanoma	resistant	Dabrafenib	Preclinical	Actionable	In a preclinical study, melanoma cells harboring BRAF V600E and expressing MAP2K1 G128V demonstrated resistance to treatment with Tafinlar (dabrafenib) in culture, resulting in sustained Map2k1/2 and Erk1/2 phosphorylation (PMID: 24265153).	24265153
BRAF V600E MAP2K1 G128V	melanoma	conflicting	Dabrafenib + Trametinib	Preclinical	Actionable	In a preclinical study, MAP2K1 G128V conferred resistance to the combination of Tafinlar (dabrafenib) and Mekinist (trametinib) in BRAF V600E-mutant melanoma cells in culture (PMID: 24265154).	24265154
BRAF V600E MAP2K1 G128V	melanoma	conflicting	Dabrafenib + Trametinib	Preclinical - Cell culture	Actionable	In a preclinical study, the combination of Tafinlar (dabrafenib) and Mekinist (trametinib) synergistically inhibited viability of a melanoma cell line harboring BRAF V600E and expressing MAP2K1 G128V in culture (PMID: 36442478).	36442478
BRAF V600E MAP2K1 G128V	melanoma	sensitive	VX-11e	Preclinical	Actionable	In a preclinical study, melanoma cells harboring BRAF V600E and expressing MAP2K1 G128V demonstrated sensitivity to treatment with VX-11e, resulting in decreased cell growth in culture (PMID: 24265153).	24265153
BRAF V600E MAP2K1 I204T	melanoma	sensitive	Trametinib	Preclinical - Cell culture	Actionable	In a preclinical study, Mekinist (trametinib) inhibited viability of a melanoma cell line harboring BRAF V600E and expressing MAP2K1 I204T in culture (PMID: 36442478).	36442478
BRAF V600E MAP2K1 S218D MAP2K1 S222D	melanoma	resistant	Dabrafenib	Preclinical - Cell culture	Actionable	In a preclinical study, expression of MAP2K1 S218D and S222D in melanoma cells harboring BRAF V600E conferred resistance to Tafinlar (dabrafenib) treatment in culture (PMID: 31925410).	31925410
CTNNB1 mut MAP2K1 S218D MAP2K1 S222D	hepatocellular carcinoma	predicted - resistant	WNTinib	Preclinical - Cell culture	Actionable	In a preclinical study, a hepatocellular carcinoma cell line harboring a deletion of CTNNB1 exons and expressing MAP2K1 S218D and S222D was resistant to WNTinib in culture (PMID: 37537299).	37537299
BRAF V600E MAP2K1 P306H	melanoma	sensitive	Trametinib	Preclinical - Cell culture	Actionable	In a preclinical study, Mekinist (trametinib) inhibited viability of a melanoma cell line harboring BRAF V600E and expressing MAP2K1 P306H in culture (PMID: 36442478).	36442478
BRAF V600E MAP2K1 P306H	melanoma	sensitive	Dabrafenib	Preclinical - Cell culture	Actionable	In a preclinical study, Tafinlar (dabrafenib) inhibited viability of a melanoma cell line harboring BRAF V600E and expressing MAP2K1 P306H in culture (PMID: 36442478).	36442478
BRAF V600E MAP2K1 P306H	melanoma	sensitive	Vemurafenib	Preclinical - Cell culture	Actionable	In a preclinical study, Zelboraf (vemurafenib) inhibited viability of a melanoma cell line harboring BRAF V600E and expressing MAP2K1 P306H in culture (PMID: 36442478).	36442478
BRAF V600E MAP2K1 P306H	melanoma	sensitive	Encorafenib	Preclinical - Cell culture	Actionable	In a preclinical study, Braftovi (encorafenib) inhibited viability of a melanoma cell line harboring BRAF V600E and expressing MAP2K1 P306H in culture (PMID: 36442478).	36442478
BRAF V600E MAP2K1 P306H	melanoma	sensitive	Binimetinib	Preclinical - Cell culture	Actionable	In a preclinical study, Mektovi (binimetinib) inhibited viability of a melanoma cell line harboring BRAF V600E and expressing MAP2K1 P306H in culture (PMID: 36442478).	36442478
BRAF V600E MAP2K1 P306H	melanoma	sensitive	Cobimetinib	Preclinical - Cell culture	Actionable	In a preclinical study, Cotellic (cobimetinib) inhibited viability of a melanoma cell line harboring BRAF V600E and expressing MAP2K1 P306H in culture (PMID: 36442478).	36442478
BRAF V600E MAP2K1 N382H	melanoma	sensitive	Trametinib	Preclinical - Cell culture	Actionable	In a preclinical study, Mekinist (trametinib) inhibited viability of a melanoma cell line harboring BRAF V600E and expressing MAP2K1 N382H in culture (PMID: 36442478).	36442478
BRAF V600E MAP2K1 N382H	melanoma	sensitive	Dabrafenib	Preclinical - Cell culture	Actionable	In a preclinical study, Tafinlar (dabrafenib) inhibited viability of a melanoma cell line harboring BRAF V600E and expressing MAP2K1 N382H in culture (PMID: 36442478).	36442478
BRAF V600E MAP2K1 N382H	melanoma	sensitive	Vemurafenib	Preclinical - Cell culture	Actionable	In a preclinical study, Zelboraf (vemurafenib) inhibited viability of a melanoma cell line harboring BRAF V600E and expressing MAP2K1 N382H in culture (PMID: 36442478).	36442478
BRAF V600E MAP2K1 N382H	melanoma	sensitive	Encorafenib	Preclinical - Cell culture	Actionable	In a preclinical study, Braftovi (encorafenib) inhibited viability of a melanoma cell line harboring BRAF V600E and expressing MAP2K1 N382H in culture (PMID: 36442478).	36442478
BRAF V600E MAP2K1 N382H	melanoma	sensitive	Binimetinib	Preclinical - Cell culture	Actionable	In a preclinical study, Mektovi (binimetinib) inhibited viability of a melanoma cell line harboring BRAF V600E and expressing MAP2K1 N382H in culture (PMID: 36442478).	36442478
BRAF V600E MAP2K1 N382H	melanoma	sensitive	Cobimetinib	Preclinical - Cell culture	Actionable	In a preclinical study, Cotellic (cobimetinib) inhibited viability of a melanoma cell line harboring BRAF V600E and expressing MAP2K1 N382H in culture (PMID: 36442478).	36442478
MAP2K1 Q56_V60del	ovarian serous carcinoma	predicted - sensitive	Selumetinib	Case Reports/Case Series	Actionable	In a Phase II trial, Koselugo (selumetinib) treatment resulted in a complete response that lasted over 5 years with continuous treatment in a patient with serous ovarian cancer harboring MAP2K1 Q56_V60del (PMID: 26324360).	26324360
MAP2K1 N122D	Advanced Solid Tumor	predicted - sensitive	SCH772984	Preclinical - Biochemical	Actionable	In a preclinical study, SCH772984 inhibited downstream signaling in transformed cells expressing MAP2K1 N122D in culture (PMID: 32641410).	32641410
MAP2K1 G128D	Advanced Solid Tumor	sensitive	Trametinib	Preclinical - Cell culture	Actionable	In a preclinical study, Mekinist (trametinib) inhibited Erk phosphorylation and decreased cell size in a cell line expressing MAP2K1 G128D (PMID: 34726260).	34726260
MAP2K1 G128D	Advanced Solid Tumor	sensitive	Trametinib	Preclinical - Cell culture	Actionable	In a preclinical study, Mekinist (trametinib) inhibited viability of a transformed cell line expressing MAP2K1 G128D in culture (PMID: 36442478).	36442478
BRAF V600E MAP2K1 G128D	melanoma	resistant	Dabrafenib	Preclinical - Cell culture	Actionable	In a preclinical study, a melanoma cell line harboring BRAF V600E and expressing MAP2K1 G128D was resistant to Tafinlar (dabrafenib) in culture (PMID: 36442478).	36442478
BRAF V600E MAP2K1 G128D	colon adenocarcinoma	resistant	Vemurafenib	Preclinical - Cell culture	Actionable	In a preclinical study, a colon adenocarcinoma cell line harboring BRAF V600E and expressing MAP2K1 G128D was resistant to Zelboraf (vemurafenib) in culture (PMID: 36442478).	36442478
BRAF V600E MAP2K1 G128D	melanoma	resistant	Vemurafenib	Preclinical - Cell culture	Actionable	In a preclinical study, a melanoma cell line harboring BRAF V600E and expressing MAP2K1 G128D was resistant to Zelboraf (vemurafenib) in culture (PMID: 36442478).	36442478
BRAF V600E MAP2K1 G128D	colon adenocarcinoma	resistant	Cobimetinib	Preclinical - Cell culture	Actionable	In a preclinical study, a colon adenocarcinoma cell line harboring BRAF V600E and expressing MAP2K1 G128D was resistant to Cotellic (cobimetinib) in culture (PMID: 36442478).	36442478
BRAF V600E MAP2K1 G128D	melanoma	resistant	Cobimetinib	Preclinical - Cell culture	Actionable	In a preclinical study, a melanoma cell line harboring BRAF V600E and expressing MAP2K1 G128D was resistant to Cotellic (cobimetinib) in culture (PMID: 36442478).	36442478
BRAF V600E MAP2K1 G128D	melanoma	sensitive	Dabrafenib + Trametinib	Preclinical - Cell culture	Actionable	In a preclinical study, the combination of Tafinlar (dabrafenib) and Mekinist (trametinib) synergistically inhibited viability of a melanoma cell line harboring BRAF V600E and expressing MAP2K1 G128D in culture (PMID: 36442478).	36442478
BRAF V600E MAP2K1 G128D	melanoma	sensitive	Cobimetinib + Vemurafenib	Preclinical - Cell culture	Actionable	In a preclinical study, the combination of Zelboraf (vemurafenib) and Cotellic (cobimetinib) synergistically inhibited viability of a melanoma cell line harboring BRAF V600E and expressing MAP2K1 G128D in culture (PMID: 36442478).	36442478
MAP2K1 L115A	Advanced Solid Tumor	decreased response	CI-1040	Preclinical - Biochemical	Actionable	In a preclinical study, MAP2K1 L115A demonstrated decreased sensitivity to CI-1040 (PD184352) in an in vitro kinase assay (PMID: 12370306).	12370306
MAP2K1 I99_K104del	Advanced Solid Tumor	resistant	Trametinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing MAP2K1 I99_K104del were resistant to Mekinist (trametinib) in culture (PMID: 36442478).	36442478
BRAF V600E MAP2K1 I99_K104del	melanoma	resistant	Trametinib	Preclinical - Cell culture	Actionable	In a preclinical study, a melanoma cell line harboring BRAF V600E and expressing MAP2K1 I99_K104del was resistant to Mekinist (trametinib) in culture (PMID: 36442478).	36442478
BRAF V600E MAP2K1 I99_K104del	melanoma	resistant	Dabrafenib	Preclinical - Cell culture	Actionable	In a preclinical study, a melanoma cell line harboring BRAF V600E and expressing MAP2K1 I99_K104del was resistant to Tafinlar (dabrafenib) in culture (PMID: 36442478).	36442478
BRAF V600E MAP2K1 I99_K104del	melanoma	resistant	Vemurafenib	Preclinical - Cell culture	Actionable	In a preclinical study, a melanoma cell line harboring BRAF V600E and expressing MAP2K1 I99_K104del was resistant to Zelboraf (vemurafenib) in culture (PMID: 36442478).	36442478
BRAF V600E MAP2K1 I99_K104del	melanoma	resistant	Encorafenib	Preclinical - Cell culture	Actionable	In a preclinical study, a melanoma cell line harboring BRAF V600E and expressing MAP2K1 I99_K104del was resistant to Braftovi (encorafenib) in culture (PMID: 36442478).	36442478
BRAF V600E MAP2K1 I99_K104del	melanoma	resistant	Binimetinib	Preclinical - Cell culture	Actionable	In a preclinical study, a melanoma cell line harboring BRAF V600E and expressing MAP2K1 I99_K104del was resistant to Mektovi (binimetinib) in culture (PMID: 36442478).	36442478
BRAF V600E MAP2K1 I99_K104del	melanoma	decreased response	Ulixertinib	Preclinical - Cell culture	Actionable	In a preclinical study, a melanoma cell line harboring BRAF V600E and expressing MAP2K1 I99_K104del was less responsive to Ulixertinib (BVD-523) compared to cells expressing wild-type MAP2K1 in culture (PMID: 36442478).	36442478
BRAF V600E MAP2K1 I99_K104del	colon adenocarcinoma	resistant	Cobimetinib	Preclinical - Cell culture	Actionable	In a preclinical study, a colon adenocarcinoma cell line harboring BRAF V600E and expressing MAP2K1 I99_K104del was resistant to Cotellic (cobimetinib) in culture (PMID: 36442478).	36442478
BRAF V600E MAP2K1 I99_K104del	melanoma	resistant	Cobimetinib	Preclinical - Cell culture	Actionable	In a preclinical study, a melanoma cell line harboring BRAF V600E and expressing MAP2K1 I99_K104del was resistant to Cotellic (cobimetinib) in culture (PMID: 36442478).	36442478
BRAF V600E MAP2K1 I99_K104del	melanoma	decreased response	Ravoxertinib	Preclinical - Cell culture	Actionable	In a preclinical study, a melanoma cell line harboring BRAF V600E and expressing MAP2K1 I99_K104del was less responsive to Ravoxertinib (GDC-0994) compared to cells expressing wild-type MAP2K1 in culture (PMID: 36442478).	36442478
MAP2K1 I103_K104del	Advanced Solid Tumor	decreased response	Trametinib	Preclinical - Biochemical	Actionable	In a preclinical study, transformed cells expressing MAP2K1 I103_K104del were less sensitive to Mekinist (trametinib) compared to similar mutations in the negative regulatory domain of the Map2k1 protein in culture (PMID: 32641410).	32641410
MAP2K1 I103_K104del	Advanced Solid Tumor	predicted - sensitive	SCH772984	Preclinical - Biochemical	Actionable	In a preclinical study, SCH772984 inhibited downstream signaling in transformed cells expressing MAP2K1 I103_K104del in culture (PMID: 32641410).	32641410
BRAF V600E MAP2K1 I103_K104del	melanoma	resistant	Dabrafenib	Preclinical - Cell culture	Actionable	In a preclinical study, a melanoma cell line harboring BRAF V600E and expressing MAP2K1 I103_K104del was resistant to Tafinlar (dabrafenib) in culture (PMID: 36442478).	36442478
BRAF V600E MAP2K1 I103_K104del	melanoma	resistant	Vemurafenib	Preclinical - Cell culture	Actionable	In a preclinical study, a melanoma cell line harboring BRAF V600E and expressing MAP2K1 I103_K104del was resistant to Zelboraf (vemurafenib) in culture (PMID: 36442478).	36442478
BRAF V600E MAP2K1 I103_K104del	melanoma	resistant	Encorafenib	Preclinical - Cell culture	Actionable	In a preclinical study, a melanoma cell line harboring BRAF V600E and expressing MAP2K1 I103_K104del was resistant to Braftovi (encorafenib) in culture (PMID: 36442478).	36442478
BRAF V600E MAP2K1 I103_K104del	melanoma	sensitive	Dabrafenib + Trametinib	Preclinical - Cell culture	Actionable	In a preclinical study, the combination of Tafinlar (dabrafenib) and Mekinist (trametinib) synergistically inhibited viability of a melanoma cell line harboring BRAF V600E and expressing MAP2K1 I103_K104del in culture (PMID: 36442478).	36442478
BRAF V600E MAP2K1 P162S	melanoma	sensitive	Trametinib	Preclinical	Actionable	In a preclinical study, Mekinist (trametinib) inhibited growth of BRAF V600E-mutant melanoma cells expressing MAP2K1 P162S in culture (PMID: 24265154).	24265154
BRAF V600E MAP2K1 P162S	melanoma	sensitive	Trametinib	Preclinical - Cell culture	Actionable	In a preclinical study, Mekinist (trametinib) inhibited viability of a melanoma cell line harboring BRAF V600E and expressing MAP2K1 P162S in culture (PMID: 36442478).	36442478
BRAF V600E MAP2K1 P162S	melanoma	sensitive	Dabrafenib	Preclinical	Actionable	In a preclinical study, Tafinlar (dabrafenib) inhibited growth of BRAF V600E-mutant melanoma cells expressing MAP2K1 P162S in culture (PMID: 24265154).	24265154
BRAF V600E MAP2K1 P162S	melanoma	sensitive	Dabrafenib	Preclinical - Cell culture	Actionable	In a preclinical study, Tafinlar (dabrafenib) inhibited viability of a melanoma cell line harboring BRAF V600E and expressing MAP2K1 P162S in culture (PMID: 36442478).	36442478
BRAF V600E MAP2K1 P162S	melanoma	sensitive	Vemurafenib	Preclinical - Cell culture	Actionable	In a preclinical study, Zelboraf (vemurafenib) inhibited viability of a melanoma cell line harboring BRAF V600E and expressing MAP2K1 P162S in culture (PMID: 36442478).	36442478
BRAF V600E MAP2K1 P162S	melanoma	sensitive	Encorafenib	Preclinical - Cell culture	Actionable	In a preclinical study, Braftovi (encorafenib) inhibited viability of a melanoma cell line harboring BRAF V600E and expressing MAP2K1 P162S in culture (PMID: 36442478).	36442478
BRAF V600E MAP2K1 P162S	melanoma	sensitive	Binimetinib	Preclinical - Cell culture	Actionable	In a preclinical study, Mektovi (binimetinib) inhibited viability of a melanoma cell line harboring BRAF V600E and expressing MAP2K1 P162S in culture (PMID: 36442478).	36442478
BRAF V600E MAP2K1 P162S	melanoma	sensitive	Cobimetinib	Preclinical - Cell culture	Actionable	In a preclinical study, Cotellic (cobimetinib) inhibited viability of a melanoma cell line harboring BRAF V600E and expressing MAP2K1 P162S in culture (PMID: 36442478).	36442478
BRAF V600E MAP2K1 P162S	melanoma	sensitive	Dabrafenib + Trametinib	Preclinical	Actionable	In a preclinical study, the combination of Mekinist (trametinib) and Tafinlar (dabrafenib) inhibited growth of BRAF V600E-mutant melanoma cells expressing MAP2K1 P162S in culture (PMID: 24265154).	24265154
MAP2K1 T55P	Advanced Solid Tumor	predicted - sensitive	Trametinib	Preclinical - Biochemical	Actionable	In a preclinical study, Mekinist (trametinib) inhibited Erk phosphorylation in transformed cells expressing MAP2K1 T55P in culture (PMID: 32641410).	32641410
MAP2K1 I111S	Advanced Solid Tumor	resistant	AZD8330	Preclinical - Cell culture	Actionable	In a preclinical study, Map2k1 I111S displayed resistance to the Mek inhibitor, AZD8330, as demonstrated by constitutive activation of Map2k1 in transformed human kidney cells (PMID: 29753091).	29753091
MAP2K1 I111S	Advanced Solid Tumor	resistant	Regorafenib	Preclinical - Cell culture	Actionable	In a preclinical study, Map2k1 I111S displayed resistance to Stivarga (regorafenib; BAY 73-4506), as demonstrated by constitutive activation of Map2k1 in transformed human kidney cells (PMID: 29753091).	29753091
MAP2K1 I111S	Advanced Solid Tumor	sensitive	Selumetinib	Preclinical - Cell culture	Actionable	In a preclinical study, Map2k1 I111S displayed sensitivity to the Mek inhibitor, Selumetinib (AZD6244), as demonstrated by reversal of active Map2k1 in transformed human kidney cells (PMID: 29753091).	29753091
MAP2K1 I111S	Advanced Solid Tumor	sensitive	PLX4720	Preclinical - Cell culture	Actionable	In a preclinical study, Map2k1 I111S displayed sensitivity to the Braf inhibitor, PLX4720, as demonstrated by reversal of active Map2k1 in transformed human kidney cells (PMID: 29753091).	29753091
MAP2K1 I111S	Advanced Solid Tumor	resistant	GDC0879	Preclinical - Cell culture	Actionable	In a preclinical study, Map2k1 I111S displayed resistance to the Braf inhibitor, GDC-0879, as demonstrated by constitutive activation of Map2k1 in transformed human kidney cells (PMID: 29753091).	29753091
MAP2K1 I111S	Advanced Solid Tumor	resistant	PD98059	Preclinical - Cell culture	Actionable	In a preclinical study, Map2k1 I111S displayed resistance to the Mek inhibitor, PD98059, as demonstrated by constitutive activation of Map2k1 in transformed human kidney cells (PMID: 29753091).	29753091
BRAF V600E MAP2K1 I111S	melanoma	sensitive	Trametinib	Preclinical - Cell culture	Actionable	In a preclinical study, Mekinist (trametinib) inhibited viability of a melanoma cell line harboring BRAF V600E and expressing MAP2K1 I111S in culture (PMID: 36442478).	36442478
BRAF V600E MAP2K1 I111S	melanoma	sensitive	Dabrafenib	Preclinical - Cell culture	Actionable	In a preclinical study, Tafinlar (dabrafenib) inhibited viability of a melanoma cell line harboring BRAF V600E and expressing MAP2K1 I111S in culture (PMID: 36442478).	36442478
MAP2K1 L98_K104delinsQ	lymphatic system cancer	predicted - resistant	Trametinib	Case Reports/Case Series	Actionable	In a clinical case study, a patient with Langerhans cell histiocytosis harboring MAP2K1 L98_K104delinsQ demonstrated progressive disease when treated with Mekinist (trametinib) (PMID: 29768711).	29768711
MAP2K1 L98_K104delinsQ	Advanced Solid Tumor	resistant	Trametinib	Preclinical - Cell culture	Actionable	In a preclinical study, Mekinist (trametinib) treatment failed to inhibit activation of Mek and Erk in human cells expressing MAP2K1 L98_K104delinsQ in culture (PMID: 29768711).	29768711
MAP2K1 L98_K104delinsQ	Advanced Solid Tumor	resistant	MK2206	Preclinical - Cell culture	Actionable	In a preclinical study, MK2206 treatment failed to inhibit activation of Mek and Erk in human cells expressing MAP2K1 L98_K104delinsQ in culture (PMID: 29768711).	29768711
MAP2K1 L98_K104delinsQ	Advanced Solid Tumor	resistant	U0126	Preclinical - Cell culture	Actionable	In a preclinical study, U0126 treatment failed to inhibit activation of Mek and Erk in human cells expressing MAP2K1 L98_K104delinsQ in culture (PMID: 29768711).	29768711
MAP2K1 L98_K104delinsQ	Advanced Solid Tumor	resistant	SCH772984	Preclinical - Cell culture	Actionable	In a preclinical study, SCH772984 treatment failed to inhibit activation of Mek and Erk in human cells expressing MAP2K1 L98_K104delinsQ in culture (PMID: 29768711).	29768711
MAP2K1 P105_I107del	lymphatic system cancer	predicted - sensitive	Cobimetinib	Case Reports/Case Series	Actionable	In a Phase II trial, treatment with Cotellic (cobimetinib) in patients with histiocytic neoplasms resulted in a PET overall response rate of 89% (16/18), with complete response in 72% (13/18) and partial response in 17% (3/18), and resulted in stable disease in 6% (1/18) of patients, including a complete response in a patient with Erdheim-Chester disease harboring MAP2K1 P105_I107del (PMID: 30867592; NCT01953926).	30867592
BRAF V600E MAP2K1 I99G	melanoma	resistant	Trametinib	Preclinical - Cell culture	Actionable	In a preclinical study, melanoma cells harboring BRAF V600E and expressing MAP2K1 I99G demonstrated resistance to Mekinist (trametinib) treatment in culture (PMID: 31925410).	31925410
BRAF V600E MAP2K1 I99G	melanoma	resistant	Dabrafenib	Preclinical - Cell culture	Actionable	In a preclinical study, melanoma cells harboring BRAF V600E and expressing MAP2K1 I99G demonstrated resistance to Tafinlar (dabrafenib) treatment in culture (PMID: 31925410).	31925410
BRAF V600E MAP2K1 I99M	melanoma	sensitive	Trametinib	Preclinical - Cell culture	Actionable	In a preclinical study, melanoma cells harboring BRAF V600E and expressing MAP2K1 I99M demonstrated sensitivity to Mekinist (trametinib) treatment similar to cells expressing wild-type MAP2K1 in culture (PMID: 31925410).	31925410
BRAF V600E MAP2K1 I99M	melanoma	sensitive	Dabrafenib	Preclinical - Cell culture	Actionable	In a preclinical study, melanoma cells harboring BRAF V600E and expressing MAP2K1 I99M demonstrated sensitivity to Tafinlar (dabrafenib) treatment similar to cells expressing wild-type MAP2K1 in culture (PMID: 31925410).	31925410
BRAF V600E MAP2K1 I99T	melanoma	resistant	Trametinib	Preclinical - Cell culture	Actionable	In a preclinical study, melanoma cells harboring BRAF V600E and expressing MAP2K1 I99T demonstrated resistance to Mekinist (trametinib) treatment in culture (PMID: 31925410).	31925410
BRAF V600E MAP2K1 I99T	melanoma	resistant	Dabrafenib	Preclinical - Cell culture	Actionable	In a preclinical study, melanoma cells harboring BRAF V600E and expressing MAP2K1 I99T demonstrated resistance to Tafinlar (dabrafenib) treatment in culture (PMID: 31925410).	31925410
BRAF V600E MAP2K1 I99T	melanoma	resistant	CI-1040	Preclinical - Cell culture	Actionable	In a preclinical study, expression of MAP2K1 I99T in melanoma cells harboring BRAF V600E conferred resistance to CI-1040 (PD184352) treatment in culture (PMID: 19915144).	19915144
BRAF V600E MAP2K1 I99T	melanoma	resistant	Selumetinib	Preclinical - Cell culture	Actionable	In a preclinical study, expression of MAP2K1 I99T in melanoma cells harboring BRAF V600E conferred resistance to Koselugo (selumetinib) treatment in culture (PMID: 19915144).	19915144
MAP2K1 P105_A106del	Advanced Solid Tumor	resistant	Trametinib	Preclinical - Biochemical	Actionable	In a preclinical study, transformed cells expressing MAP2K1 P105_A106del were less sensitive to Mekinist (trametinib) compared to similar mutations in the negative regulatory domain of the Map2k1 protein in culture (PMID: 32641410).	32641410
MAP2K1 P105_A106del	Advanced Solid Tumor	resistant	Trametinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing MAP2K1 P105_A106del were resistant to Mekinist (trametinib) in culture (PMID: 36442478).	36442478
MAP2K1 P105_A106del	Advanced Solid Tumor	predicted - sensitive	SCH772984	Preclinical - Biochemical	Actionable	In a preclinical study, SCH772984 inhibited downstream signaling in transformed cells expressing MAP2K1 P105_A106del in culture (PMID: 32641410).	32641410
BRAF V600E MAP2K1 P105_A106del	melanoma	resistant	Dabrafenib	Preclinical - Cell culture	Actionable	In a preclinical study, a melanoma cell line harboring BRAF V600E and expressing MAP2K1 P105_A106del was resistant to Tafinlar (dabrafenib) in culture (PMID: 36442478).	36442478
BRAF V600E MAP2K1 P105_A106del	melanoma	resistant	Vemurafenib	Preclinical - Cell culture	Actionable	In a preclinical study, a melanoma cell line harboring BRAF V600E and expressing MAP2K1 P105_A106del was resistant to Zelboraf (vemurafenib) in culture (PMID: 36442478).	36442478
BRAF V600E MAP2K1 P105_A106del	melanoma	resistant	Encorafenib	Preclinical - Cell culture	Actionable	In a preclinical study, a melanoma cell line harboring BRAF V600E and expressing MAP2K1 P105_A106del was resistant to Braftovi (encorafenib) in culture (PMID: 36442478).	36442478
BRAF V600E MAP2K1 P105_A106del	melanoma	resistant	Binimetinib	Preclinical - Cell culture	Actionable	In a preclinical study, a melanoma cell line harboring BRAF V600E and expressing MAP2K1 P105_A106del was resistant to Mektovi (binimetinib) in culture (PMID: 36442478).	36442478
BRAF V600E MAP2K1 P105_A106del	melanoma	sensitive	Dabrafenib + Trametinib	Preclinical - Cell culture	Actionable	In a preclinical study, the combination of Tafinlar (dabrafenib) and Mekinist (trametinib) synergistically inhibited viability of a melanoma cell line harboring BRAF V600E and expressing MAP2K1 P105_A106del in culture (PMID: 36442478).	36442478
BRAF V600E MAP2K1 P105_A106del	melanoma	sensitive	Binimetinib + Encorafenib	Preclinical - Cell culture	Actionable	In a preclinical study, the combination of Braftovi (encorafenib) and Mektovi (binimetinib) synergistically inhibited viability of a melanoma cell line harboring BRAF V600E and expressing MAP2K1 P105_A106del in culture (PMID: 36442478).	36442478
MAP2K1 E41_L54del	lung cancer	sensitive	Trametinib	Preclinical - Cell culture	Actionable	In a preclinical study, Mekinist (trametinib) inhibited growth of transformed human lung cells expressing MAP2K1 E41_L54del in culture (PMID: 32122926).	32122926
MAP2K1 E41_L54del	Advanced Solid Tumor	sensitive	Trametinib	Preclinical - Cell culture	Actionable	In a preclinical study, Mekinist (trametinib) inhibited growth of transformed cells expressing MAP2K1 E41_L54del in culture (PMID: 32122926).	32122926
MAP2K1 E41_L54del	lung cancer	sensitive	Selumetinib	Preclinical - Cell culture	Actionable	In a preclinical study, Koselugo (selumetinib) inhibited growth of transformed human lung cells expressing MAP2K1 E41_L54del in culture (PMID: 32122926).	32122926
MAP2K1 E41_L54del	Advanced Solid Tumor	sensitive	Selumetinib	Preclinical - Cell culture	Actionable	In a preclinical study, Koselugo (selumetinib) inhibited growth of transformed cells expressing MAP2K1 E41_L54del in culture (PMID: 32122926).	32122926
MAP2K1 E41_L54del	lung cancer	sensitive	Cobimetinib	Preclinical - Cell culture	Actionable	In a preclinical study, Cotellic (cobimetinib) inhibited growth of transformed human lung cells expressing MAP2K1 E41_L54del in culture (PMID: 32122926).	32122926
MAP2K1 E41_L54del	Advanced Solid Tumor	sensitive	Cobimetinib	Preclinical - Cell culture	Actionable	In a preclinical study, Cotellic (cobimetinib) inhibited growth of transformed cells expressing MAP2K1 E41_L54del in culture (PMID: 32122926).	32122926
MAP2K1 E41_L54del	lung cancer	no benefit	LY3009120	Preclinical - Cell culture	Actionable	In a preclinical study, transformed human lung cells expressing MAP2K1 E41_L54del were not sensitive to LY3009120 in culture (PMID: 32122926).	32122926
MAP2K1 E41_L54del	Advanced Solid Tumor	no benefit	LY3009120	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing MAP2K1 E41_L54del were not sensitive to LY3009120 in culture (PMID: 32122926).	32122926
BRAF V600E MAP2K1 E203V	melanoma	resistant	Vemurafenib	Preclinical - Cell culture	Actionable	In a preclinical study, a melanoma cell line harboring BRAF V600E and expressing MAP2K1 E203V was resistant to Zelboraf (vemurafenib) in culture (PMID: 36442478).	36442478
BRAF V600E MAP2K1 E203V	melanoma	sensitive	Dabrafenib + Trametinib	Preclinical - Cell culture	Actionable	In a preclinical study, the combination of Tafinlar (dabrafenib) and Mekinist (trametinib) synergistically inhibited viability of a melanoma cell line harboring BRAF V600E and expressing MAP2K1 E203V in culture (PMID: 36442478).	36442478
BRAF V600E MAP2K1 E203V	melanoma	sensitive	Binimetinib + Encorafenib	Preclinical - Cell culture	Actionable	In a preclinical study, the combination of Braftovi (encorafenib) and Mektovi (binimetinib) synergistically inhibited viability of a melanoma cell line harboring BRAF V600E and expressing MAP2K1 E203V in culture (PMID: 36442478).	36442478
BRAF V600E MAP2K1 E203V	melanoma	sensitive	Cobimetinib + Vemurafenib	Preclinical - Cell culture	Actionable	In a preclinical study, the combination of Zelboraf (vemurafenib) and Cotellic (cobimetinib) synergistically inhibited viability of a melanoma cell line harboring BRAF V600E and expressing MAP2K1 E203V in culture (PMID: 36442478).	36442478
BRAF V600E MAP2K1 R201H	melanoma	sensitive	Trametinib	Preclinical - Cell culture	Actionable	In a preclinical study, Mekinist (trametinib) inhibited viability of a melanoma cell line harboring BRAF V600E and expressing MAP2K1 R201H in culture (PMID: 36442478).	36442478
BRAF V600E MAP2K1 R201H	melanoma	sensitive	Dabrafenib	Preclinical - Cell culture	Actionable	In a preclinical study, Tafinlar (dabrafenib) inhibited viability of a melanoma cell line harboring BRAF V600E and expressing MAP2K1 R201H in culture (PMID: 36442478).	36442478
BRAF V600E MAP2K1 R201H	melanoma	sensitive	Vemurafenib	Preclinical - Cell culture	Actionable	In a preclinical study, Zelboraf (vemurafenib) inhibited viability of a melanoma cell line harboring BRAF V600E and expressing MAP2K1 R201H in culture (PMID: 36442478).	36442478
BRAF V600E MAP2K1 R201H	melanoma	sensitive	Encorafenib	Preclinical - Cell culture	Actionable	In a preclinical study, Braftovi (encorafenib) inhibited viability of a melanoma cell line harboring BRAF V600E and expressing MAP2K1 R201H in culture (PMID: 36442478).	36442478
BRAF V600E MAP2K1 R201H	melanoma	sensitive	Binimetinib	Preclinical - Cell culture	Actionable	In a preclinical study, Mektovi (binimetinib) inhibited viability of a melanoma cell line harboring BRAF V600E and expressing MAP2K1 R201H in culture (PMID: 36442478).	36442478
BRAF V600E MAP2K1 R201H	melanoma	sensitive	Cobimetinib	Preclinical - Cell culture	Actionable	In a preclinical study, Cotellic (cobimetinib) inhibited viability of a melanoma cell line harboring BRAF V600E and expressing MAP2K1 R201H in culture (PMID: 36442478).	36442478
BRAF V600E MAP2K1 R49H	melanoma	sensitive	Trametinib	Preclinical - Cell culture	Actionable	In a preclinical study, Mekinist (trametinib) inhibited viability of a melanoma cell line harboring BRAF V600E and expressing MAP2K1 R49H in culture (PMID: 36442478).	36442478
BRAF V600E MAP2K1 R49H	melanoma	sensitive	Dabrafenib	Preclinical - Cell culture	Actionable	In a preclinical study, Tafinlar (dabrafenib) inhibited viability of a melanoma cell line harboring BRAF V600E and expressing MAP2K1 R49H in culture (PMID: 36442478).	36442478
BRAF V600E MAP2K1 R49H	melanoma	sensitive	Vemurafenib	Preclinical - Cell culture	Actionable	In a preclinical study, Zelboraf (vemurafenib) inhibited viability of a melanoma cell line harboring BRAF V600E and expressing MAP2K1 R49H in culture (PMID: 36442478).	36442478
BRAF V600E MAP2K1 R49H	melanoma	sensitive	Encorafenib	Preclinical - Cell culture	Actionable	In a preclinical study, Braftovi (encorafenib) inhibited viability of a melanoma cell line harboring BRAF V600E and expressing MAP2K1 R49H in culture (PMID: 36442478).	36442478
BRAF V600E MAP2K1 R49H	melanoma	sensitive	Binimetinib	Preclinical - Cell culture	Actionable	In a preclinical study, Mektovi (binimetinib) inhibited viability of a melanoma cell line harboring BRAF V600E and expressing MAP2K1 R49H in culture (PMID: 36442478).	36442478
BRAF V600E MAP2K1 R49H	melanoma	sensitive	Cobimetinib	Preclinical - Cell culture	Actionable	In a preclinical study, Cotellic (cobimetinib) inhibited viability of a melanoma cell line harboring BRAF V600E and expressing MAP2K1 R49H in culture (PMID: 36442478).	36442478
MAP2K1 K57_G61del	lymphatic system cancer	predicted - sensitive	Trametinib	Case Reports/Case Series	Actionable	In a clinical case study, a pediatric patient with Langerhans cell histiocytosis harboring MAP2K1 K57_G61del treated with Mekinist (trametinib) achieved a rapid complete response and had no active disease over 22 months of treatment (PMID: 32991018).	32991018
MAP2K1 K57_G61del	Advanced Solid Tumor	sensitive	Trametinib	Preclinical - Cell culture	Actionable	In a preclinical study, Mekinist (trametinib) inhibited viability of a transformed cell line expressing MAP2K1 K57_G61del in culture (PMID: 36442478).	36442478
BRAF V600E MAP2K1 K57_G61del	melanoma	sensitive	Trametinib	Preclinical - Cell culture	Actionable	In a preclinical study, Mekinist (trametinib) inhibited viability of a melanoma cell line harboring BRAF V600E and expressing MAP2K1 K57_G61del in culture (PMID: 36442478).	36442478
MAP2K1 N109_R113del	Advanced Solid Tumor	predicted - sensitive	Trametinib	Preclinical - Biochemical	Actionable	In a preclinical study, Mekinist (trametinib) inhibited Erk phosphorylation in transformed cells expressing MAP2K1 N109_R113del in culture (PMID: 32641410).	32641410
MAP2K1 N109_R113del	Advanced Solid Tumor	predicted - sensitive	SCH772984	Preclinical - Biochemical	Actionable	In a preclinical study, SCH772984 inhibited downstream signaling in transformed cells expressing MAP2K1 N109_R113del in culture (PMID: 32641410).	32641410
MAP2K1 P105_I107delinsL	Advanced Solid Tumor	decreased response	Trametinib	Preclinical - Biochemical	Actionable	In a preclinical study, transformed cells expressing MAP2K1 P105_I107delinsL were less sensitive to Mekinist (trametinib) compared to similar mutations in the negative regulatory domain of the Map2k1 protein in culture (PMID: 32641410).	32641410
MAP2K1 P105_I107delinsL	Advanced Solid Tumor	predicted - sensitive	SCH772984	Preclinical - Biochemical	Actionable	In a preclinical study, SCH772984 inhibited downstream signaling in transformed cells expressing MAP2K1 P105_I107delinsL in culture (PMID: 32641410).	32641410
MAP2K1 I111D	Advanced Solid Tumor	predicted - resistant	CI-1040	Preclinical - Biochemical	Actionable	In a preclinical study, CI-1040 (PD184352) did not inhibit kinase activity of MAP2K1 I111D in an in vitro assay (PMID: 12370306).	12370306
MAP2K1 I139G	Advanced Solid Tumor	predicted - resistant	CI-1040	Preclinical - Biochemical	Actionable	In a preclinical study, CI-1040 (PD184352) did not inhibit kinase activity of MAP2K1 I139G in an in vitro assay (PMID: 12370306).	12370306
MAP2K1 I139R	Advanced Solid Tumor	decreased response	CI-1040	Preclinical - Biochemical	Actionable	In a preclinical study, MAP2K1 I139R demonstrated decreased sensitivity to CI-1040 (PD184352) in an in vitro kinase assay (PMID: 12370306).	12370306
MAP2K1 I139N	Advanced Solid Tumor	decreased response	CI-1040	Preclinical - Biochemical	Actionable	In a preclinical study, MAP2K1 I139N demonstrated decreased sensitivity to CI-1040 (PD184352) in an in vitro kinase assay (PMID: 12370306).	12370306
MAP2K1 L118D	Advanced Solid Tumor	predicted - resistant	CI-1040	Preclinical - Biochemical	Actionable	In a preclinical study, CI-1040 (PD184352) did not inhibit kinase activity of MAP2K1 L118D in an in vitro assay (PMID: 12370306).	12370306
MAP2K1 L118P	Advanced Solid Tumor	predicted - resistant	CI-1040	Preclinical - Biochemical	Actionable	In a preclinical study, CI-1040 (PD184352) did not inhibit kinase activity of MAP2K1 L118P in an in vitro assay (PMID: 12370306).	12370306
MAP2K1 L118G	Advanced Solid Tumor	decreased response	CI-1040	Preclinical - Biochemical	Actionable	In a preclinical study, MAP2K1 L118G demonstrated decreased sensitivity to CI-1040 (PD184352) in an in vitro kinase assay (PMID: 12370306).	12370306
MAP2K1 L118Q	Advanced Solid Tumor	predicted - resistant	CI-1040	Preclinical - Biochemical	Actionable	In a preclinical study, CI-1040 (PD184352) did not inhibit kinase activity of MAP2K1 L118Q in an in vitro assay (PMID: 12370306).	12370306
BRAF V600E MAP2K1 P264L	melanoma	sensitive	Trametinib	Preclinical - Cell culture	Actionable	In a preclinical study, Mekinist (trametinib) inhibited growth of a melanoma cell line harboring BRAF V600E and expressing MAP2K1 P264L in culture (PMID: 28986383).	28986383
BRAF V600E MAP2K1 P264L	melanoma	resistant	Vemurafenib	Preclinical - Cell culture	Actionable	In a preclinical study, a melanoma cell line harboring BRAF V600E and expressing MAP2K1 P264L was resistant to Zelboraf (vemurafenib) in culture (PMID: 28986383).	28986383
BRAF V600E MAP2K1 A14S	melanoma	sensitive	Trametinib	Preclinical - Cell culture	Actionable	In a preclinical study, Mekinist (trametinib) inhibited viability of a melanoma cell line harboring BRAF V600E and expressing MAP2K1 A14S in culture (PMID: 36442478).	36442478
BRAF V600E MAP2K1 A14S	melanoma	sensitive	Dabrafenib	Preclinical - Cell culture	Actionable	In a preclinical study, Tafinlar (dabrafenib) inhibited viability of a melanoma cell line harboring BRAF V600E and expressing MAP2K1 A14S in culture (PMID: 36442478).	36442478
BRAF V600E MAP2K1 A14S	melanoma	sensitive	Encorafenib	Preclinical - Cell culture	Actionable	In a preclinical study, Braftovi (encorafenib) inhibited viability of a melanoma cell line harboring BRAF V600E and expressing MAP2K1 A14S in culture (PMID: 36442478).	36442478
BRAF V600E MAP2K1 A14S	melanoma	sensitive	Binimetinib	Preclinical - Cell culture	Actionable	In a preclinical study, Mektovi (binimetinib) inhibited viability of a melanoma cell line harboring BRAF V600E and expressing MAP2K1 A14S in culture (PMID: 36442478).	36442478
BRAF V600E MAP2K1 A14S	melanoma	sensitive	Cobimetinib	Preclinical - Cell culture	Actionable	In a preclinical study, Cotellic (cobimetinib) inhibited viability of a melanoma cell line harboring BRAF V600E and expressing MAP2K1 A14S in culture (PMID: 36442478).	36442478
MAP2K1 L42_K57del	Advanced Solid Tumor	sensitive	Trametinib	Preclinical - Cell culture	Actionable	In a preclinical study, Mekinist (trametinib) inhibited viability of a transformed cell line expressing MAP2K1 L42_K57del in culture (PMID: 36442478).	36442478
BRAF V600E MAP2K1 L54P	melanoma	sensitive	Trametinib	Preclinical - Cell culture	Actionable	In a preclinical study, Mekinist (trametinib) inhibited viability of a melanoma cell line harboring BRAF V600E and expressing MAP2K1 L54P in culture (PMID: 36442478).	36442478
MAP2K1 G61_D65del	Advanced Solid Tumor	sensitive	Trametinib	Preclinical - Cell culture	Actionable	In a preclinical study, Mekinist (trametinib) inhibited viability of a transformed cell line expressing MAP2K1 G61_D65del in culture (PMID: 36442478).	36442478
BRAF V600E MAP2K1 G61_D65del	melanoma	sensitive	Trametinib	Preclinical - Cell culture	Actionable	In a preclinical study, Mekinist (trametinib) inhibited viability of a melanoma cell line harboring BRAF V600E and expressing MAP2K1 G61_D65del in culture (PMID: 36442478).	36442478
MAP2K1 L63_D67del	Advanced Solid Tumor	sensitive	Trametinib	Preclinical - Cell culture	Actionable	In a preclinical study, Mekinist (trametinib) inhibited viability of a transformed cell line expressing MAP2K1 L63_D67del in culture (PMID: 36442478).	36442478
BRAF V600E MAP2K1 L63_D67del	melanoma	sensitive	Trametinib	Preclinical - Cell culture	Actionable	In a preclinical study, Mekinist (trametinib) inhibited viability of a melanoma cell line harboring BRAF V600E and expressing MAP2K1 L63_D67del in culture (PMID: 36442478).	36442478
BRAF V600E MAP2K1 L63_D67del	melanoma	sensitive	Dabrafenib	Preclinical - Cell culture	Actionable	In a preclinical study, Tafinlar (dabrafenib) inhibited viability of a melanoma cell line harboring BRAF V600E and expressing MAP2K1 L63_D67del in culture (PMID: 36442478).	36442478
BRAF V600E MAP2K1 L63_D67del	melanoma	sensitive	Vemurafenib	Preclinical - Cell culture	Actionable	In a preclinical study, Zelboraf (vemurafenib) inhibited viability of a melanoma cell line harboring BRAF V600E and expressing MAP2K1 L63_D67del in culture (PMID: 36442478).	36442478
BRAF V600E MAP2K1 L63_D67del	melanoma	sensitive	Encorafenib	Preclinical - Cell culture	Actionable	In a preclinical study, Braftovi (encorafenib) inhibited viability of a melanoma cell line harboring BRAF V600E and expressing MAP2K1 L63_D67del in culture (PMID: 36442478).	36442478
BRAF V600E MAP2K1 L63_D67del	melanoma	sensitive	Binimetinib	Preclinical - Cell culture	Actionable	In a preclinical study, Mektovi (binimetinib) inhibited viability of a melanoma cell line harboring BRAF V600E and expressing MAP2K1 L63_D67del in culture (PMID: 36442478).	36442478
BRAF V600E MAP2K1 D67Y	melanoma	sensitive	Trametinib	Preclinical - Cell culture	Actionable	In a preclinical study, Mekinist (trametinib) inhibited viability of a melanoma cell line harboring BRAF V600E and expressing MAP2K1 D67Y in culture (PMID: 36442478).	36442478
BRAF V600E MAP2K1 D67Y	melanoma	sensitive	Binimetinib	Preclinical - Cell culture	Actionable	In a preclinical study, Mektovi (binimetinib) inhibited viability of a melanoma cell line harboring BRAF V600E and expressing MAP2K1 D67Y in culture (PMID: 36442478).	36442478
BRAF V600E MAP2K1 S72G	melanoma	sensitive	Trametinib	Preclinical - Cell culture	Actionable	In a preclinical study, Mekinist (trametinib) inhibited viability of a melanoma cell line harboring BRAF V600E and expressing MAP2K1 S72G in culture (PMID: 36442478).	36442478
BRAF V600E MAP2K1 S72G	melanoma	sensitive	Dabrafenib	Preclinical - Cell culture	Actionable	In a preclinical study, Tafinlar (dabrafenib) inhibited viability of a melanoma cell line harboring BRAF V600E and expressing MAP2K1 S72G in culture (PMID: 36442478).	36442478
BRAF V600E MAP2K1 S72G	melanoma	sensitive	Vemurafenib	Preclinical - Cell culture	Actionable	In a preclinical study, Zelboraf (vemurafenib) inhibited viability of a melanoma cell line harboring BRAF V600E and expressing MAP2K1 S72G in culture (PMID: 36442478).	36442478
BRAF V600E MAP2K1 S72G	melanoma	sensitive	Encorafenib	Preclinical - Cell culture	Actionable	In a preclinical study, Braftovi (encorafenib) inhibited viability of a melanoma cell line harboring BRAF V600E and expressing MAP2K1 S72G in culture (PMID: 36442478).	36442478
BRAF V600E MAP2K1 S72G	melanoma	sensitive	Binimetinib	Preclinical - Cell culture	Actionable	In a preclinical study, Mektovi (binimetinib) inhibited viability of a melanoma cell line harboring BRAF V600E and expressing MAP2K1 S72G in culture (PMID: 36442478).	36442478
BRAF V600E MAP2K1 S72G	melanoma	sensitive	Cobimetinib	Preclinical - Cell culture	Actionable	In a preclinical study, Cotellic (cobimetinib) inhibited viability of a melanoma cell line harboring BRAF V600E and expressing MAP2K1 S72G in culture (PMID: 36442478).	36442478
BRAF V600E MAP2K1 A76V	melanoma	sensitive	Trametinib	Preclinical - Cell culture	Actionable	In a preclinical study, Mekinist (trametinib) inhibited viability of a melanoma cell line harboring BRAF V600E and expressing MAP2K1 A76V in culture (PMID: 36442478).	36442478
BRAF V600E MAP2K1 A76V	melanoma	sensitive	Dabrafenib	Preclinical - Cell culture	Actionable	In a preclinical study, Tafinlar (dabrafenib) inhibited viability of a melanoma cell line harboring BRAF V600E and expressing MAP2K1 A76V in culture (PMID: 36442478).	36442478
BRAF V600E MAP2K1 A76V	melanoma	sensitive	Vemurafenib	Preclinical - Cell culture	Actionable	In a preclinical study, Zelboraf (vemurafenib) inhibited viability of a melanoma cell line harboring BRAF V600E and expressing MAP2K1 A76V in culture (PMID: 36442478).	36442478
BRAF V600E MAP2K1 A76V	melanoma	sensitive	Encorafenib	Preclinical - Cell culture	Actionable	In a preclinical study, Braftovi (encorafenib) inhibited viability of a melanoma cell line harboring BRAF V600E and expressing MAP2K1 A76V in culture (PMID: 36442478).	36442478
BRAF V600E MAP2K1 A76V	melanoma	sensitive	Binimetinib	Preclinical - Cell culture	Actionable	In a preclinical study, Mektovi (binimetinib) inhibited viability of a melanoma cell line harboring BRAF V600E and expressing MAP2K1 A76V in culture (PMID: 36442478).	36442478
BRAF V600E MAP2K1 A76V	melanoma	sensitive	Cobimetinib	Preclinical - Cell culture	Actionable	In a preclinical study, Cotellic (cobimetinib) inhibited viability of a melanoma cell line harboring BRAF V600E and expressing MAP2K1 A76V in culture (PMID: 36442478).	36442478
BRAF V600E MAP2K1 M94I	melanoma	sensitive	Trametinib	Preclinical - Cell culture	Actionable	In a preclinical study, Mekinist (trametinib) inhibited viability of a melanoma cell line harboring BRAF V600E and expressing MAP2K1 M94I in culture (PMID: 36442478).	36442478
BRAF V600E MAP2K1 M94I	melanoma	sensitive	Dabrafenib	Preclinical - Cell culture	Actionable	In a preclinical study, Tafinlar (dabrafenib) inhibited viability of a melanoma cell line harboring BRAF V600E and expressing MAP2K1 M94I in culture (PMID: 36442478).	36442478
BRAF V600E MAP2K1 M94I	melanoma	sensitive	Encorafenib	Preclinical - Cell culture	Actionable	In a preclinical study, Braftovi (encorafenib) inhibited viability of a melanoma cell line harboring BRAF V600E and expressing MAP2K1 M94I in culture (PMID: 36442478).	36442478
BRAF V600E MAP2K1 M94I	melanoma	sensitive	Binimetinib	Preclinical - Cell culture	Actionable	In a preclinical study, Mektovi (binimetinib) inhibited viability of a melanoma cell line harboring BRAF V600E and expressing MAP2K1 M94I in culture (PMID: 36442478).	36442478
BRAF V600E MAP2K1 M94I	melanoma	sensitive	Cobimetinib	Preclinical - Cell culture	Actionable	In a preclinical study, Cotellic (cobimetinib) inhibited viability of a melanoma cell line harboring BRAF V600E and expressing MAP2K1 M94I in culture (PMID: 36442478).	36442478
BRAF V600E MAP2K1 V127M	melanoma	sensitive	Trametinib	Preclinical - Cell culture	Actionable	In a preclinical study, Mekinist (trametinib) inhibited viability of a melanoma cell line harboring BRAF V600E and expressing MAP2K1 V127M in culture (PMID: 36442478).	36442478
BRAF V600E MAP2K1 V127M	melanoma	sensitive	Dabrafenib	Preclinical - Cell culture	Actionable	In a preclinical study, Tafinlar (dabrafenib) inhibited viability of a melanoma cell line harboring BRAF V600E and expressing MAP2K1 V127M in culture (PMID: 36442478).	36442478
BRAF V600E MAP2K1 V127M	melanoma	sensitive	Vemurafenib	Preclinical - Cell culture	Actionable	In a preclinical study, Zelboraf (vemurafenib) inhibited viability of a melanoma cell line harboring BRAF V600E and expressing MAP2K1 V127M in culture (PMID: 36442478).	36442478
BRAF V600E MAP2K1 V127M	melanoma	sensitive	Encorafenib	Preclinical - Cell culture	Actionable	In a preclinical study, Braftovi (encorafenib) inhibited viability of a melanoma cell line harboring BRAF V600E and expressing MAP2K1 V127M in culture (PMID: 36442478).	36442478
BRAF V600E MAP2K1 V127M	melanoma	sensitive	Binimetinib	Preclinical - Cell culture	Actionable	In a preclinical study, Mektovi (binimetinib) inhibited viability of a melanoma cell line harboring BRAF V600E and expressing MAP2K1 V127M in culture (PMID: 36442478).	36442478
BRAF V600E MAP2K1 D136N	melanoma	sensitive	Trametinib	Preclinical - Cell culture	Actionable	In a preclinical study, Mekinist (trametinib) inhibited viability of a melanoma cell line harboring BRAF V600E and expressing MAP2K1 D136N in culture (PMID: 36442478).	36442478
BRAF V600E MAP2K1 D136N	melanoma	sensitive	Dabrafenib	Preclinical - Cell culture	Actionable	In a preclinical study, Tafinlar (dabrafenib) inhibited viability of a melanoma cell line harboring BRAF V600E and expressing MAP2K1 D136N in culture (PMID: 36442478).	36442478
BRAF V600E MAP2K1 D136N	melanoma	sensitive	Vemurafenib	Preclinical - Cell culture	Actionable	In a preclinical study, Zelboraf (vemurafenib) inhibited viability of a melanoma cell line harboring BRAF V600E and expressing MAP2K1 D136N in culture (PMID: 36442478).	36442478
BRAF V600E MAP2K1 D136N	melanoma	sensitive	Encorafenib	Preclinical - Cell culture	Actionable	In a preclinical study, Braftovi (encorafenib) inhibited viability of a melanoma cell line harboring BRAF V600E and expressing MAP2K1 D136N in culture (PMID: 36442478).	36442478
BRAF V600E MAP2K1 D136N	melanoma	sensitive	Binimetinib	Preclinical - Cell culture	Actionable	In a preclinical study, Mektovi (binimetinib) inhibited viability of a melanoma cell line harboring BRAF V600E and expressing MAP2K1 D136N in culture (PMID: 36442478).	36442478
BRAF V600E MAP2K1 D136N	melanoma	sensitive	Cobimetinib	Preclinical - Cell culture	Actionable	In a preclinical study, Cotellic (cobimetinib) inhibited viability of a melanoma cell line harboring BRAF V600E and expressing MAP2K1 D136N in culture (PMID: 36442478).	36442478
BRAF V600E MAP2K1 S150F	melanoma	sensitive	Trametinib	Preclinical - Cell culture	Actionable	In a preclinical study, Mekinist (trametinib) inhibited viability of a melanoma cell line harboring BRAF V600E and expressing MAP2K1 S150F in culture (PMID: 36442478).	36442478
BRAF V600E MAP2K1 S150F	melanoma	sensitive	Dabrafenib	Preclinical - Cell culture	Actionable	In a preclinical study, Tafinlar (dabrafenib) inhibited viability of a melanoma cell line harboring BRAF V600E and expressing MAP2K1 S150F in culture (PMID: 36442478).	36442478
BRAF V600E MAP2K1 S150F	melanoma	sensitive	Vemurafenib	Preclinical - Cell culture	Actionable	In a preclinical study, Zelboraf (vemurafenib) inhibited viability of a melanoma cell line harboring BRAF V600E and expressing MAP2K1 S150F in culture (PMID: 36442478).	36442478
BRAF V600E MAP2K1 S150F	melanoma	sensitive	Encorafenib	Preclinical - Cell culture	Actionable	In a preclinical study, Braftovi (encorafenib) inhibited viability of a melanoma cell line harboring BRAF V600E and expressing MAP2K1 S150F in culture (PMID: 36442478).	36442478
BRAF V600E MAP2K1 S150F	melanoma	sensitive	Binimetinib	Preclinical - Cell culture	Actionable	In a preclinical study, Mektovi (binimetinib) inhibited viability of a melanoma cell line harboring BRAF V600E and expressing MAP2K1 S150F in culture (PMID: 36442478).	36442478
BRAF V600E MAP2K1 S150F	melanoma	sensitive	Cobimetinib	Preclinical - Cell culture	Actionable	In a preclinical study, Cotellic (cobimetinib) inhibited viability of a melanoma cell line harboring BRAF V600E and expressing MAP2K1 S150F in culture (PMID: 36442478).	36442478
BRAF V600E MAP2K1 V154I	melanoma	sensitive	Trametinib	Preclinical - Cell culture	Actionable	In a preclinical study, Mekinist (trametinib) inhibited viability of a melanoma cell line harboring BRAF V600E and expressing MAP2K1 V154I in culture (PMID: 36442478).	36442478
BRAF V600E MAP2K1 V154I	melanoma	sensitive	Dabrafenib	Preclinical - Cell culture	Actionable	In a preclinical study, Tafinlar (dabrafenib) inhibited viability of a melanoma cell line harboring BRAF V600E and expressing MAP2K1 V154I in culture (PMID: 36442478).	36442478
BRAF V600E MAP2K1 V154I	melanoma	sensitive	Vemurafenib	Preclinical - Cell culture	Actionable	In a preclinical study, Zelboraf (vemurafenib) inhibited viability of a melanoma cell line harboring BRAF V600E and expressing MAP2K1 V154I in culture (PMID: 36442478).	36442478
BRAF V600E MAP2K1 V154I	melanoma	sensitive	Encorafenib	Preclinical - Cell culture	Actionable	In a preclinical study, Braftovi (encorafenib) inhibited viability of a melanoma cell line harboring BRAF V600E and expressing MAP2K1 V154I in culture (PMID: 36442478).	36442478
BRAF V600E MAP2K1 V154I	melanoma	sensitive	Binimetinib	Preclinical - Cell culture	Actionable	In a preclinical study, Mektovi (binimetinib) inhibited viability of a melanoma cell line harboring BRAF V600E and expressing MAP2K1 V154I in culture (PMID: 36442478).	36442478
BRAF V600E MAP2K1 V154I	melanoma	sensitive	Cobimetinib	Preclinical - Cell culture	Actionable	In a preclinical study, Cotellic (cobimetinib) inhibited viability of a melanoma cell line harboring BRAF V600E and expressing MAP2K1 V154I in culture (PMID: 36442478).	36442478
BRAF V600E MAP2K1 G176S	melanoma	sensitive	Trametinib	Preclinical - Cell culture	Actionable	In a preclinical study, Mekinist (trametinib) inhibited viability of a melanoma cell line harboring BRAF V600E and expressing MAP2K1 G176S in culture (PMID: 36442478).	36442478
BRAF V600E MAP2K1 G176S	melanoma	sensitive	Dabrafenib	Preclinical - Cell culture	Actionable	In a preclinical study, Tafinlar (dabrafenib) inhibited viability of a melanoma cell line harboring BRAF V600E and expressing MAP2K1 G176S in culture (PMID: 36442478).	36442478
BRAF V600E MAP2K1 G176S	melanoma	sensitive	Vemurafenib	Preclinical - Cell culture	Actionable	In a preclinical study, Zelboraf (vemurafenib) inhibited viability of a melanoma cell line harboring BRAF V600E and expressing MAP2K1 G176S in culture (PMID: 36442478).	36442478
BRAF V600E MAP2K1 G176S	melanoma	sensitive	Encorafenib	Preclinical - Cell culture	Actionable	In a preclinical study, Braftovi (encorafenib) inhibited viability of a melanoma cell line harboring BRAF V600E and expressing MAP2K1 G176S in culture (PMID: 36442478).	36442478
BRAF V600E MAP2K1 G176S	melanoma	sensitive	Binimetinib	Preclinical - Cell culture	Actionable	In a preclinical study, Mektovi (binimetinib) inhibited viability of a melanoma cell line harboring BRAF V600E and expressing MAP2K1 G176S in culture (PMID: 36442478).	36442478
BRAF V600E MAP2K1 S200Y	melanoma	sensitive	Trametinib	Preclinical - Cell culture	Actionable	In a preclinical study, Mekinist (trametinib) inhibited viability of a melanoma cell line harboring BRAF V600E and expressing MAP2K1 S200Y in culture (PMID: 36442478).	36442478
BRAF V600E MAP2K1 S200Y	melanoma	sensitive	Dabrafenib	Preclinical - Cell culture	Actionable	In a preclinical study, Tafinlar (dabrafenib) inhibited viability of a melanoma cell line harboring BRAF V600E and expressing MAP2K1 S200Y in culture (PMID: 36442478).	36442478
BRAF V600E MAP2K1 S200Y	melanoma	sensitive	Encorafenib	Preclinical - Cell culture	Actionable	In a preclinical study, Braftovi (encorafenib) inhibited viability of a melanoma cell line harboring BRAF V600E and expressing MAP2K1 S200Y in culture (PMID: 36442478).	36442478
BRAF V600E MAP2K1 S200Y	melanoma	sensitive	Binimetinib	Preclinical - Cell culture	Actionable	In a preclinical study, Mektovi (binimetinib) inhibited viability of a melanoma cell line harboring BRAF V600E and expressing MAP2K1 S200Y in culture (PMID: 36442478).	36442478
BRAF V600E MAP2K1 S200Y	melanoma	sensitive	Cobimetinib	Preclinical - Cell culture	Actionable	In a preclinical study, Cotellic (cobimetinib) inhibited viability of a melanoma cell line harboring BRAF V600E and expressing MAP2K1 S200Y in culture (PMID: 36442478).	36442478
BRAF V600E MAP2K1 S212N	melanoma	sensitive	Trametinib	Preclinical - Cell culture	Actionable	In a preclinical study, Mekinist (trametinib) inhibited viability of a melanoma cell line harboring BRAF V600E and expressing MAP2K1 S212N in culture (PMID: 36442478).	36442478
BRAF V600E MAP2K1 S212N	melanoma	sensitive	Dabrafenib	Preclinical - Cell culture	Actionable	In a preclinical study, Tafinlar (dabrafenib) inhibited viability of a melanoma cell line harboring BRAF V600E and expressing MAP2K1 S212N in culture (PMID: 36442478).	36442478
BRAF V600E MAP2K1 S212N	melanoma	sensitive	Vemurafenib	Preclinical - Cell culture	Actionable	In a preclinical study, Zelboraf (vemurafenib) inhibited viability of a melanoma cell line harboring BRAF V600E and expressing MAP2K1 S212N in culture (PMID: 36442478).	36442478
BRAF V600E MAP2K1 S212N	melanoma	sensitive	Encorafenib	Preclinical - Cell culture	Actionable	In a preclinical study, Braftovi (encorafenib) inhibited viability of a melanoma cell line harboring BRAF V600E and expressing MAP2K1 S212N in culture (PMID: 36442478).	36442478
BRAF V600E MAP2K1 S212N	melanoma	sensitive	Binimetinib	Preclinical - Cell culture	Actionable	In a preclinical study, Mektovi (binimetinib) inhibited viability of a melanoma cell line harboring BRAF V600E and expressing MAP2K1 S212N in culture (PMID: 36442478).	36442478
BRAF V600E MAP2K1 S212N	melanoma	sensitive	Cobimetinib	Preclinical - Cell culture	Actionable	In a preclinical study, Cotellic (cobimetinib) inhibited viability of a melanoma cell line harboring BRAF V600E and expressing MAP2K1 S212N in culture (PMID: 36442478).	36442478
BRAF V600E MAP2K1 Y229H	melanoma	sensitive	Trametinib	Preclinical - Cell culture	Actionable	In a preclinical study, Mekinist (trametinib) inhibited viability of a melanoma cell line harboring BRAF V600E and expressing MAP2K1 Y229H in culture (PMID: 36442478).	36442478
BRAF V600E MAP2K1 Y229H	melanoma	sensitive	Dabrafenib	Preclinical - Cell culture	Actionable	In a preclinical study, Tafinlar (dabrafenib) inhibited viability of a melanoma cell line harboring BRAF V600E and expressing MAP2K1 Y229H in culture (PMID: 36442478).	36442478
BRAF V600E MAP2K1 Y229H	melanoma	sensitive	Vemurafenib	Preclinical - Cell culture	Actionable	In a preclinical study, Zelboraf (vemurafenib) inhibited viability of a melanoma cell line harboring BRAF V600E and expressing MAP2K1 Y229H in culture (PMID: 36442478).	36442478
BRAF V600E MAP2K1 Y229H	melanoma	sensitive	Encorafenib	Preclinical - Cell culture	Actionable	In a preclinical study, Braftovi (encorafenib) inhibited viability of a melanoma cell line harboring BRAF V600E and expressing MAP2K1 Y229H in culture (PMID: 36442478).	36442478
BRAF V600E MAP2K1 Y229H	melanoma	sensitive	Binimetinib	Preclinical - Cell culture	Actionable	In a preclinical study, Mektovi (binimetinib) inhibited viability of a melanoma cell line harboring BRAF V600E and expressing MAP2K1 Y229H in culture (PMID: 36442478).	36442478
BRAF V600E MAP2K1 Y229H	melanoma	sensitive	Cobimetinib	Preclinical - Cell culture	Actionable	In a preclinical study, Cotellic (cobimetinib) inhibited viability of a melanoma cell line harboring BRAF V600E and expressing MAP2K1 Y229H in culture (PMID: 36442478).	36442478
BRAF V600E MAP2K1 S231L	melanoma	sensitive	Trametinib	Preclinical - Cell culture	Actionable	In a preclinical study, Mekinist (trametinib) inhibited viability of a melanoma cell line harboring BRAF V600E and expressing MAP2K1 S231L in culture (PMID: 36442478).	36442478
BRAF V600E MAP2K1 S231L	melanoma	sensitive	Dabrafenib	Preclinical - Cell culture	Actionable	In a preclinical study, Tafinlar (dabrafenib) inhibited viability of a melanoma cell line harboring BRAF V600E and expressing MAP2K1 S231L in culture (PMID: 36442478).	36442478
BRAF V600E MAP2K1 S231L	melanoma	sensitive	Vemurafenib	Preclinical - Cell culture	Actionable	In a preclinical study, Zelboraf (vemurafenib) inhibited viability of a melanoma cell line harboring BRAF V600E and expressing MAP2K1 S231L in culture (PMID: 36442478).	36442478
BRAF V600E MAP2K1 S231L	melanoma	sensitive	Encorafenib	Preclinical - Cell culture	Actionable	In a preclinical study, Braftovi (encorafenib) inhibited viability of a melanoma cell line harboring BRAF V600E and expressing MAP2K1 S231L in culture (PMID: 36442478).	36442478
BRAF V600E MAP2K1 S231L	melanoma	sensitive	Binimetinib	Preclinical - Cell culture	Actionable	In a preclinical study, Mektovi (binimetinib) inhibited viability of a melanoma cell line harboring BRAF V600E and expressing MAP2K1 S231L in culture (PMID: 36442478).	36442478
BRAF V600E MAP2K1 S231L	melanoma	sensitive	Cobimetinib	Preclinical - Cell culture	Actionable	In a preclinical study, Cotellic (cobimetinib) inhibited viability of a melanoma cell line harboring BRAF V600E and expressing MAP2K1 S231L in culture (PMID: 36442478).	36442478
BRAF V600E MAP2K1 R291K	melanoma	sensitive	Trametinib	Preclinical - Cell culture	Actionable	In a preclinical study, Mekinist (trametinib) inhibited viability of a melanoma cell line harboring BRAF V600E and expressing MAP2K1 R291K in culture (PMID: 36442478).	36442478
BRAF V600E MAP2K1 R291K	melanoma	sensitive	Dabrafenib	Preclinical - Cell culture	Actionable	In a preclinical study, Tafinlar (dabrafenib) inhibited viability of a melanoma cell line harboring BRAF V600E and expressing MAP2K1 R291K in culture (PMID: 36442478).	36442478
BRAF V600E MAP2K1 R291K	melanoma	sensitive	Vemurafenib	Preclinical - Cell culture	Actionable	In a preclinical study, Zelboraf (vemurafenib) inhibited viability of a melanoma cell line harboring BRAF V600E and expressing MAP2K1 R291K in culture (PMID: 36442478).	36442478
BRAF V600E MAP2K1 R291K	melanoma	sensitive	Encorafenib	Preclinical - Cell culture	Actionable	In a preclinical study, Braftovi (encorafenib) inhibited viability of a melanoma cell line harboring BRAF V600E and expressing MAP2K1 R291K in culture (PMID: 36442478).	36442478
BRAF V600E MAP2K1 R291K	melanoma	sensitive	Binimetinib	Preclinical - Cell culture	Actionable	In a preclinical study, Mektovi (binimetinib) inhibited viability of a melanoma cell line harboring BRAF V600E and expressing MAP2K1 R291K in culture (PMID: 36442478).	36442478
BRAF V600E MAP2K1 R291K	melanoma	sensitive	Cobimetinib	Preclinical - Cell culture	Actionable	In a preclinical study, Cotellic (cobimetinib) inhibited viability of a melanoma cell line harboring BRAF V600E and expressing MAP2K1 R291K in culture (PMID: 36442478).	36442478
BRAF V600E MAP2K1 P293S	melanoma	sensitive	Trametinib	Preclinical - Cell culture	Actionable	In a preclinical study, Mekinist (trametinib) inhibited viability of a melanoma cell line harboring BRAF V600E and expressing MAP2K1 P293S in culture (PMID: 36442478).	36442478
BRAF V600E MAP2K1 P293S	melanoma	sensitive	Dabrafenib	Preclinical - Cell culture	Actionable	In a preclinical study, Tafinlar (dabrafenib) inhibited viability of a melanoma cell line harboring BRAF V600E and expressing MAP2K1 P293S in culture (PMID: 36442478).	36442478
BRAF V600E MAP2K1 P293S	melanoma	sensitive	Vemurafenib	Preclinical - Cell culture	Actionable	In a preclinical study, Zelboraf (vemurafenib) inhibited viability of a melanoma cell line harboring BRAF V600E and expressing MAP2K1 P293S in culture (PMID: 36442478).	36442478
BRAF V600E MAP2K1 P293S	melanoma	sensitive	Encorafenib	Preclinical - Cell culture	Actionable	In a preclinical study, Braftovi (encorafenib) inhibited viability of a melanoma cell line harboring BRAF V600E and expressing MAP2K1 P293S in culture (PMID: 36442478).	36442478
BRAF V600E MAP2K1 P293S	melanoma	sensitive	Binimetinib	Preclinical - Cell culture	Actionable	In a preclinical study, Mektovi (binimetinib) inhibited viability of a melanoma cell line harboring BRAF V600E and expressing MAP2K1 P293S in culture (PMID: 36442478).	36442478
BRAF V600E MAP2K1 P293S	melanoma	sensitive	Cobimetinib	Preclinical - Cell culture	Actionable	In a preclinical study, Cotellic (cobimetinib) inhibited viability of a melanoma cell line harboring BRAF V600E and expressing MAP2K1 P293S in culture (PMID: 36442478).	36442478
BRAF V600E MAP2K1 P326H	melanoma	sensitive	Trametinib	Preclinical - Cell culture	Actionable	In a preclinical study, Mekinist (trametinib) inhibited viability of a melanoma cell line harboring BRAF V600E and expressing MAP2K1 P326H in culture (PMID: 36442478).	36442478
BRAF V600E MAP2K1 P326H	melanoma	sensitive	Dabrafenib	Preclinical - Cell culture	Actionable	In a preclinical study, Tafinlar (dabrafenib) inhibited viability of a melanoma cell line harboring BRAF V600E and expressing MAP2K1 P326H in culture (PMID: 36442478).	36442478
BRAF V600E MAP2K1 P326H	melanoma	sensitive	Vemurafenib	Preclinical - Cell culture	Actionable	In a preclinical study, Zelboraf (vemurafenib) inhibited viability of a melanoma cell line harboring BRAF V600E and expressing MAP2K1 P326H in culture (PMID: 36442478).	36442478
BRAF V600E MAP2K1 P326H	melanoma	sensitive	Encorafenib	Preclinical - Cell culture	Actionable	In a preclinical study, Braftovi (encorafenib) inhibited viability of a melanoma cell line harboring BRAF V600E and expressing MAP2K1 P326H in culture (PMID: 36442478).	36442478
BRAF V600E MAP2K1 P326H	melanoma	sensitive	Binimetinib	Preclinical - Cell culture	Actionable	In a preclinical study, Mektovi (binimetinib) inhibited viability of a melanoma cell line harboring BRAF V600E and expressing MAP2K1 P326H in culture (PMID: 36442478).	36442478
BRAF V600E MAP2K1 P326H	melanoma	sensitive	Cobimetinib	Preclinical - Cell culture	Actionable	In a preclinical study, Cotellic (cobimetinib) inhibited viability of a melanoma cell line harboring BRAF V600E and expressing MAP2K1 P326H in culture (PMID: 36442478).	36442478
BRAF V600E MAP2K1 N345T	melanoma	sensitive	Trametinib	Preclinical - Cell culture	Actionable	In a preclinical study, Mekinist (trametinib) inhibited viability of a melanoma cell line harboring BRAF V600E and expressing MAP2K1 N345T in culture (PMID: 36442478).	36442478
BRAF V600E MAP2K1 N345T	melanoma	sensitive	Dabrafenib	Preclinical - Cell culture	Actionable	In a preclinical study, Tafinlar (dabrafenib) inhibited viability of a melanoma cell line harboring BRAF V600E and expressing MAP2K1 N345T in culture (PMID: 36442478).	36442478
BRAF V600E MAP2K1 N345T	melanoma	sensitive	Vemurafenib	Preclinical - Cell culture	Actionable	In a preclinical study, Zelboraf (vemurafenib) inhibited viability of a melanoma cell line harboring BRAF V600E and expressing MAP2K1 N345T in culture (PMID: 36442478).	36442478
BRAF V600E MAP2K1 N345T	melanoma	sensitive	Encorafenib	Preclinical - Cell culture	Actionable	In a preclinical study, Braftovi (encorafenib) inhibited viability of a melanoma cell line harboring BRAF V600E and expressing MAP2K1 N345T in culture (PMID: 36442478).	36442478
BRAF V600E MAP2K1 N345T	melanoma	sensitive	Binimetinib	Preclinical - Cell culture	Actionable	In a preclinical study, Mektovi (binimetinib) inhibited viability of a melanoma cell line harboring BRAF V600E and expressing MAP2K1 N345T in culture (PMID: 36442478).	36442478
BRAF V600E MAP2K1 N345T	melanoma	sensitive	Cobimetinib	Preclinical - Cell culture	Actionable	In a preclinical study, Cotellic (cobimetinib) inhibited viability of a melanoma cell line harboring BRAF V600E and expressing MAP2K1 N345T in culture (PMID: 36442478).	36442478
BRAF V600E MAP2K1 E367K	melanoma	sensitive	Trametinib	Preclinical - Cell culture	Actionable	In a preclinical study, Mekinist (trametinib) inhibited viability of a melanoma cell line harboring BRAF V600E and expressing MAP2K1 E367K in culture (PMID: 36442478).	36442478
BRAF V600E MAP2K1 E367K	melanoma	sensitive	Dabrafenib	Preclinical - Cell culture	Actionable	In a preclinical study, Tafinlar (dabrafenib) inhibited viability of a melanoma cell line harboring BRAF V600E and expressing MAP2K1 E367K in culture (PMID: 36442478).	36442478
BRAF V600E MAP2K1 E367K	melanoma	sensitive	Encorafenib	Preclinical - Cell culture	Actionable	In a preclinical study, Braftovi (encorafenib) inhibited viability of a melanoma cell line harboring BRAF V600E and expressing MAP2K1 E367K in culture (PMID: 36442478).	36442478
BRAF V600E MAP2K1 E367K	melanoma	sensitive	Binimetinib	Preclinical - Cell culture	Actionable	In a preclinical study, Mektovi (binimetinib) inhibited viability of a melanoma cell line harboring BRAF V600E and expressing MAP2K1 E367K in culture (PMID: 36442478).	36442478
BRAF V600E MAP2K1 E367K	melanoma	sensitive	Cobimetinib	Preclinical - Cell culture	Actionable	In a preclinical study, Cotellic (cobimetinib) inhibited viability of a melanoma cell line harboring BRAF V600E and expressing MAP2K1 E367K in culture (PMID: 36442478).	36442478
BRAF V600E MAP2K1 L215F	melanoma	sensitive	Trametinib	Preclinical - Cell culture	Actionable	In a preclinical study, Mekinist (trametinib) inhibited viability of a melanoma cell line harboring BRAF V600E and expressing MAP2K1 L215F in culture (PMID: 36442478).	36442478
BRAF V600E MAP2K1 L215F	melanoma	sensitive	Dabrafenib	Preclinical - Cell culture	Actionable	In a preclinical study, Tafinlar (dabrafenib) inhibited viability of a melanoma cell line harboring BRAF V600E and expressing MAP2K1 L215F in culture (PMID: 36442478).	36442478
BRAF V600E MAP2K1 L215F	melanoma	sensitive	Vemurafenib	Preclinical - Cell culture	Actionable	In a preclinical study, Zelboraf (vemurafenib) inhibited viability of a melanoma cell line harboring BRAF V600E and expressing MAP2K1 L215F in culture (PMID: 36442478).	36442478
BRAF V600E MAP2K1 L215F	melanoma	sensitive	Encorafenib	Preclinical - Cell culture	Actionable	In a preclinical study, Braftovi (encorafenib) inhibited viability of a melanoma cell line harboring BRAF V600E and expressing MAP2K1 L215F in culture (PMID: 36442478).	36442478
BRAF V600E MAP2K1 L215F	melanoma	sensitive	Binimetinib	Preclinical - Cell culture	Actionable	In a preclinical study, Mektovi (binimetinib) inhibited viability of a melanoma cell line harboring BRAF V600E and expressing MAP2K1 L215F in culture (PMID: 36442478).	36442478
BRAF V600E MAP2K1 Q58*	melanoma	sensitive	Trametinib	Preclinical - Cell culture	Actionable	In a preclinical study, Mekinist (trametinib) inhibited viability of a melanoma cell line harboring BRAF V600E and expressing MAP2K1 Q58* in culture (PMID: 36442478).	36442478
BRAF V600E MAP2K1 Q58*	melanoma	sensitive	Dabrafenib	Preclinical - Cell culture	Actionable	In a preclinical study, Tafinlar (dabrafenib) inhibited viability of a melanoma cell line harboring BRAF V600E and expressing MAP2K1 Q58* in culture (PMID: 36442478).	36442478
BRAF V600E MAP2K1 Q58*	melanoma	sensitive	Vemurafenib	Preclinical - Cell culture	Actionable	In a preclinical study, Zelboraf (vemurafenib) inhibited viability of a melanoma cell line harboring BRAF V600E and expressing MAP2K1 Q58* in culture (PMID: 36442478).	36442478
BRAF V600E MAP2K1 Q58*	melanoma	sensitive	Encorafenib	Preclinical - Cell culture	Actionable	In a preclinical study, Braftovi (encorafenib) inhibited viability of a melanoma cell line harboring BRAF V600E and expressing MAP2K1 Q58* in culture (PMID: 36442478).	36442478
BRAF V600E MAP2K1 Q58*	melanoma	sensitive	Binimetinib	Preclinical - Cell culture	Actionable	In a preclinical study, Mektovi (binimetinib) inhibited viability of a melanoma cell line harboring BRAF V600E and expressing MAP2K1 Q58* in culture (PMID: 36442478).	36442478
BRAF V600E MAP2K1 Q58*	melanoma	sensitive	Cobimetinib	Preclinical - Cell culture	Actionable	In a preclinical study, Cotellic (cobimetinib) inhibited viability of a melanoma cell line harboring BRAF V600E and expressing MAP2K1 Q58* in culture (PMID: 36442478).	36442478
BRAF V600E MAP2K1 D303N	melanoma	sensitive	Dabrafenib	Preclinical - Cell culture	Actionable	In a preclinical study, Tafinlar (dabrafenib) inhibited viability of a melanoma cell line harboring BRAF V600E and expressing MAP2K1 D303N in culture (PMID: 36442478).	36442478
BRAF V600E MAP2K1 D303N	melanoma	sensitive	Encorafenib	Preclinical - Cell culture	Actionable	In a preclinical study, Braftovi (encorafenib) inhibited viability of a melanoma cell line harboring BRAF V600E and expressing MAP2K1 D303N in culture (PMID: 36442478).	36442478
BRAF V600E MAP2K1 D303N	melanoma	sensitive	Binimetinib	Preclinical - Cell culture	Actionable	In a preclinical study, Mektovi (binimetinib) inhibited viability of a melanoma cell line harboring BRAF V600E and expressing MAP2K1 D303N in culture (PMID: 36442478).	36442478
BRAF V600E MAP2K1 D303N	melanoma	sensitive	Cobimetinib	Preclinical - Cell culture	Actionable	In a preclinical study, Cotellic (cobimetinib) inhibited viability of a melanoma cell line harboring BRAF V600E and expressing MAP2K1 D303N in culture (PMID: 36442478).	36442478
BRAF V600E MAP2K1 G276W	melanoma	sensitive	Trametinib	Preclinical - Cell culture	Actionable	In a preclinical study, Mekinist (trametinib) inhibited viability of a melanoma cell line harboring BRAF V600E and expressing MAP2K1 G276W in culture (PMID: 36442478).	36442478
BRAF V600E MAP2K1 G276W	melanoma	sensitive	Dabrafenib	Preclinical - Cell culture	Actionable	In a preclinical study, Tafinlar (dabrafenib) inhibited viability of a melanoma cell line harboring BRAF V600E and expressing MAP2K1 G276W in culture (PMID: 36442478).	36442478
BRAF V600E MAP2K1 G276W	melanoma	sensitive	Encorafenib	Preclinical - Cell culture	Actionable	In a preclinical study, Braftovi (encorafenib) inhibited viability of a melanoma cell line harboring BRAF V600E and expressing MAP2K1 G276W in culture (PMID: 36442478).	36442478
BRAF V600E MAP2K1 G276W	melanoma	sensitive	Binimetinib	Preclinical - Cell culture	Actionable	In a preclinical study, Mektovi (binimetinib) inhibited viability of a melanoma cell line harboring BRAF V600E and expressing MAP2K1 G276W in culture (PMID: 36442478).	36442478
BRAF V600E MAP2K1 S241Y	melanoma	sensitive	Encorafenib	Preclinical - Cell culture	Actionable	In a preclinical study, Braftovi (encorafenib) inhibited viability of a melanoma cell line harboring BRAF V600E and expressing MAP2K1 S241Y in culture (PMID: 36442478).	36442478
MAP2K1 Q56_G61delinsR	Advanced Solid Tumor	sensitive	Trametinib	Preclinical - Cell culture	Actionable	In a preclinical study, Mekinist (trametinib) inhibited viability of a transformed cell line expressing MAP2K1 Q56_G61delinsR in culture (PMID: 36442478).	36442478
BRAF V600E MAP2K1 Q56_G61delinsR	melanoma	resistant	Trametinib	Preclinical - Cell culture	Actionable	In a preclinical study, a melanoma cell line harboring BRAF V600E and expressing MAP2K1 Q56_G61delinsR was resistant to Mekinist (trametinib) in culture (PMID: 36442478).	36442478
BRAF V600E MAP2K1 Q56_G61delinsR	melanoma	resistant	Dabrafenib	Preclinical - Cell culture	Actionable	In a preclinical study, a melanoma cell line harboring BRAF V600E and expressing MAP2K1 Q56_G61delinsR was resistant to Tafinlar (dabrafenib) in culture (PMID: 36442478).	36442478
BRAF V600E MAP2K1 Q56_G61delinsR	melanoma	resistant	Vemurafenib	Preclinical - Cell culture	Actionable	In a preclinical study, a melanoma cell line harboring BRAF V600E and expressing MAP2K1 Q56_G61delinsR was resistant to Zelboraf (vemurafenib) in culture (PMID: 36442478).	36442478
BRAF V600E MAP2K1 Q56_G61delinsR	melanoma	resistant	Encorafenib	Preclinical - Cell culture	Actionable	In a preclinical study, a melanoma cell line harboring BRAF V600E and expressing MAP2K1 Q56_G61delinsR was resistant to Braftovi (encorafenib) in culture (PMID: 36442478).	36442478
BRAF V600E MAP2K1 Q56_G61delinsR	melanoma	resistant	Binimetinib	Preclinical - Cell culture	Actionable	In a preclinical study, a melanoma cell line harboring BRAF V600E and expressing MAP2K1 Q56_G61delinsR was resistant to Mektovi (binimetinib) in culture (PMID: 36442478).	36442478
BRAF V600E MAP2K1 Q56_G61delinsR	melanoma	resistant	Cobimetinib	Preclinical - Cell culture	Actionable	In a preclinical study, a melanoma cell line harboring BRAF V600E and expressing MAP2K1 Q56_G61delinsR was resistant to Cotellic (cobimetinib) in culture (PMID: 36442478).	36442478
BRAF V600E MAP2K1 Q56_G61delinsR	melanoma	resistant	Dabrafenib + Trametinib	Preclinical - Cell culture	Actionable	In a preclinical study, the combination of Tafinlar (dabrafenib) and Mekinist (trametinib) synergistically inhibited viability of a melanoma cell line harboring BRAF V600E and expressing MAP2K1 Q56_G61delinsR in culture (PMID: 36442478).	36442478
BRAF V600E MAP2K1 Q56_G61delinsR	melanoma	sensitive	Binimetinib + Encorafenib	Preclinical - Cell culture	Actionable	In a preclinical study, the combination of Braftovi (encorafenib) and Mektovi (binimetinib) synergistically inhibited viability of a melanoma cell line harboring BRAF V600E and expressing MAP2K1 Q56_G61delinsR in culture (PMID: 36442478).	36442478
BRAF V600E MAP2K1 Q56_G61delinsR	melanoma	sensitive	Cobimetinib + Vemurafenib	Preclinical - Cell culture	Actionable	In a preclinical study, the combination of Zelboraf (vemurafenib) and Cotellic (cobimetinib) synergistically inhibited viability of a melanoma cell line harboring BRAF V600E and expressing MAP2K1 Q56_G61delinsR in culture (PMID: 36442478).	36442478
BRAF V600E MAP2K1 H100_I103delinsPL	melanoma	resistant	Dabrafenib	Preclinical - Cell culture	Actionable	In a preclinical study, a melanoma cell line harboring BRAF V600E and expressing MAP2K1 H100_I103delinsPL was resistant to Tafinlar (dabrafenib) in culture (PMID: 36442478).	36442478
BRAF V600E MAP2K1 H100_I103delinsPL	melanoma	resistant	Encorafenib	Preclinical - Cell culture	Actionable	In a preclinical study, a melanoma cell line harboring BRAF V600E and expressing MAP2K1 H100_I103delinsPL was resistant to Braftovi (encorafenib) in culture (PMID: 36442478).	36442478

Gene Detail

Contact

Filtering

Sorting